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Prostate cancer (PCa) ranks as the second most frequent cancer and the fifth 
leading cause of cancer death in men worldwide. Androgen-deprivation therapy 
is the principal treatment for locally advanced and metastatic PCa. However, 
most patients will progress to castration-resistant PCa (CRPC), which contributes 
to the majority of PCa deaths. This project aims to investigate the utility of two 
main types of liquid biopsy, plasma exosomes and circulating tumour cells 
(CTCs), in monitoring PCa progression and treatment response.  
We performed RNA-sequencing of plasma exosomal miRNAs in 24 treatment-
naive PCa and 24 CRPC patients and identified different miRNA expression 
profiles. Several miRNAs were confirmed by reverse transcriptase quantitative 
polymerase chain reaction in 108 treatment-naive PCa, 42 CRPC and 36 treated 
non-CRPC patients. The most significantly differentially expressed miRNA, miR-
423-3p, was also validated in 30 treatment-naive PCa and 30 CRPC patients at 
a separate centre. The differentially expressed exosomal miRNAs showed good 
prediction value for CRPC and showed better prediction value than prostate 
specific antigen when predicting CRPC from treated non-CRPC. The in vitro 
study of one miRNA, miR-423-3p, showed that it could enhanced LNCaP cell 
migration and invasion in hormone-depleted environment. The hormone-
independent subline of LNCaP had higher miR-423-3p expression and increased 
migration and invasion ability.  
CTC culture provides a good platform for establishing patient-specific tumour 
models and study of treatment response. I tested different CTC isolation methods 
and culture conditions for CTC propagation. Viable CTCs could be isolated from 
PCa patients’ blood and potentially be propagated in vitro. However, the purity of 
tumour cells remain low in cultured population and long-term culture remains 
challenging. 
This study demonstrated that plasma exosomal miRNAs play important roles in 
CRPC development and may serve as prediction biomarkers for CRPC 
occurrence. Long-term culture of PCa CTCs remains challenging and needs 




Table of Contents 
Statement of originality ....................................................................................... 2 




List of figures ..................................................................................................... 16 
List of tables ...................................................................................................... 23 
Chapter I  Introduction and aims .................................................................... 26 
1.1  Prostate cancer (PCa) ......................................................................... 26 
  Prostate anatomy and physiology ................................................. 26 
  PCa incidence, mortality and survival ............................................ 28 
  Risk factors ................................................................................... 29 
  PSA test ........................................................................................ 30 
  Grading and staging of prostate adenocarcinoma ......................... 31 
  Treatments for PCa ....................................................................... 35 
1.1.6.1  Treatments for localised PCa .................................................. 35 
1.1.6.2  Treatments for locally advanced PCa ..................................... 36 
1.1.6.3  Treatments for metastatic/ recurrent/ progressive diseases ... 36 
  Molecular alterations in PCa ......................................................... 37 
1.1.7.1  Germline variants in PCa patients .......................................... 37 
1.1.7.2  Somatic alterations in PCa ..................................................... 38 
  CRPC ............................................................................................ 39 
1.2  MicroRNA (miRNA) .............................................................................. 42 
  MiRNA biogenesis ......................................................................... 42 
  Deregulation of miRNAs in cancer ................................................ 44 
7 
 
  MiRNAs as biomarkers .................................................................. 44 
1.3  Exosomes ............................................................................................ 46 
  Biogenesis of exosomes ............................................................... 46 
  Exosome cargos ............................................................................ 47 
  Exosome isolation and detection ................................................... 48 
  Exosome function .......................................................................... 50 
  Clinical applications of exosomes in cancer .................................. 51 
1.3.5.1  Exosomes as biomarker ......................................................... 51 
1.3.5.2  Exosomes as drug delivery tools ............................................ 52 
1.3.5.3  Exosomes as cancer vaccine and immunotherapy ................. 53 
1.4  Circulating tumour cells (CTCs) ........................................................... 53 
  Origin ............................................................................................. 53 
  Isolation methods .......................................................................... 54 
  Clinical applications of CTCs ......................................................... 56 
  CTC culture ................................................................................... 57 
1.4.4.1  Short-term culture ................................................................... 57 
1.4.4.2  Long-term culture .................................................................... 58 
1.5  Other liquid biopsy ............................................................................... 59 
1.6  Aims ..................................................................................................... 61 
Chapter II  Materials and methods .................................................................. 63 
2.1  Cell lines .............................................................................................. 63 
2.2  Patient samples ................................................................................... 63 
2.3  Exosome isolation ................................................................................ 64 
  Exosome isolation from cell culture media .................................... 64 
  Exosome isolation from plasma .................................................... 64 
2.4  Nanoparticle tracking analysis ............................................................. 66 
8 
 
2.5  RNA extraction ..................................................................................... 66 
2.5.1.1  RNA extraction from plasma exosomes .................................. 66 
2.5.1.2  RNA extraction from cell line exosomes ................................. 67 
2.5.1.3  RNA extraction from cell lines ................................................. 68 
2.6  RNA detection assays .......................................................................... 68 
  Reverse transcription real-time quantitative polymerase chain 
reaction (RT-qPCR) ................................................................................... 68 
2.6.1.1  cDNA synthesis ...................................................................... 68 
2.6.1.2  RT-qPCR ................................................................................ 69 
  Fluidigm multiple RT-qPCR ........................................................... 70 
2.6.2.1  cDNA synthesis ...................................................................... 70 
2.6.2.2  Pre-amplification ..................................................................... 71 
2.6.2.3  Multiple RT-qPCR ................................................................... 74 
  RNA-sequencing ........................................................................... 74 
2.6.3.1  Exosome RNA-sequencing ..................................................... 74 
2.6.3.2  RNA-sequencing data analysis ............................................... 74 
2.7  Transient miR-423-3p over-expression ................................................ 75 
2.8  Cell viability assay ............................................................................... 75 
2.9  Cell migration assay ............................................................................. 76 
2.10  Cell invasion assay ........................................................................... 76 
2.11  WB .................................................................................................... 77 
  Protein extraction .......................................................................... 77 
  Bradford assay .............................................................................. 78 
  Sodium Dodecyl Sulphate-Polyacrylamide gel electrophoresis and 
Polyvinylidene difluoride (PVDF) membrane transfer ................................ 78 
  Antibody incubation and protein detection ..................................... 79 
2.12  CTC isolation .................................................................................... 80 
9 
 
  Ficoll centrifugation ....................................................................... 80 
  Parsortix™ .................................................................................... 81 
2.12.2.1  For CTC enumeration ............................................................ 81 
2.12.2.2  For CTC culture ..................................................................... 82 
  EasySep™ .................................................................................... 83 
  RossetteSep™ .............................................................................. 84 
2.13  CTC culture ...................................................................................... 84 
  Culture media ................................................................................ 84 
  Culture condition ........................................................................... 86 
2.14  Immunofluorescence staining ........................................................... 86 
2.15  Fluorescent in situ hybridisation (FISH) ............................................ 87 
2.16  Mouse engrafting and xenograft cells in vitro culture ........................ 88 
2.17  Metaphase spreads preparation ....................................................... 89 
2.18  Immunohistochemistry (IHC) staining ............................................... 90 
2.19  Statistical analysis ............................................................................ 91 
Chapter III  Identification of plasma exosomal miRNA profile in PCa and 
CRPC-associated miRNAs by RNA-sequencing ............................................... 92 
3.1  Introduction .......................................................................................... 92 
3.2  Results ................................................................................................. 93 
  Enrichment of exosomes ............................................................... 93 
  Analysis of exosomal miRNA by RNA-sequencing........................ 95 
  MiRNAs differential expression analysis ..................................... 101 
  Prediction value of exosomal miRNA for CRPC .......................... 102 
  In silicon analysis of published publically available plasma exosomal 
RNA-sequencing ...................................................................................... 104 
3.3  Discussion ......................................................................................... 107 
  Exosomal miRNA profiling ........................................................... 107 
10 
 
  Differentially expressed miRNAs between treatment-naive PCa and 
CRPC identified by RNA-sequencing ...................................................... 109 
Chapter IV  Identification of plasma exosomal miRNAs as biomarkers for 
CRPC…………………. .................................................................................... 111 
4.1  Introduction ........................................................................................ 111 
4.2  Results ............................................................................................... 112 
  Fluidigm validation of differentially expressed exosomal 
miRNAs……………. ................................................................................. 112 
  RT-qPCR confirmation of differentially expressed plasma exosomal 
miRNAs in treatment-naive PCa and CRPC patients .............................. 117 
  Independent validation of miR-423-3p in MCW centre ................ 121 
  RT-qPCR identified differentially expressed plasma exosomal 
miRNAs between treated non-CRPC and CRPC patients ....................... 123 
  Evaluation of plasma exosomal miRNAs as potential biomarkers for 
CRPC……………….. ............................................................................... 126 
  Association of exosomal miRNA expression with serum PSA 
level……………. ...................................................................................... 130 
  Technical investigation of the reason for inconsistence results 
between techniques used for plasma exosomal miRNA detection .......... 132 
4.3  Discussion ......................................................................................... 133 
  The potential prediction value of plasma exosomal miRNAs for 
CRPC………. ........................................................................................... 133 
  Different techniques influence evaluation of miRNA expression . 137 
  Validation of RNA-sequencing data by RT-qPCR ....................... 138 
Chapter V  Function of miR-423-3p for castration-resistance acquisition ...... 139 
5.1  Introduction ........................................................................................ 139 
5.2  Results ............................................................................................... 140 
  Overexpression of miR-423-3p did not affect LNCaP cell proliferation 
in hormone-depleted medium .................................................................. 140 
11 
 
  Overexpression of miR-423-3p leads to increased cell migration and 
invasion.................................................................................................... 142 
  MiR-423-3p expressed at higher level in the C4-2 cells and C4-2 
cells have better migration and invasion ability ........................................ 145 
  Investigation of potential MiR-423-3p targets .............................. 147 
  Technical development for functional evaluation of exosome 
miRNAs in vitro ........................................................................................ 150 
5.3  Discussion ......................................................................................... 154 
Chapter VI  In vitro propagation of PCa CTCs ............................................ 157 
6.1  Introduction ........................................................................................ 157 
6.2  Results ............................................................................................... 158 
  CTC enumeration using Parsortix ............................................... 158 
  Initial test of CTC culture from clinical samples ........................... 158 
  Test of CTC isolation methods and culture conditions ................ 162 
6.2.3.1  Test of CTC isolation methods .............................................. 162 
6.2.3.2  Test of culture media and conditions .................................... 164 
  CTC culture using Avatar system and Xcell liquid biopsy kit ....... 169 
  Immunofluorescence-staining and FISH analysis of cultured 
CTCs……….. ........................................................................................... 179 
  Xenografts of cultured CTCs ....................................................... 181 
6.3  Discussion ......................................................................................... 185 
  CTC isolation methods for CTC culture ....................................... 185 
  Culture media and conditions for CTC culture ............................. 186 
  In vitro culture of prostate CTCs .................................................. 188 
Chapter VII  Final discussion and future research ....................................... 192 
7.1  Final discussion ................................................................................. 192 
7.2  Future plans ....................................................................................... 197 
12 
 
  Further evaluation of plasma exosomal miRNAs as biomarkers . 197 
  Investigation of exosomal miRNAs function ................................ 199 
  Other plasma exosomal RNA in PCa .......................................... 200 
  CTC culture, molecular analysis and drug test ............................ 200 
References ..................................................................................................... 202 
Appendix 1. Clinical characteristics of patients for exosome study. ................ 231 








ADT androgen deprivation therapy 
AFMS anterior fibromuscular stroma  
AR androgen receptor  
AR-V7 androgen receptor splice variant 7  
AS active surveillance  
AUC area under the curve 
BPH benign prostatic hyperplasia  
cfDNA Cell-free DNA  
CI confidence interval 
CK cytokeratin 
CPM Counts per million  
CRPC Castration-resistant prostate cancer 
CTCs circulating tumour cells  
ctDNA circulating tumour DNA  
CZ central zone  
DAPI 4,6-diamidino-2-phenylindole dihydrochloride 
DEX dendritic cell-derived exosomes  
DHT 5α-dihydrotestosterone  
dNTP deoxy ribonucleotide triphosphate 
DPX Di-n-butyle phthalate in xylene 
14 
 
EpCAM epithelial cell adhesion molecule 
Evs extracellular vesicles  
FCS Foetal Calf Serum  
FDA Food and Drug Administration  
FFPE formalin-fixed, paraffin-embedded 
FISH fluorescence in situ hybridisation 
GS Gleason score 
GWAS genome-wide association studies  
HSPC hormone-sensitive prostate cancer 
IQR interquartile range 
ISUP International Society of Urological Pathology  
mCRPC metastatic castration-resistant prostate cancer 
miRNA microRNA 
mRNA messenger RNA 
MVBs multivesicular bodies 
NaCl Sodium chloride 
NSCLC non-small-cell lung cancer  
PBMCs peripheral blood mononuclear cells  
PBS phosphate buffered saline  
PCa prostate cancer 
pre-miRNA precursor microRNA  
15 
 
pri-miRNA primary microRNA 
PSA prostate-specific antigen  
PSMA Prostate-specific membrane antigen  
PTEN phosphatase and tensin homolog 
PZ peripheral zone  
RT-qPCR reverse transcriptase real-time quantitative polymerase chain reaction
ROC Receiver operating characteristic  
RPM read counts per million mapped reads  
RT room temperature 
SNPs single-nucleotide polymorphisms  
TBST Tris Buffer Saline/0.1% Tween-20 
TEPs tumour-educated platelets 
TMM trimmed mean of M-value normalisation  
TNM Tumour-Node-Metastasis 
TZ transitional zone  
Vim Vimentin 
V volt 
WB Western-blotting  





List of figures 
Figure 1. Location of human prostate gland. (Adapted from 
https://www.hopkinsmedicine.org/healthlibrary/conditions/prostate_health/anato
my_of_the_prostate_gland_85,P01257) ........................................................... 27 
Figure 2. Zones of the prostate. (Adopted from http://www.cancer.ca/en/cancer-
information/cancer-type/prostate/prostate-cancer/the-prostate/?region=on) ..... 28 
Figure 3. Differentiated cell types in the prostate. [4] ........................................ 28 
Figure 4. MiRNA biogenesis process in human. Adopted from [119]. ............... 43 
Figure 5. Exosome biogenesis and release process. (Adopted from Borges, F. T., 
2013 [51]) .......................................................................................................... 47 
Figure 6. Parsortix system overview and cassette design. ............................... 82 
Figure 7. Illustration of EasySep work flow for CTC enrichment. ...................... 83 
Figure 8. Illustration of RossetteSep work flow for CTC enrichment. ................ 84 
Figure 9. Nanoparticle tracking analysis of exosomes isolated from plasma of 
PCa patients using the Total Exosome Isolation Kit (from plasma) (Invitrogen). A. 
Exosomes from BCI150, mean size=122 nm, mode size=32 nm, 
concentration=5.47×108 particles/ml; B. Exosomes from BCI025, mean size=73 
nm, mode size=28 nm, concentration=19.51×108 particles/ml; C. Exosomes from 
BCI158, mean size=69 nm, mode size=28 nm, concentration=13.96×108 
particles/ml. X-axis: size (nm), Y-axis: Concentration (106 particles/ml) ............ 94 
Figure 10. Nanoparticle tracking analysis of exosomes and EVs isolated from 
plasma of BCI150 with ExoEasy kit (Qiagen). Mean size=188nm, mode 
size=56nm, concentration= 0.99×108 particles/ml. X-axis: size (nm), Y-axis: 
Concentration (106 particles/ml). ....................................................................... 95 
Figure 11. Representative Bioanalyzer results of exosomal RNA. .................... 97 
Figure 12. ROC curves analyses of PSA and miRNAs which showed significant 
difference between treatment-naive PCa and CRPC in all three RNA-sequencing 
analyses. This ROC curves analyses of miRNAs were performed using the count-
per-million values from RNA-sequencing data. Large under the curve area 
indicates good prediction value with high sensitivity and high specificity. ....... 103 
17 
 
Figure 13. ROC analysis of Fluidigm data of plasma exosomal miRNAs and PSA 
for prediction of CRPC from treatment-naive PCa. Large under the curve area 
indicates good prediction value with high sensitivity and high specificity. ....... 115 
Figure 14. RT-qPCR evaluation of plasma exosomal miRNAs in treatment-naive 
PCa and CRPC. A. MiRNAs identified by three RNA-sequencing analyses; B. 
MiRNAs identified by two RNA-sequencing analyses. .................................... 120 
Figure 15. RT-qPCR evaluation of plasma exosomal miRNAs in treatment-naive 
PCa and CRPC which were identified by one RNA-sequencing analysis. ...... 121 
Figure 16. RT-qPCR evaluation of miR-423-3p for its CRPC prediction value in a 
MCW cohort. A. Scatter plots of plasma exosomal miR-423-3p expression levels; 
significance is defined by raw p-value (*p< 0.05); B. ROC analysis of the 
efficiencies of miR-423-3p (AUC= 0.679, p= 0.017), serum PSA (AUC = 0.716, 
p= 0.0044) and the combination model of PSA and miR-423-3p (AUC = 0.729, p 
= 0.0026) in discriminating CRPC from treatment-naive PCa. Large under the 
curve area indicates good prediction value with high sensitivity and high 
specificity. ....................................................................................................... 122 
Figure 17. RT-qPCR evaluation of plasma exosomal miRNAs in treatment-naive 
PCa, non-CRPC and CRPC. ........................................................................... 124 
Figure 18. RT-qPCR evaluation of plasma exosomal miRNAs which showed no 
difference in treatment-naive PCa and CRPC................................................. 125 
Figure 19. ROC analyses of exosomal miRNAs for prediction of CRPC from 
treatment-naive PCa using RT-qPCR data. A. MiRNAs showed significant 
different expression between CRPC and treatment-naive PCa; B. MiR-423-3p, 
PSA and miR-423-3p combine PSA. Large under the curve area indicates good 
prediction value with high sensitivity and high specificity. ............................... 127 
Figure 20. ROC analysis of exosomal miRNAs for prediction of CRPC from non-
CRPC using RT-qPCR data. A. MiRNAs showed significant different expression 
between CRPC and treatment-naive PCa also showed significant different 
expression between CRPC and treated non-CRPC; B. MiRNAs showed 
significant different expression only between CRPC and non-CRPC. Large under 




Figure 21. Correlations of expression levels of plasma exosomal miRNAs with 
PSA. ................................................................................................................ 131 
Figure 22. Correlation of Cts of let7b-3p from Fluidigm and RT-qPCR using pre-
amplified and non-amplified cDNA. ................................................................. 133 
Figure 23. Correlation of Cts of miR-320b using cDNA sythesized with HiFlex 
buffer and HiSpec buffer. ................................................................................ 133 
Figure 24. Transient overexpression of miR-423-3p in LNCaP cells. MiR-423-3p 
level was measured at different time points after transfection. NC, negative 
control. Expression of miR-423-3p was normalised to U6. ............................. 141 
Figure 25. The effect of miR-423-3p overexpression of LNCaP cell proliferation. 
Cell viability measured by MTS assay at 96 h post transfection showed that the 
proliferation of LNCaP cells transfected with miR-423-3p mimics and negative 
control (NC) were not different. Relative cell viability was normalised to NC. Data 
were obtained from three experiments and triplicate wells were used in each 
experiment. ..................................................................................................... 141 
Figure 26. Overexpression of miR-423-3p leads to increased LNCaP cell 
migration in hormone-depleted medium. A.  Transwell migration assay showed 
1.5 fold increased cell migration in LNCaP transfected with miR-423-3p mimics 
compared to negative control (NC); B. Representative images of transwell 
membranes to show increased cell number in LNCaP transfected with miR-423-
3p mimics compared to NC; C. Morphology difference was observed between 
LNCaP cells overexpressing miR-423-3p and LNCaP cells transfected with 
negative control, that LNCaP cells overexpressing miR-423-3p had more 
stretched morphology. Cells were incubated for 24 h to migrate. Photos were 
taken using Hamamatsu NanoZoomer S210 system under 200× magnification. 
Data were obtained from three experiments and triplicate wells were used in each 
experiment. Relative migration was normalised to NC. *p<0.05. .................... 143 
Figure 27. Overexpression of miR-423-3p leads to increased LNCaP cell invasion 
in hormone-depleted medium. A. Single cell invasion assay showed increased 
cell invasion (1.6 fold) in LNCaP transfected with miR-423-3p mimics compared 
to negative control (NC); data were obtained from three experiments and triplicate 
wells were used in each experiment; *p<0.05. B. Representative images of single 
19 
 
cell invasion assay showing increased invading cells (arrow) after LNCaP cell 
overexpressing miR-423-3p.  Cells were incubated for 24 h to invade. Photos 
were taken under 400× magnification. ............................................................ 144 
Figure 28. Expression level of miR-423-3p in LNCaP and C4-2 cells evaluated by 
RT-qPCR showed C4-2 cells have 1.6 fold higher expression of miR-423-3p than 
LNCaP cells. Expression of miR-423-3p was normalised to U6. *p <0.05 ...... 145 
Figure 29. C4-2 cells have better migration and invasion ability compared to 
LNCaP cells in hormone-depleted medium. A. Transwell migration assay showed 
better migration ability of C4-2 (3.8 folds) compared to LNCaP; B. Representative 
images of transwell membranes to show better migration ability of C4-2 compared 
to LNCaP cells; C. Matrigel invasion chamber assay showed better invasion 
ability of C4-2 (3.7 folds) compared to LNCaP cells; D. Representative images of 
Matrigel invasion chamber membranes, showing C4-2 has more cells invaded 
than LNCaP. Data were obtained from three experiments and triplicate wells were 
used in each experiment. Cells were incubated for 24 h to migrate/invade. Photos 
were taken using Hamamatsu NanoZoomer S210 system under 200× 
magnification. ***p<0.001. ............................................................................... 146 
Figure 30. Images of two WB showing that overexpression of miR-423-3p slightly 
down-regulated MEIS1 protein expression in LNCaP cells in hormone-depleted 
medium. Band density was measured using ImageJ. The relative expression of 
MEIS1 in each sample is firstly normalised to β-actin and expression in cells 
transfected with miR-423-3p mimic was further normalised to negative control 
(NC). ............................................................................................................... 150 
Figure 31. Nanosight nanoparticle tracking analysis of exosomes isolated from 
cell culture media by ultracentrifugation. A. Exosome isolated from PC3 cell 
culture media, with mean size=71 nm, mode size=35 nm, 
concentration=13.81×108 particles per ml; B. Exosome isolated from DU145 cell 
culture media, with mean size=52 nm, mode size=32 nm, concentration=9.3×108 
particles per ml. X-axis: size (nm), Y-axis: Concentration (106 particles/ml). ... 152 
Figure 32. WB detection of ALIX in exosomes from DU145 and PC3 cells. Both 
bands are ALIX. .............................................................................................. 153 
20 
 
Figure 33. Bioanalyzer evaluation of RNA extracted from PC3 cell exosomes. 
MiRNAs are < 40 nt and the peak at 60 nt represents tRNAs. ........................ 154 
Figure 34. Representative immunofluorescence images for different types of cells 
in PCa patients. A. A representative CK+Vim-CD45- cell (arrow); B. A 
representative CK-Vim+CD45- cell (arrow); C. Two representative cells with 
CK+Vim+CD45- (arrow). Photos were taken using Ariol under 200× magnification. 
Part of this image has been published [339]. .................................................. 158 
Figure 35. Illustration of three cell culture conditions for initial test of CTC culture 
from clinical samples. ...................................................................................... 159 
Figure 36. Image of VCaP cells harvested from different CTC isolation methods 
and cultured in four different conditions. No image shown for VCaP cells 
harvested from Parsortix as the cells were contaminated. White arrows indicate 
spheres; Black arrows indicate single cells. Photos were taken uder 40× 
magnification. .................................................................................................. 163 
Figure 37. Image of PC3 cells harvested from three different CTC isolation 
methods and cultured in four different conditions. Photos were taken uder 40× 
magnification. .................................................................................................. 164 
Figure 38. VCaP cells cultured in different media and conditions. Three replicates 
were done for each condition. White arrows indicate colonies; yellow arrows 
indicate single cells. White arrows indicate spheres; yellow arrows indicate single 
cells. Photos were taken uder 40× magnification. ........................................... 165 
Figure 39. Test of different culture media and conditions using DU145 cells. A. 
Cells grown in normal plates; B. Cells grown in low-attachment plates; C. Cells 
grown in Matrigel-coated plates. Three replicates were done for each condition. 
Photos were taken uder 40× magnification. .................................................... 167 
Figure 40. Test of different culture media and conditions using 22Rv1 cells. A. 
Cells grown in normal plates; B. Cells grown in low-attachment plates; C. Cells 
grown in Matrigel-coated plates. Three replicates were done for each condition. 
Photos were taken uder 40× magnification. .................................................... 168 
Figure 41. The rotary cell culture system. ....................................................... 169 
21 
 
Figure 42. Cells from BCI255 isolated by Ficoll-Easysep and cultured in RPMI-
1640 in Avatar system at day 4. Photos were taken uder 100× magnification.
 ........................................................................................................................ 170 
Figure 43. Representative images of cultured CTCs in XCR 6-well plate with 
different morphologies. A. Culture cells from BCI263 at day 14; B. Cultured cells 
from BCI125 at day 18; C. Cultured cells from BCI267 at day 25. Photos were 
taken uder 100× magnification. ....................................................................... 177 
Figure 44. Representative image of culture CTCs in XCR 6-well plates and 
Matrigel-coated plates. A. BCI267 cells cultured in XCR 6-well plate at day 25; B. 
BCI267 cells cultured in Matrigel-coated plate at day 28; C. BCI174 cells cultured 
in XCR 6-well plate; D. BCI174 cells cultured in Matrigel-coated plate at day 28. 
Photos were taken uder 100× magnification. .................................................. 178 
Figure 45. Immunoflorescence-staning of cultued CTCs from BCI267 that 
dropped on slide. Photos were taken using Ariol under 200× magnification. Blue: 
DAPI; Yellow: Vimentin; Green: CK, Red: CD45. ............................................ 179 
Figure 46. Immunoflorescence-staining of cultured CTCs from  BCI278 that 
grown on slide. A big multi-nucleus cell is indicated by arrow. Photos were taken 
using Ariol under 200× magnification. Blue: DAPI; Yellow: Vimentin; Green: CK, 
Red: CD45. ..................................................................................................... 180 
Figure 47. FISH images (left) and corresponded immunofluorescence-staining 
(right) of cultured CTC cells from BCI267. A. White arrow indicates a cell with AR 
gain; B. Two cells with PTEN loss. Immunofluorescence-staining images were 
taken using Ariol under 200× magnification and FISH images were taken using 
Ariol under 400× magnification. ...................................................................... 181 
Figure 48. Immunofluorescence staining of NIH/3T3 cells and mixed population 
of cultured CTCs. Immunofluorescence-staining images were taken using Ariol 
under 200× magnification. ............................................................................... 182 
Figure 49. Nude mouse engrafted with cultured CTCs in the flank formed tumour 
(red circle) after 11 weeks. .............................................................................. 182 
Figure 50. In vitro culture of cells from CTC xenograft. A. Cells climbed out of 
tissue clump; B. Some cells attached in the shredded tissue culture. Photos were 
taken under 40× magnification. ....................................................................... 183 
22 
 
Figure 51. Metaphase spread analysis of cultured cells from CTC xenograft. The 
cells presented two karyotypes with 61 chromosomes (A) and 125 chromosomes 
(B). Red circles label metacentric chromosomes. Images were taken under 400× 
magnification. .................................................................................................. 184 
Figure 52. Detection of AR expression in FFPE sections by IHC. A. Human BPH 
section as positive control where AR present nuclear stain; B. CTC-derived 
xenograft tissue section where AR present cytoplasmic stain; C. Human BPH 
section without primary antibody. Images were taken under 200× magnification.
 ........................................................................................................................ 184 
Figure 53. Detection of PSA expression in FFPE sections by IHC. A. Human BPH 
section as positive control; B. CTC-derived xenograft tissue section; C. Human 







List of tables 
Table 1. International Society of Urological Pathology (ISUP) 2014 grades. 
Adapted from [27]. ............................................................................................ 32 
Table 2. Definitions of American Joint Committee on cancer TNM criteria. 
(Adapted from [34]). .......................................................................................... 34 
Table 3. Risk stratification for biochemical recurrence of localised and locally 
advanced PCa. Adapted from [23] .................................................................... 35 
Table 4. Reverse-transcription reaction components for cDNA preparation for RT-
qPCR. ............................................................................................................... 69 
Table 5. RT-qPCR reaction components. ......................................................... 69 
Table 6. Cycling conditions for RT-qPCR. ........................................................ 70 
Table 7. Reverse-transcription reaction components for cDNA preparation for 
Fluidigm. ........................................................................................................... 71 
Table 8. List of primer assays used in Fluidigm multiple RT-qPCR. ................. 71 
Table 9. Pre-amplification reaction components for Fluidigm sample preparation.
 .......................................................................................................................... 73 
Table 10. Cycling conditions for pre-amplification for Fluidigm sample preparation.
 .......................................................................................................................... 73 
Table 11. Cell lysis buffer for protein extraction. ............................................... 77 
Table 12. Sodium Dodecyl Sulphate-polyacrylamide gel preparation. .............. 78 
Table 13. Antibodies and dilutions used for Western-blotting. .......................... 79 
Table 14. Supplements in organoid culture medium. ........................................ 85 
Table 15. Antibodies and dilution used in immunofluorescence staining. ......... 87 
Table 16. Primary antibodies used for IHC and their dilutions. ......................... 91 
Table 17. Summary of clinical characteristics of patients in the RNA-sequencing.
 .......................................................................................................................... 96 
Table 18. Plasma exosomal miRNAs expressed in all RNA-sequencing samples/ 
all treatment-naive PCa samples/ all CRPC samples. ...................................... 99 
24 
 
Table 19. The top ten most abundant miRNAs in plasma exosomes from RNA-
sequencing. .................................................................................................... 100 
Table 20. Significantly differentially expressed plasma exosomal miRNAs with 
p<0.01 between treatment-naive PCa and CRPC identified by RNA-sequencing.
 ........................................................................................................................ 101 
Table 21. AUCs and p-values from ROC curves analysis results of PSA level and 
miRNAs which showed significant difference between treatment-naive PCa and 
CRPC in all three RNA-sequencing analyses for CRPC prediction. ............... 103 
Table 22. Top ten most abundant miRNAs in plasma exosomes in data from 
Huang et al. [346]. ........................................................................................... 104 
Table 23. Top ten differentially expressed miRNAs in plasma exosomes between 
healthy individuals and hormone-sensitive PCa patients in data from Huang et al. 
[346]. ............................................................................................................... 106 
Table 24. Top ten most significantly differentially expressed miRNAs in plasma 
exosomes between hormone-sensitive PCa and CRPC patients in data from 
Huang et al. [346] ............................................................................................ 107 
Table 25. Summary of clinical characteristics of patients in the Fluidigm validation 
cohort. ............................................................................................................. 112 
Table 26. List of plasma exosomal miRNAs and their p-values/ corrected p-values 
evaluetd using Fluidigm. ................................................................................. 113 
Table 27. ROC curves to predict CRPC from treatment by Fluidigm data of 
plasma exosomal miRNAs and PSA level. ..................................................... 115 
Table 28. Summary of significantly differentially (adjusted p-value <0.01) 
expressed plasma exosomal miRNAs between treatment-naive PCa and CRPC 
identified by Fluidigm and their expression patterns in RNA-sequencing*. ..... 116 
Table 29. Summary of clinical characteristics of patients in the RT-qPCR 
validation cohort. ............................................................................................. 118 
Table 30. Summary of clinical characteristics of patients in the MCW centre 
validation cohort. ............................................................................................. 121 
25 
 
Table 31. ROC curves to predict CRPC from treatment-naive PCa by exosomal 
miRNAs and PSA level. .................................................................................. 128 
Table 32. ROC curves to predict CRPC from non-CRPC by plasma exosomal 
miRNAs and PSA level. .................................................................................. 129 
Table 33. Predicted targets of miR-423-3p with conserved sites in TargetScan 
7.1*. ................................................................................................................ 148 
Table 34. Summary of CTC culture using blood samples from prostate cancer 
patients. .......................................................................................................... 161 
Table 35. Summary of samples used for CTC culture with RPMI-1640 in Avatar 
system and the CTC counts. ........................................................................... 171 
Table 36. Summary of samples used for CTC culture using Avatar system and 




Chapter I  Introduction and aims 
1.1 Prostate cancer (PCa) 
 Prostate anatomy and physiology 
The prostate is a tubuloalveolar exocrine gland of the male reproductive system. 
It is located between the bladder and the penis and is situated in front of the 
rectum, with the urethra running through its centre (Figure 1). There is a widely 
accepted anatomical model of the prostate established by McNeal in the early 
1980s. This model describes the prostate as a gland consisting of three zones, 
namely, the central zone (CZ), the transitional zone (TZ), the peripheral zone (PZ), 
and a fibromuscular band of tissue named anterior fibromuscular stroma (AFMS) 
(Figure 2) [1]. The PZ is the largest area of the prostate, constituting about 70% 
of the glandular prostate. Most PCas start in the PZ. The TZ surrounds the part 
of the urethra which passes through the prostate (called the prostatic urethra), 
representing only 5% of the gland. The volume of the TZ increases with age and 
it is the primary site of benign prostatic hyperplasia (BPH). The CZ lies behind 
the TZ and surrounds the ejaculatory ducts, occupying approximately 25% of the 
glandular prostate. Very few PCas start in the CZ. The AFMS is a thickened area 
of tissue that surrounds the apex of the prostate. It is predominantly fibromuscular 
with little or no glandular structures [2, 3]. 
Adult prostate is composed of two compartments, the stroma and the epithelium. 
The epithelia include basal cells, secretory luminal cells, and rare intermediate 
and neuroendocrine cell populations. The epithelial ducts are adjacent to a 
stromal compartment that includes smooth muscle cells, fibroblasts, and vascular 
and neural components (Figure 3) [4]. The main function of the prostate is to 
secret prostatic fluid which constitutes approximately one-fifth to one-third of the 
volume of the entire ejaculate. The prostate epithelial compartment provides the 
main glandular function to secrete the prostatic fluid. Prostatic fluid contains a 
number of factors that control the ejaculation process and regulate proteins (from 
the other accessory gland secretions) that activate sperm maturation. These 
factors in prostatic fluid are necessary for semen liquefaction, the clotting cycle 
and sperm motility [3]. 
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Androgen plays a pivotal role in prostate development and homeostatic 
maintenance. Testosterone is the principal circulating androgen in males. 
Approximately 90% of testosterone is from the testis and 10% from the adrenals. 
Within the prostate, testosterone is converted to 5α-dihydrotestosterone (DHT) 
by the 5α-reductase enzyme. The androgen receptor (AR) which presents in 
almost all prostate cells can bind both testosterone and DHT, though it has 
greater affinity for DHT. The androgen-AR complex then enters the nucleus and 
stimulates transcription of AR-regulated genes via binding to androgen 
responsive elements [5, 6]. 
 











Figure 3. Differentiated cell types in the prostate. [4] 
 
 PCa incidence, mortality and survival 
There was an estimate of 1,276,106 new cases and 358,989 deaths of PCa 
worldwide in 2018. PCa is the most frequently diagnosed cancer in male in 105 
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countries in a 185-country statistic. Globally, PCa is the second mostly diagnosed 
male cancer [7]. There are wide geographic variations of PCa incidence rate, as 
the highest incidence rate (in Australia/New Zealand) is around 17-fold higher 
than the lowest (in South Central Asia) [7]. In males in the United Kingdom (UK), 
PCa is the most common cancer, with around 47,200 new cases in 2015. PCa 
European age-standardised incidence rates have increased by 44% in the UK 
between 1993-1995 and 2013-2015. The incidence rates are projected to further 
rise by 12% in the UK between 2014 and 2035 [8]. This can be attributed to the 
practice of prostate-specific antigen (PSA) testing. 
PCa is estimated as the fifth leading cause of cancer death in men worldwide, 
however the mortality rates also have geographical variations and they do not 
follow the variations of incidence [7]. In the UK, PCa is the second leading cause 
of cancer death in males [9]. The highest PCa mortality rates are among 
populations in the Caribbean and Southern Africa and the lowest PCa mortality 
rates are observed in South-central Asia [7]. 
Although PCa has high incidence rate, the survival is generally good. Age and 
the stage of the PCa at diagnosis have great effect on the survival. Five year 
survival gradually increases from 91% in men aged 15-49 and peaks at 94% in 
60-69 year olds diagnosed with PCa. The survival falls thereafter, reaching its 
lowest point of 66% in 80-99 year olds patients diagnosed with PCa in England 
during 2009-2013 [10]. In cases where the cancer is localised or locally advanced 
at diagnosis, five year survival rate is almost 100%. However, for distant 
metastatic disease, five year survival rate is approximately 30% [10, 11].  
 
 Risk factors 
Age, family history and race/ethnicity are the established risk factors for PCa. The 
risk of developing PCa increases with age, as PCa is rarely found in men younger 
than 40, but the risk increases significantly after the age of 50. A positive 
relationship between family history of PCa and PCa risk has been observed in 
many studies. Three systematic reviews and meta-analysis published in 2003 
have shown consistent results that men with affected relative have greater risk of 
PCa [12-14]. The relative risk increases with decreasing age of the affected family 
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members at diagnosis, with increasing genetic relatedness of the affected 
relatives, and with increasing number of individuals affected [12-14]. Ethnicity is 
another main risk factor for PCa. In the United States (US), non-Hispanic black 
men have higher PCa incidence and mortality compared to men of other ethics 
[15]. In addition to age, family history, and race/ethnicity, there are also other risk 
factors reported, such as genetic factors, diet and obesity [16]. 
 
 PSA test 
PSA is a serine protease which is mainly responsible for gel dissolution in freshly 
ejaculated semen by proteolysis of the major gel-forming proteins, semenogelin 
I, semenogelin II and fibronectin. PSA is secreted by prostate epithelia. In normal 
males, PSA presents in the blood at very low concentration. Serum PSA level 
can elevate at the presence of PCa and other prostate diseases such as chronic 
inflammation and BPH, which is believed to result from the disruption of prostate 
architecture [17]. The PSA test is now routinely used for the diagnosis and 
monitoring of PCa, as well as PCa response to treatment.  
In early 1990s,  PSA screening was recommended for routine annual PCa 
screening in the US [18]. However, accumulating evidence raised concerns of 
PSA screening over the false-negative and false-positive issues and potential 
over-diagnosis and over-treatment. Two major screening trials, European 
Randomized Study of Screening for Prostate Cancer [19] and Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening trial [20], published cancer survival 
data in 2009. The European Randomized Study of Screening for Prostate Cancer 
reported a modest PCa survival benefit with screening and a later follow up 
showed similar results [21], whereas the Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening trial found no benefit of screening. Recent publication from the 
Cluster Randomized Trial of PSA Testing for Prostate Cancer in UK reported 
there was no significant difference in PCa mortality after a median follow-up of 10 
years among practices randomised to a single PSA screening intervention 
compared to standard practice without screening, but the detection of low-risk 
PCa cases increased [22]. As data suggested more harm than benefit of PSA 
screening, current guidelines are against population-based screening of PSA and 
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propose individualised strategy and informed decision making for men to do the 
test [23]. 
Monitoring of PSA after definitive local therapy for PCa provides a mean of 
detecting recurrent PCa long before the tumour is detectable by any other means 
(for example, imaging or symptoms). This monitoring of PSA after treatment of 
localised PCa leads to the identification of men with a PSA-only (biochemical) 
recurrence, but the prognosis of men with PCa following a PSA relapse is diverse 
[24]. PSA is also used to monitor disease progression in patients undergoing 
androgen-deprivation therapy (ADT). However, PSA alone is not reliable enough 
for monitoring disease activity in advanced castration-resistant PCa (CRPC) as 
visceral metastases may develop in men without rising PSA [25]. Thus 
radiological tests are normally done to confirm the disease progression and 
facilitate clinical decisions. 
 
 Grading and staging of prostate adenocarcinoma 
The grading system that is used for determining PCa aggressiveness is Gleason 
score (GS). In 1966, Dr. Donald Gleason created the grading system, which 
grades the different histologic patterns from 1 to 5, where a lower grade indicates 
well-differentiated glandular pattern.  A GS contains two grades from the two most 
common grade patterns in a tumour, thus a GS scores range from 2 to 10 after 
added up the two grades. After that, the PCa grading system had undergone two 
major revisions in 2005 and 2014. In 2005, the International Society of Urological 
Pathology (ISUP) modified GS of biopsy-detected PCa comprising the GS of the 
most extensive pattern (primary pattern), plus the second most common pattern 
(secondary pattern). If only one pattern is present, it needs to be doubled to yield 
the GS. In cases with three or more grade patterns, the GS should comprise the 
most common grade plus the highest grade, irrespective of its extent. When a 
carcinoma is largely grade 4/5, identification of < 5% of grade 2 or 3 glands should 
not be incorporated in the GS. A GS < 4 should not be given based on prostate 
biopsies [26]. In 2014, ISUP consensus conference agreed upon a 5-tier ISUP 
grading system (Table 1), as grade 1 tumours being GS ≤6, grade 2 being GS 
3+4, grade 3 being GS 4+3, grade 4 being GS 8, and grade 5 being GS 9 to 10 
[27]. This new system eliminated the anomaly that the most highly differentiated 
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PCa have a GS 6 and further defined the clinically highly significant distinction 
between GS 7 (3 + 4) and 7 (4 + 3) PCa.  
GS has been the single most powerful predictor of PCa prognosis, as higher GS 
correlates with poorer prognosis. Studies have grouped GS scores based on the 
assumption that patients diagnosed with these GSs have a similar prognosis, for 
example the most commonly used grouping is 2-6, 7, and 8-10 [28]. Although GS 
7 has initially considered as a single score, later studies have found that 4+3 has 
significantly worse prognosis than 3+4 [29, 30]. GS 9 and 10 also showed 
significantly worse outcomes compared with GS 8 disease [31]. Thus, current 
ISUP grades has listed GS 3+4 and 4+3 as single grades and separated GS 8 
and GS 9-10. Recent studies showed the new five-grade group system had great 
prognostic discrimination for biochemical recurrence [32, 33]. 
 
Table 1. International Society of Urological Pathology (ISUP) 2014 grades. 
Adapted from [27]. 




8 (4+4 or 3+5 or 5+3) 4 
9-10 5 
 
Staging describes where the cancer is located, whether it has spread and where 
it has spread, and whether it has metastasis to other parts of the body. There are 
two types of staging for PCa, clinical staging and pathologic staging. The clinical 
staging is based on the results of digital rectum examination, lab tests, prostate 
biopsy, and imaging tests which are available prior to treatment or the surgical 
removal of the tumour. Pathologic staging is based on information gathered 
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during an examination of prostate tissue removed during radical prostatectomy 
and pelvic lymph nodes if pelvic lymph node dissection is performed. Staging is 
important to estimate prognosis and guide treatment decision making. Tumour-
Node-Metastasis (TNM) classification system is the most widely used staging 
system for PCa. The American Joint Committee on Cancer published the first 
edition of the Cancer Staging Manual in 1977. Since then, they have published 
several editions. The recently updated edition was published in 2017 and has 




Table 2. Definitions of American Joint Committee on cancer TNM criteria. 




TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour that is not palpable 
T1a Tumour incidental histologic finding in 5% or less of 
tissue resected
T1b Tumour incidental histologic finding in more than 
5% of tissue resected
T1c Tumour identified by needle biopsy found in one or 
both sides, but not palpable
T2 Tumour is palpable and confined within prostate 
T2a Tumour involves one-half of one side or less 
T2b Tumour involves more than one-half of one side but 
not both sides
T2c Tumour involves both sides 
T3 Extraprostatic tumour that is not fixed or does not 
invade adjacent structures
T3a Extraprostatic extension (unilateral or bilateral) 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures 
other than seminal vesicles, such as external 





T2 Organ confined 
T3 Extraprostatic extension 
T3a Extraprostatic extension (unilateral or bilateral) or 
microscopic invasion of bladder neck 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures 
other than seminal vesicles, such as external 




NX Regional lymph nodes were not assessed 
N0 No positive regional lymph nodes 
N1 Metastases in regional lymph node(s) 
M 
category 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 




 Treatments for PCa 
A risk classification system is used to assist offering appropriate treatment to 
patients diagnosed with PCa. Current clinical guidelines for PCa diagnosis and 
management published by the National Institute for Health and Clinical 
Excellence (https://www.nice.org.uk/guidance/ng131) and the European 
Association of Urology [23] categorise localised PCa to low, intermediate and 
high risk groups (Table 3) based on the risk of biochemical recurrence after 
surgery or external beam radiotherapy.  
 
Table 3. Risk stratification for biochemical recurrence of localised and locally 
advanced PCa. Adapted from [23] 
Low-risk Intermediate-risk High-risk 
PSA<10 ng/mL 
and GS<7(ISUP 
grade 1) and cT1-
2a 
PSA 10-20 ng/mL or 
GS 7(ISUP grade 
2/3) or cT2 
PSA >20 
ng/mL or GS > 
7(ISUP grade 
4/5) or cT2c 
any PSA any 
GS any ISUP  
cT3-4 or cN+ 
Localised Locally advanced 
 
1.1.6.1 Treatments for localised PCa 
After diagnosis of localised PCa, there can be several options for patients, 
including active surveillance (AS), watchful waiting (WW) and several radical 
treatments. Radical prostatectomy is a surgery process which removes prostate 
cancer. It remains the most effective treatment and shows benefit over WW and 
AS [35-37]. However, as PCa often grows very slowly, some patients may not 
need active treatment and treatments will cause side effects and may affect the 
quality of life. AS, which conducts a routine protocol of close monitoring with 
digital rectal examination, periodic biopsy, and serial PSA testing and 
consultations, is often used as a mean to monitor the cancer more closely in low-
risk patients who do not need active treatments [23]. A study with ten years of 
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follow up showed the similar cancer specific survival and overall survival (OS) 
between patients who were actively treated and on AS. However metastatic 
progression was higher in AS group (6% in the AS group as compared to 2.6% 
in the treated group) [35]. Although the metastatic progression risk needs to be 
considered, this study suggests that AS is as effective as active treatment at ten 
years, avoided unnecessary treatment for most patients. WW can be 
recommended to elderly patients with limited expectancy with no symptoms of 
PCa. WW normally has less tests than AS and relies on the changes of symptoms 
and of re-biopsy results to decide if treatment is needed [23]. 
 
1.1.6.2 Treatments for locally advanced PCa 
Locally advanced PCa has extended clinically beyond the prostatic capsule, with 
invasion of the pericapsular tissue, bladder neck, or seminal vesicles, but without 
lymph node involvement or distant metastases. Treatment options for patients 
with locally advanced PCa include external beam radiotherapy with ADT (and 
sometimes with high dose-rate brachytherapy), radical prostatectomy (often 
followed by ADT and radiotherapy), ADT alone and WW [23]. There are different 
types of ADT which aim at reducing the effect of androgen. The main types of 
ADT include surgical castration which removes testicles, luteinizing hormone-
releasing hormone agonists (e.g. Goserelin) and antagonists (e.g. degarelix) 
which lower the amount of androgen, anti-androgens (e.g. Flutamide, 
Enzalutamide, and Bicalutamide) which compete with androgen to reduce the 
binding of androgen to AR, and CYP17 inhibitor (e.g. Abiraterone) which blocks 
androgen formation[38].  
 
1.1.6.3 Treatments for metastatic/ recurrent/ progressive diseases 
As prostate epithelial cells and almost all PCa cells rely on androgen to grow, 
ADT is an efficient therapy for PCa. While in the case of local recurrence or local 
progression after radical treatment, consideration should be given to cancer re-
staging and treating with further local radical therapy (radiotherapy or surgery), 
while ADT is the standard care for metastatic disease [39]. In recent years, three 
large clinical trials were conducted comparing ADT alone as the standard of care 
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to ADT combined with chemotherapy (docetaxel) in metastatic PCa patients 
within three months of ADT initiation [40-42]. In all three trials, ADT combined 
with docetaxel showed better OS. Based on these findings, docetaxel combined 
with ADT are now being considered as a new standard in men presenting with 
metastases at first presentation, providing they are fit enough to receive the drug 
[39]. 
ADT is initially effective in most patients, however, resistance inevitably arises. 
CRPC refers to a progressed disease, with evidence of either radiologic or 
biochemical progression, in the presence of castration level of circulating 
testosterone (< 50ng/dl) [43]. Of note, CRPC is not fully hormone refractory, as 
other forms of ADT as second line hormone therapies can be effective in CRPC 
[44]. 
CRPC is an incurable stage of PCa and the majority of patients have developed 
metastases with poor prognosis [45]. Treatment for CRPC was very limited with 
minimal survival benefits before the discovery of docetaxel. Two landmark phase 
III trials demonstrated better OS and improvement of pain in metastatic CRPC 
(mCRPC) patients treated with docetaxel [46, 47]. Docetaxel was then approval 
by the US Food and Drug Administration (FDA) in 2004 as a first-line 
chemotherapy agent and it has been a mainstay of therapy for patients with 
mCRPC. Currently, there are a few therapeutic options available for patients with 
mCRPC, for example ADT including abiraterone [48] and enzalutamide [49], 
immunotherapy sipuleucel-T which uses activated patient-derived antigen-
presenting cells as an immune modulator or vaccine [50], and alpha emitter Ra 
223 [51]. Many CPRC patients have benefited from these treatments with 
prolonged survival. However, not all patients respond well to the given therapy. 
For example, only approximately 50% of patients respond to first-line docetaxel 
[46, 47].  
 
 Molecular alterations in PCa 
1.1.7.1 Germline variants in PCa patients 
Multiple studies have demonstrated a genetic component to the aetiology of PCa. 
Evidence of the heritability of PCa from epidemiological as well as twin studies 
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point towards a significant genetic component contributing to PCa development 
[52]. Large-scale genome-wide association studies (GWAS), which screen for 
disease-related single-nucleotide polymorphisms (SNPs), have identified 
approximately 170 PCa susceptibility variants [53]. Most large-scale GWAS 
studies have been performed in European populations, but recent studies have 
also included some other populations and population-specific differences have 
been reported [54-56], which may help explain geographical and ethinic 
differences in PCa incidence rates. Linkage studies into the genetic 
predisposition in PCa had few significant findings, such as the identification of 
8q24 as a significant PCa risk region [57, 58] and the identification of the 
missense G84E variant in HOXB13 [59, 60]. SNPs have been found associated 
with aggressive disease [61] and lethal disease after radiotherapy [62]. Pathway-
based analyses that examine GWAS loci have found genes assigned to risk loci 
are enriched in some pathways, for example the ERK-MAPK, WNT-β-catenin, 
p53 and ATM signalling pathways, G2-M DNA damage pathways and oestrogen-
mediated S phase entry checkpoint regulation pathways [63, 64]. It has been 
shown that most of the GWAS-identified PCa variants are located in non-coding 
regions of the genome [65], which may modify transcriptional regulation. 
Identification of germline variants could facilitate the development of strategies 
for population-based risk stratification for PCa screening in men with an increased 
genetic risk of disease and, based on the genetic profile develop specific 
treatment strategies for PCa patients in early disease setting. However, the 
biological mechanisms underlying the susceptibility loci remain largely unknown 
[66]. 
 
1.1.7.2 Somatic alterations in PCa 
Significant efforts have been made to characterise recurrent genomic alterations 
in PCa. Several large-scale genomic studies in both primary prostate tumours 
and mCRPC have identified recurrent DNA copy number changes, mutations, 
rearrangements, and gene fusions [67-71]. The most common alterations in PCa 
genomes are fusions of androgen-regulated promoters with ERG and other 
members of the ETS family of transcription factors. In particular, the fusion of 5′-
UTR of TMPRSS2 (21q22) with 3′-end of ETS family member ERG (21q22) is the 
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most common molecular alteration [72, 73]. Significantly mutated genes include 
AR, SPOP, FOXA1, IDH1, TP53, MED12, and CDKN1B2 [68, 74]. In addition to 
somatic mutations, somatic copy number alterations are recurrently seen in PCa.  
In general, PCa exhibits more somatic copy number alterations than most of the 
other types of cancer [75]. Recurrent focal amplifications included known 
oncogenes such as CCND1, MYC, as well as FGFR1 and WHSC1L1 (8p11.23, 
8%). Recurrent focal deletions were much more common, including homozygous 
deletions spanning the tumour suppressor PTEN, deletions of the region between 
the TMPRSS2 and ERG genes on 21q22.3 which result in TMPRSS2-ERG 
fusions, TP53, CDKN1B, MAP3K1, FANCD2, SPOPL, and the complex locus 
spanning FOXP1/RYBP/SHQ1 and MAP3K7 [68]. PTEN is one of the most 
frequently deleted tumour suppressor genes in PCa, leading to the activity of 
phosphoinositide 3-kinase-protein kinase B-mechanistic target of rapamycin 
(PI3K-Akt-mTOR) pathway. Monoallelic loss of PTEN is present in up to 60% of 
localised PCas [76]. In metastatic castration-resistant tumours, aberrations of AR, 
ETS genes, TP53 and PTEN are frequently (40-60% of cases) found, with TP53 
and AR alterations enriched compared to primary tumour [68, 77, 78]. 
 
 CRPC 
CRPC, previously called hormone-refractory PCa or hormone-resistant PCa, is 
defined by disease progression despite normal testosterone level. The term 
change is based on the understanding that androgen axis still play important roles 
in CRPC [44]. The CRPC is usually suspected in patients with new symptoms on 
ADT. According to European Association of Urology (EAU) - European Society 
for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric 
Oncology (SIOG) Guidelines on Prostate Cancer published in 
2017(http://uroweb.org/guideline/prostate-cancer/), CRPC is diagnosed as 
patients with castrate serum testosterone < 50 ng/dL or 1.7 nmol/L with either, 1) 
Biochemical progression: Three consecutive rises in PSA one week apart 
resulting in two 50% increases over the nadir, and a PSA > 2 ng/mL or, 2) 
Radiological progression: The appearance of new lesion of either two or more 
new bone lesions on bone scan or a soft tissue lesion. CRPC is a late stage of 
disease with poor prognosis [45]. Most CRPCs are diagnosed with metastasis 
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and roughly one third of non-metastatic CRPCs with a rising PSA will develop 
bone metastases within two years [79]. Docetaxel is the standard first line 
chemotherapy for CRPC which significantly improved patients’ survival compared 
to mitoxantrone [47, 80]. New systemic therapies, including the androgen 
biosynthesis inhibitor abiraterone acetate [48, 81], and the next-generation AR 
antagonist enzalutamide [49, 82] have demonstrated benefits in both before and 
post docetaxel settings and have been implemented in clinics. Other treatment 
options include Radium 223, and the immunotherapeutic sipuleucel-T [83] and 
the taxoid cabazitaxel [84].  
Numerous mechanisms have been characterised in the development of CRPC. 
The majority of resistance mechanisms identified are AR or androgen axis-
mediated [85]. In CRPC patients, low levels of androgen persist despite androgen 
blockade with ADT. Tumour cells could develop resistance either through 
amplification of the AR and overexpression of AR protein which causes AR 
hypersensitive to low level of androgen [86, 87], or development of AR mutations 
which could increase AR transactivation activity and decreased ligand specificity 
[88]. In recent years the role of AR splice variants in CRPC have been implicated. 
For example, AR-V7 has been found to be overexpressed in CRPC, localised in 
the nuclei and are constitutively active [89, 90]. Expression of AR-V7 has been 
associated with more advanced malignance and reduced survival in patients with 
mCRPC [90, 91]. Altered expression and function of AR co-regulators are also 
involved in CRPC development [92]. Synthesis of adrenal androgens and 
increased levels of intratumoural androgens is another mechanism that tumour 
cells sustain their growth with low circulating concentration of androgens [93]. 
Aberrant activation of other pathways such as PI3K-Akt-mTOR pathway, Src 
signalling pathway and growth factor pathways have also been identified in CRPC 
development [85]. Defects and mutations in DNA damage repair genes have 
been reported related to CRPC [77].  
Identifying CRPC prognostic and treatment-response prediction markers have 
been intensively investigated. A number of factors such as PSA based testing 
results, performance status score, haemoglobin level, age, albumin, LDH or ALP 
levels, Gleason score, pain intensity and metastases characteristics, have been 
validated and included in nomograms, which help physicians to estimate patients’ 
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survival [94, 95]. More recently, novel biomarkers from liquid biopsy have been 
extensively investigated. CTC enumeration has shown prognostic value [96-98]. 
Using CellSearch system, a cut-off of five CTCs per 7.5ml blood was set as 
favourable and unfavourable, correlating with good and poor CRPC prognosis 
respectively [96-98]. AR-V7 has not only showed functional role in CRPC, but 
also has emerged as a valuable marker in CRPC. In addition of detection in 
tissues, AR-V7 can be detected in CTCs, that expression of AR-V7 in CTCs is 
associated with poor response to abiraterone and enzalutamide [99], but has no 
predictive value for response to docetaxel or cabazitaxel [100-102]. Analyses of 
plasma exosomal miRNAs revealed that miR-1290 and miR-375 could be 
promising prognostic biomarkers for CRPC [103]. Other molecular prognostic and 
predictive biomarkers have also been identified, such RNA panel in whole blood 
[104, 105] and circulating cell-free DNA (cfDNA)[106]. 
Monitoring disease progression to CRPC has been relying on serum PSA levels 
along with serum testosterone measurements, and it is indeed effective in 
detecting mCRPC prior to clinical evidence of progression in most cases. 
However, disease progression may develop in men without rising PSA [25]. In 
addition, the serum level of PSA may be inconsistent to its tissue expression level 
during ADT, which challenged its use as a reliable surrogate for assessing tissue 
response to ADT [107]. Thus, there is a need for identifying new biomarkers for 
monitoring PCa progression. Studies of molecular mechanisms of CRPC 
development may reveal biomarkers for CRPC, while the detection methods of 
those molecular changes need further investigation for clinical use. CRPC 
prognostic and treatment-response predicting markers may also be evaluated as 
biomarkers for CRPC. For example, AR-V7 has been found functionally involved 
in CRPC development and its value as prognostic biomarker has been revealed 
[92, 99]. Further studies are needed to investigate its potential as a marker to 




1.2 MicroRNA (miRNA) 
 MiRNA biogenesis 
MiRNAs are short non-coding RNAs of ∼22 nucleotides. The main process of 
mature miRNA biogenesis is characterised by several steps: transcription to 
primary miRNA (pri-miRNA), cropping to precursor miRNA (pre-miRNA), 
exporting to the cytoplasm and dicing to mature miRNA (Figure 4). The miRNA 
biogenesis begins with transcription by RNA polymerase II or RNA polymerase 
III [108], which results in a 5′ capped and 3′ polyadenylated large primary 
transcript known as pri-miRNA, containing a 33 bp hairpin stem, a terminal loop 
and a flanking single stranded sequence of hundreds of bases or even several 
kilobases [109]. The pri-miRNAs are then cleaved in the nucleus by a 
microprocessor complex, composed of RNA-binding protein DiGeorge syndrome 
critical region gene 8 (DGCR8) and type III RNase Drosha, into a small hairpin 
structure called precursor miRNA (pre-miRNA) [110, 111]. Then, pre-miRNAs are 
transported to the cytoplasm mediated by Exportin-5, a Ran-GTP-dependent 
double-strand RNA-binding protein, in a GTP dependent process [112, 113]. The 
pre-miRNA is processed in the cytoplasm by the RNAse III enzyme Dicer, 
producing a mature miRNA duplex of about 22 nucleotides [114]. During this 
process, Dicer is associated with other proteins like TAR RNA binding protein 
and protein kinase R-activating protein to increase its stability and its processing 
activity [115]. Following the Dicer cleavage, the miRNA double strands bind to 
the RNA-induced silencing complex (RISC) composed of TAR RNA binding 
protein, protein kinase R-activating protein and Argonaute 2 (Ago 2), where one 
strand of the miRNA duplex remains in Ago2 as a mature miRNA (the guide 
strand or miRNA), and the other strand (the passenger strand or miRNA*) is 
degraded [116]. The strand selection is often not a stringent process that miRNAs 





MiRNAs typically direct the RISC to the target mRNAs through imperfect base 
pairing to their 3′ untranslated regions (3′UTR), leading to post-transcriptional 
repression through translation inhibition and mRNA destabilization [119, 120]. 
There is also evidence suggesting that some miRNAs could upregulate gene 
expression in specific cell types and conditions with distinct transcripts and 
proteins [121]. The miRNA-mRNA binding site is short (6-8 base pairs), and each 
miRNA has the potential to target multiple different mRNAs. 
 
Figure 4. MiRNA biogenesis process in human. Adopted from [119]. 
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 Deregulation of miRNAs in cancer 
A number of miRNAs have been found up- or down-regulated in malignant tissues 
compared to the normal counterpart. They are considered as oncogenes or 
tumour-suppressors respectively. The earliest finding of a correlation between 
miRNA deregulation and cancer was reported by Croce and colleagues in 2002, 
revealing that the miR15a/16-1 cluster is frequently deleted in chronic 
lymphocytic leukemia [122]. After this, much work has been done identifying 
cancer-related miRNAs. Several studies showed that profiling of miRNA 
expression signatures could distinguish tumour from normal tissue and 
discriminate cancer tissue origin with high accuracy [123-125]. Recent years, 
large number of studies on miRNAs using microarrays, RT-qPCR and RNA-
sequencing have provided more evidences that miRNA expression is 
dysregulated in cancer. The importance of miRNA alterations in cancer is further 
highlighted by functional studies in cancer cell lines and mouse models, revealing 
important roles of miRNAs in tumour initiation and progression. For example, it 
has been shown that miR-101 is down regulated in PCa and one or two of the 
genomic loci encoding miR-101 is lost in one-third of the localised PCa cells and 
in two-thirds of the metastatic cancer cells [126]. Overexpression of miR-101 
could decrease PCa cell proliferation in vitro [127, 128]. MiR-101 expressing PCa 
cells also had decreased tumour growth in xenograft mouse models [128]. 
Studies also revealed the mechanisms underlying miRNA deregulation in cancer, 
which include chromosomal abnormalities, transcriptional control changes, 
epigenetic changes and defects in the miRNA biogenesis machinery [129]. 
 
 MiRNAs as biomarkers 
Due to the fact that miRNAs play vital roles in cancers and they are relatively 
stable, miRNAs have been an attractive source of biomarkers. It has been shown 
that miRNAs can be isolated and quantitated from fresh tissue samples, fresh-
frozen specimens and formalin-fixed paraffin-embedded specimens [130-132]. 
MiRNA in situ hybridisation technology has been developed, which enables in 
situ detection of specific miRNAs in tissue samples [133-135]. MiRNAs in 
biofluids, for example blood and urine, have been particularly intensively studied 
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for biomarker value, as they are easy to access and be evaluated in a real-time 
manner. 
For PCa research, massive studies have been done looking for miRNAs as 
biomarkers for PCa diagnosis, prognosis, disease progression and treatment 
response. The expression of aberrant miRNAs has been demonstrated in PCa 
using different materials and methods by multiple groups. However, each study 
identifies distinct miRNAs panels and some inconsistent outcomes regarding the 
miRNAs expression profile were raised, with only a few miRNAs presenting 
consistent effects [136]. MiR-21 is one of the oncomiRs that has been found 
overexpressed in multiple cancer types [137]. Several studies showed consistent 
results that miR-21 is up-regulated in PCa patients’ tissue [133, 138, 139], 
serum/plasma [138, 140] and urine [141, 142]. Plasma/serum level of miR-21 has 
been found related to metastatic disease [143]. MiR-375 is another highlighted 
miRNA in PCa. It has been reported up-regulated in PCa patients’ tissue [139, 
144, 145], serum/plasma [138, 140, 146] and urine [144, 147], making it a good 
candidate of biomarker for PCa diagnosis. It has also been reported that miR-375 
is correlated with high risk PCa (N1 or GS 8) and metastatic disease [145]. 
Exosomal miR-375 is also identified as a prognostic marker together with miR-
1290 in CRPC [103]. Dysregulation of miR-141 is also frequently found up-
regulated in PCa [138, 139, 146, 148, 149] and it is correlated with bone 
metastases[150]. A recent meta-analyses study on 104 studies published in 
between 2007 and 2017 showed miRNAs had great diagnostic and predictive 
potential to discriminate PCa from BPH/normal controls, to differentiate 
metastatic PC from local/primary PCa, and predict recurrence-free survival and 
OS of PCa [151]. However, inconsistent data for certain miRNAs from different 
sample resources were found. For example, the expression of miR-100 was 
increased in the patients’ urine samples, which was contrary to its expression in 
cancer tissues [151]. The authors also pointed out that data for each single 
miRNA was limited which resulted in poor statistical significance [151]. The 





 Biogenesis of exosomes 
Exosomes are a type of small extracellular vesicle (EV) measuring around 30-
150 nm that present in almost all body fluids. The process of exosome release 
was first visualized in rat reticulocytes in 1983 [152], and then in sheep 
reticulocytes in 1985 [153]. Rose M. Johnstone used the term “exosome” to name 
these membrane-bound vesicles in 1987 [154]. Early in 1983 when Hardings, et 
al. described the existence of these vesicles, they found that the vesicles were 
released from multivesicular endosomes (or “multivesicular bodies” (MVBs)) 
through exocytosis [152]. Further insight into this process has found that 
exosomes have unique biogenesis and release mechanisms different from that 
of microvesicles (MVs), which are generated from plasma membrane outbudding. 
The release of exosomes involves more complex cellular steps including 
formation of intraluminal vesicles in MVBs, transport of MVBs to the plasma 
membrane and fusion of MVBs with the plasma membrane [155]. Exosome 
biogenesis starts within the endosomal system. Early endosomes are formed 
from endocytosis processes and then undergo maturation, forming the late 
endosome or MVBs. During this process, early endosomes can communicate 
with the Golgi apparatus and the endoplasmic reticulum through bidirectional 
vesicle exchange. Inward budding of the membrane forms the intraluminal 
vesicles that will be released to the extracellular space as exosomes, or will fuse 
with lysosomes where an active degradation process will take place [156, 157]. 





 Exosome cargos 
Exosomes contain varies of proteins, lipids, RNAs and even DNAs. The contents 
of exosomes from different donor cells can have big difference. In fact, exosomes 
from single cell line present heterogeneous subpopulations carrying different 
cargos [158, 159].   
Exosomes have been found enriched with tetraspanins (e.g. CD9 and CD63) [160] 
and proteins associated with endosomal sorting complexes required for transport 
machinery (e.g. TSG101 and ALIX) [161, 162]. These proteins are frequently 
used as markers for exosomes. Despite the fact that exosomes have some 
general protein families, vast diversity and variation still exists between 
exosomes from different donor cells and cells cultured under different conditions. 
The exosomal expression of known proteins in exosome have been massively 
evaluated by western-blotting (WB), ELISA and fluorescence-activated cell 
Figure 5. Exosome biogenesis and release process. (Adopted from
Borges, F. T., 2013 [51]) 
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sorting analysis [163]. In addition, a number of proteomics studies have been 
performed in exosomes isolated from different materials and have demonstrated 
the diversity of exosomal proteins and the specific protein expression under 
different conditions [164-166]. 
In terms of lipids, studies have analysed the composition of exosomal lipids and 
delivered general information that exosomes bear different lipid composition 
compared to the parental cells and exosomes from different cells in culture have 
different profiles [167, 168]. In general, exosomes are enriched in sphingolipids, 
CHOL, and PS compared with the donor cells. The lipid composition of exosomes 
shows similarities with lipid rafts, and exosomes have a higher lipid order and a 
higher stability against detergents than other EVs [169]. However, the lipid 
composition of exosomes in biofluids is poorly characterized and only limited data 
has been reported [170]. 
Several DNA species in exosomes/MVs have been identified including single 
strand DNA [171], mitochondrial DNA [172] and double strand DNA [173, 174]. 
These discoveries are exciting, however, the mechanism of DNA sorting into 
exosomes and the biological significance of exosomal DNA remain largely 
unknown.  
RNA is one of the most-well studied contents in exosome. Large number of 
miRNAs and mRNAs have been detected in exosomes and other RNA types 
including ribosomal RNA (rRNA), long non-coding RNA, piwi-interacting RNA, 
transfer RNA, small nuclear RNA, and small nucleolar RNA have also been 
identified in exosomes [175-177]. Exosomes isolated from different biomaterial 
could have different RNA species representation. For example, it has been 
reported that exosomes from plasma contains more miRNA, while urine 
exosomes contained more rRNA[178]. Expression levels of RNAs in exosomes 
can also be different from those in the origin cells [179]. 
 
 Exosome isolation and detection 
The most commonly used isolation method for exosomes is ultra-centrifugation. 
Other methods include ultrafiltration and size-exclusion chromatography, 
antibody-based capture, polymer-based precipitation and microfluidics. Each 
49 
 
method has its advantages and limitations. Ultra-centrifugation is widely used to 
prepare fractionate exosomes for down-stream analysis. It is easy to use, 
requires very little technical expertise, and is able to process large volume 
samples (e.g. cell culture media) with little or no sample pre-treatment. There are 
two types of ultracentrifugation: differential ultracentrifugation and density 
gradient ultracentrifugation. Differential ultracentrifugation consists of a series of 
centrifugation cycles from low speed to high speed to separate exosomes from 
other components based on the size and density. Density gradient 
ultracentrifugation uses a density gradient medium to enrich exosomes in a 
certain range of medium from other solutes into a discrete zone exclusively 
depends on their density difference from those of other solutes [180, 181].  
Ultrafiltration and size-exclusion chromatography isolate exosomes mainly base 
on size difference. Size-based isolation methods are capable of enriching 
exosomes with good purity and have good reproducibility, however, 
contamination of other nanoparticles (some non-vesicular) with the similar size 
as exosomes may occur. Size-exclusion chromatography needs dedicated 
equipment and its long run time limits its scalability for high throughput 
applications [180].  
Antibody-based isolation and detection of exosomes relies on the specifically 
expressed proteins and receptors in the membrane of exosomes. CD9 and CD63 
are commonly used as markers for exosome capture and using specific proteins 
enables selective capturing of exosomes of a specific origin or some 
subpopulations of exosomes. For example, isolation and analysis of glypican-1+ 
exosomes using flow cytometry in pancreatic cancer patients was found as a 
specific and sensitive method to distinguish healthy subjects and patients with a 
benign pancreatic disease from patients with early- and late-stage pancreatic 
cancer [182]. Prostate-specific membrane antigen (PSMA) was used as a tag for 
PCa exosome isolation [183, 184]. However, because of the heterogeneity of 
exosomes and cancer, only a subset of exosomes, expressing the antibody-
recognised proteins, can be captured, potentially leading to low yield and false 
negative results. In addition, other biological material expressing the protein can 
also be captured.  
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Precipitation is another commonly used and efficient method for exosome 
isolation. Currently, several exosome precipitation kits are commercially available 
which utilise a decrease in the solubility of compounds in the solutions by a 
superhydrophilic polymer, polyethylene glycol [185, 186]. Mixing the sample with 
the precipitation reagent diminishing the hydration of the exosomes, which allows 
exosomes being pelleted via low-speed centrifugation. Exosome precipitation 
methods are attractive for clinical research as they are simple, time-saving and 
do not require special equipment, therefore enable processing of large number 
of samples. Other precipitation strategies were also proposed [187, 188], but 
haven’t been broadly used. 
Microfluidic devices have been developed in recent years to facilitate exosome 
isolation from various biological materials. Microfluidic devices employ a wide 
range of exosome isolation approaches, such as immunoaffinity, membrane-
based filtration, trapping on nanowires, acoustic nanofiltration, and deterministic 
lateral displacement sorting. Integrated systems have been developed to perform 
downstream analysis of exosomes. Microfluidic technologies are fast developing 
and bear great potential for exosome isolation in clinical use [189, 190]. 
 
 Exosome function 
When exosomes were firstly characterised, they were reported as a means of 
cells to extrude unwanted membrane proteins [152]. With the improvement of 
isolation methods, more research has been conducted on exosomes and has 
revealed distinct biological functions of exosomes secreted by different cell types.  
As exosomes carry biologically active molecules including RNAs, lipids, and 
proteins and can transport between donor cells to recipient cells, they are 
believed to function as a novel mechanism for intercellular communication. 
Studies have demonstrated that exosomes play a significant role in various 
pathological conditions, such as different types of cancer [191], infectious 
diseases [192], metabolic diseases [193] and pregnancy [194].  
Exosomes have been described as important mediators in cancer development, 
progression, metastasis and therapy response [195]. Many studies have reported 
the role of exosomes in influencing cancer cell proliferation and migration by 
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transferring specific cargos into the recipient cells [196-199]. The formation of 
pre-metastatic niches is one of the major events in cancer metastasis, which 
provides suitable environment for tumour cells to colonise in a distant site. 
Tumour-derived exosomes could prepare the pre-metastatic niche through a 
number of mechanisms such as inducing vascular leakiness and pro-
inflammatory, reprograming metabolism, and remodelling extracellular matrix 
[200-203]. In turn, cells in the microenvironment could influence tumour cells via 
exosomes. For example, it is shown that tumour cells with normal expression of 
PTEN, an important tumour suppressor, could lose PTEN expression after 
dissemination to the brain, but not to other organs. This is regulated by astrocyte-
derived exosomes which mediated an intercellular transfer of PTEN-targeting 
miRNAs [204].  
Tumour-derived exosomes are found to be involved in immune response. It is 
reported that tumour exosomes could promote regulatory T cell expansion and 
induce the apoptosis of activated T cells, thus supress immune response facilitate 
immune-escape of tumour cells [205, 206]. It is found that exosomes secreted 
from tumour cells carry PD-L1 that could inhibit T cells function [207, 208]. 
Prostate-cancer-derived exosomes were found to be immunosuppressive by 
regulating dendritic cell function [209]. In addition, it is found that poorly 
metastatic melanoma cells can secret exosomes which stimulate an innate 
immune response, which then cause cancer cell clearance at the pre-metastatic 
niche [210]. 
 
 Clinical applications of exosomes in cancer 
1.3.5.1 Exosomes as biomarker 
Exosomes are present in varies body fluids and stably carry different types of 
cellular cargos, making them a good candidate for non-invasive biomarkers. 
Many studies have demonstrated that exosomes hold potential as diagnostic, 
prognostic, and pharmacodynamic biomarkers in several cancer types, including 
breast cancer [211-213], PCa [214-216], lung cancer [217-219], colon cancer 
[220, 221], and pancreatic cancer [182, 222, 223].  
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Bryant et al. reported their study on circulating miRNAs in PCa. They identified 
miR-375 and miR-141 in plasma MVs and serum MVs and exosomes, which are 
correlated with metastatic disease, although MV miRNAs did not present better 
diagnostic value than PSA, nor increased diagnostic value of PSA when 
combined together [146]. Recently, McKiernan et al. developed a non-invasive 
detection test, ExoDx Prostate (IntelliScore) urine exosome assay, which has 
been approved by FDA for the detection of high-grade PCa. The assay which 
evaluates the expression level of three genes, PCA3, ERG (including TMPRSS2: 
ERG) and SPDEF (as normaliser) in urine exosomes and construct a score 
(ExoDx Prostate IntelliScore), which in combination with standard clinical 
parameters (PSA level, age, race, and family history), could discriminate high-
grade PCa (Gleason score ≥7) from low-grade cancers and benign diseases [214, 
224]. Huang et al. identified two miRNAs in plasma exosomes (miR-1290 and 
miR-375) as prognostic markers in castration-resistant PCa by RNA-sequencing 
and quantitative real-time polymerase chain reaction (RT-qPCR) [103]. Del Re et 
al. reported a method of using digital droplet PCR to detect AR-V7 in plasma 
exosomes. Their results showed that exosomal AR-V7 can be a predictive 
biomarker of resistance to second-line hormonal therapy in CRPC patients [225]. 
 
1.3.5.2 Exosomes as drug delivery tools 
Recent years, there has been intense interest in exploiting exosomes as a tool 
for drug delivery. Exosomes have some ideal characteristics, such as stability in 
blood and can travel long distance, intrinsic ability to target tissues, good 
biocompatibility, and minimal or no inherent toxicity [226]. Therefore, exosomes 
emerge as ideal vehicles which can be isolated and modified for drug or gene 
delivery. To date, several studies have reported that administration of exosomes 
can potentially serve as therapeutic strategies. Kim et al. engineered 
macrophage exosomes loaded with paclitaxel to target pulmonary metastases 
and have good antineoplastic effect in a mouse model [227]. Kalimuthu et al. 
have demonstrated that paclitaxel-loaded mesenchymal stem cell exosomes 
could inhibit breast cancer growth in vitro and in vivo [228]. Ohno et al. reported 
that intravenously injected engineered exosomes could deliver miRNA to EGFR-
expressing breast cancer tissue xenograft in RAG2–/– mice and supress tumour 
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growth [229]. Kamerkar et al. reported the study of using engineered exosomes 
from normal fibroblast-like mesenchymal cells carrying short interfering RNA or 
short hairpin RNA specific to oncogenic Kras mutation as therapy for pancreatic 
cancer [230, 231]. They showed that engineered exosomes could suppress 
cancer in multiple mouse models of pancreatic cancer and significantly increased 
OS [230, 231], revealing the clinical value of exosome-based therapies. 
 
1.3.5.3 Exosomes as cancer vaccine and immunotherapy 
The findings that exosomes are involved in modulating immune system illustrate 
the potential of exosomes as a cancer vaccine. Early in 1998, Zitvogel et al. 
reported that dendritic cell-derived exosomes (Dex) could present tumour-
associated antigens and induce T-cell activation, resulting in the suppression of 
tumour growth in vivo [232]. Since then, Dex have received much attention as 
immunotherapeutic anticancer agents which can induce immune cell-dependent 
tumour rejection. Dex have been developed for use as cell-free cancer vaccines 
and put into clinical trials for melanoma [233] and lung cancer [234]. These two 
studies confirmed the safety of Dex administration in patients, however showed 
limited Dex-induced T cell responses. Later studies found that exosomes from 
matured dendritic cells can induce greater T cell stimulation [235-237], which led 
to second generation of Dex immunotherapies. However, a phase II trial in lung 
cancer patients after chemotherapy cessation using a second generation Dex as 
maintenance immunotherapy failed to detect T-cell response [238]. The patients 
showed good tolerance, which encourages further investigation of Dex 
immunotherapies to increase its efficiency.  
 
1.4 Circulating tumour cells (CTCs) 
Part of this section has been published[239]. 
 Origin 
Tumour cells can escape the primary tumour site (involving invasion and 
intravasation) and disseminated to distant sites (involving extravasation to distal 
tissues). The tumour cells which enter the bloodstream are referred to as 
54 
 
circulating tumour cells (CTCs). CTCs are a rare population of cell in the 
circulation blood at a ratio of one CTC to 106-107 nucleated blood cells. CTCs 
have long been considered as a substrate for cancer metastasis. Metastasis 
involves several main steps, starting with intravasation from the primary site 
which may be an active process supported by epithelial-to-mesenchymal 
transition (EMT). The CTCs then circulate in the blood stream as single cells or 
clusters. Then CTCs may extravasate to a new location, where CTCs may form 
a new metastasis site, and this extravasation is possibly supported by 
mesenchymal-to-epithelial transition (MET) [240, 241]. CTCs have been 
proposed as a main representative of “liquid biopsy” which may be used as 
biomarkers and provide a minimally invasive approach to the tumour tissue [242]. 
  
 Isolation methods  
CTCs were firstly described in 1869. However, the rarity of CTCs has largely 
hindered the research of them. Only in the past decades, owing to the 
development of technologies, researchers have achieved reasonable efficacy of 
enrichment of CTCs [243]. Current existing techniques of CTC isolation can be 
roughly divided into three types: antibody-based approaches, physical property-
based approaches and function-based approaches [244].  
Cell surface proteins are often used as targets in antibody-based CTC isolation 
methods. Due to the absence of strictly tumour-specific antigens, epithelial-
specific proteins such as EpCAM and cytokeratins (CKs) have been employed 
for the positive selection of CTCs and antibodies against leukocyte-specific 
surface antigens, such as CD45, have been used to deplete leukocytes from the 
blood sample for negative selection [245]. Immune-magnetic separation [246, 
247], flow cytometry [248], and immuno-affinity based microfluidic platforms have 
also been developed and employed to enrich CTCs. The representative platform 
of immune-magnetic separation CTC isolation is CellSearch, which is the first and 
the only CTC enumeration system cleared by FDA in clinic use for metastatic 
breast cancer, colorectal cancer and PCa [98, 249, 250]. A number of immune-
affinity base CTC isolation platforms have been reported, for example, CTC-chip 
[251] and CTC-iChip [252, 253]. The overt drawback of positive selection is 
missing of heterogeneous CTCs, such as losing EMT cells when only epithelial 
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markers are used. Another strategy is negative selection, which depletes 
leukocytes, may circumvent the problem of losing some subtypes of CTCs. There 
are several commercially available products for negative selection. RosetteSep® 
antibody cocktail, which crosslinks unwanted cells in human whole blood to 
multiple red blood cells forming immunorosettes, has been used to enrich viable 
CTCs [247, 254]. However a negative selection will cause heavy leukocytes 
contamination, thus usually accompanied by further purification process or used 
for CTC culture where leukocytes can be eliminated during culture. 
Physical property-based techniques take a large part in CTC isolation. “Ficoll,” a 
synthetic low-viscosity, high-molecular-weight hydrophilic sucrose, and 
epichlorohydrine polymer and sodium diatrizoate, has been extensively used for 
depleting red blood cells through density gradient centrifugation [255]. It is often 
used before further purification steps to deplete lymphocytes. Recently, a large 
number of size-based devices have been developed for CTC isolation, for 
example membrane capture of CTCs [256-260] and microfluidic devices [261-
263]. They were designed based on the principle that tumour cells present 
different physical properties compared to blood cells, in size, deformability, 
density and electric properties [262, 264-267].  Physical property-based 
techniques are also facing the challenge of isolating heterogeneous tumour cells. 
For instance, although tumour cells are believed to be larger in size than blood 
cells, it cannot be guaranteed that all CTCs are bigger compared to blood cells 
and actually small CTCs have been identified [268, 269]. 
A unique strategy to enrich CTCs is taking the advantage of CTCs’ invasion ability. 
A method, which is based on tumour cells’ ability to attach and digest collagen 
adhesion matrix, has been described as collagen adhesion matrix (CAM) assay 
[270]. To enrich tumour cells, blood samples were simply transferred into a CAM-
coated tube and incubated for several hours. Unattached cells were then washed 
off and adherent cells were collected [270, 271]. Similarly, Wang et al. developed 
an invasion assay to detect CTCs which could invade into Matrigel [272]. These 
methods enable enrichment of viable CTCs which are invasive. However, the 
captured CTCs cannot represent the whole population of CTCs in blood as 
apoptotic CTCs or fragmented CTCs are frequently found in the peripheral blood 




 Clinical applications of CTCs 
The clinical value of CTCs has been revealed in many aspects. The prognostic 
value of CTC enumeration has been demonstrated in many cancer types [249, 
274, 275]. Detection of CTCs has been associated with an increased risk of local 
and regional recurrence as well as the development of distant metastases [276]. 
In CRPC, enumeration of CTCs has been demonstrated as an independent 
predictor of OS in several cohorts [96, 97, 277-279]. It has been demonstrated 
that CTC counts hold independent prognostic value for OS similar to clinical and 
radiologic response in CRPC patients receiving docetaxel [278].  
CTCs may also provide genetic information that can be used for cancer diagnosis 
and prognosis. Using high-quality whole-genome sequencing on single CTCs 
from a PCa patient, Jiang et al. identified shared genomic alterations between 
CTCs and tumour tissue [280]. Comprehensive sequencing and confident 
determination of genomic variants in CTCs could help understanding the 
heterogeneous between patients and monitoring the transiting status within 
single patient, thus facilitate targeted therapy [281].  
Moreover, gene expression levels in CTCs has also been exploited as potential 
biomarkers for cancer diagnosis and prognosis [282-284]. AR-V7 in CTCs from 
CRPC patients was recently demonstrated to be associated with resistance to 
abiraterone and enzalutamide, but not taxanes [100]. Some markers for 
chemotherapy response have been demonstrated using cell lines or tumour 
tissue [285], but very few data has been published regarding detection of these 
markers in CTCs [286]. Some studies have also employed RNA-sequencing in 
CTCs to investigate the gene expression changes in primary, metastatic, and 
recurrent cancer non-invasively [287-289]. However, CTC sequencing still faces 
technical challenges for example different CTC isolation methods may affect CTC 
population, limited material could be obtained from CTCs for library preparation, 




 CTC culture 
Expanding CTCs bears great potential of providing material for functional study 
and establishing patient-specific tumour models for individualised therapeutic 
prediction. In the past decades, many research teams have attempted to 
establish CTC cultures. Although some achievements have been made, CTC 
culture remains challenging, especially for long-term culture. 
 
1.4.4.1 Short-term culture 
Some techniques have been developed for short-term in vitro culture of CTCs. 
An in-situ capture and culture methodology using MetaCell®, which is a size-
based enrichment process is based on the filtration of peripheral blood through a 
porous polycarbonate membrane (pores with 8 μm diameter), has been used for 
CTC capture and short-term culture in non-small-cell lung cancer (NSCLC) [291], 
PCa [257, 292], pancreatic cancer [260] and gastric cancer patients [293]. In 
these studies, CTCs could be maintained on the membrane for over two weeks 
with some cells escaped the membrane. Some biological tests could be done in 
the cultured cells, characterising specific gene expression that are tumour-related 
[257, 291-293]. In 2015, Khoo et al. proposed a method which cultured breast 
CTCs in laser-ablated microwells under hypoxia condition after red blood cell lysis 
and indicated that the CTC cluster formation ability may predict treatment 
response [294]. Cells could form clusters in the microwells and could be 
maintained for over two weeks. In addition, several passages of the cultured 
clusters were achieved when cultured in Geltrex® or ultra-low adhesive dishes. 
It is also found that the cell cluster formation was not always correlated, indicating 
that the CTC enumeration methods may lead to an underestimation of a 
heterogeneous population of CTCs [294]. The authors reported that the method 
could enable establishment of clusters from >50% of clinical blood samples 
screened [295], which is promising for CTC culture. Recently, collecting 
mononuclear cells from apheresis and then isolating of CTCs has enabled 
enrichment of CTCs from large volume of blood that largely increased CTC yield 
[296, 297]. Maryou et al. reported that CTCs enriched from apheresis could form 
spheroids and could be cultured over 4-6 weeks [297]. However, this is a single 
case report that success rate is unknown. Short-term culture of CTCs bears the 
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advantages of short turn-over time for providing information and may potentially 
better representative of the original tumour with less passage and selection 
procedures compared to long-term culture. However, short-term culture also has 
limitations that limited material can be obtained from short-term culture with only 
a few analyses can be performed.  
 
1.4.4.2 Long-term culture 
Long-term culture of CTCs is more difficult with limited success cases reported. 
In 2013, Zhang et al. established CTC cell lines from three brain metastatic breast 
cancer patients [298]. Interestingly, in this study, only EpCAM- population 
survived over 14 days and be established to cell lines, but EpCAM+  would die 
out during culture [298].  The EpCAM-/HER2+/EGFR+/HPSE+/Notch1+  CTC lines 
were highly invasive and capable of generating brain and lung metastases when 
xenografted in nude mice, indicating the significance of EpCAM- CTCs in forming 
tumour metastasis [298]. In 2014, Yu et al. reported their success of developing 
CTC cell lines from six luminal subtype breast cancer patients, with 20% success 
rate [299]. Genome sequencing of the CTC lines revealed the same mutation 
status in the PIK3CA gene between CTC lines and primary tumours. Drug 
sensitivity screening on these cell lines showed that certain drug sensitivity 
features of the CTC cell lines were concordant with clinical response and 
revealed potential new therapeutic targets [299]. Although the success rate is low, 
this results is encouraging for CTC culture. One colon cancer CTC-derived cell 
line has been established [300]. For PCa, Gao et al. has reported success in long-
term culture of CTCs from one mCRPC patient using organoid culture medium 
[246]. The in vitro expanded CTCs bear the potential to form xenograft when 
grafted to nude mice and some can form distant metastases, indicating the 
tumourigenic and metastatic ability of expanded CTCs. Both the CTC-derived 
organoid and xenograft histologically resembled the primary tumour [246]. In this 
study, 67% of point mutations found in the CTC-derived organoid line were 
identified in the lymph node metastasis of the same patient [246]. The additional 
mutations may be acquired during the cell culture. Directly injecting enriched 
CTCs into mice and generating CTC-derived xenografts is another strategy to 
establish CTC-derived tumour model. Dive’s group reported their success in 
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generating CTC-derived xenografts of lung cancer [247, 254] and they later 
cultured the xenograft cells in vitro [301]. Rossi et al. also used a xenograft assay 
by injecting isolated EpCAM+ CTCs from PCa patients into immunodeficient mice. 
Eight CTC xenografts were derived from 7 consecutive patients. However, after 
a median follow-up of 10.3 months (range 6.5-12 months) none of the CTC-
injected mice developed clinical evidence of tumour, neither at the injection, nor 
at secondary sites, with only human CK+ cells detected in the murine blood, bone 
marrow and spleen [302]. Bacelli et al. developed a CTC xenograft assay in a 
large set of luminal breast cancer patients by injecting CTCs to the femurs of 
NOD mice and showed that the luminal breast cancer CTCs bear the ability to 
form bone, lung and liver metastases in mice. However, only six recipient mice 
receiving at least 1,109 CellSearch-evaluated CTCs developed multiple bone, 
lung and liver metastases within 6-12 months after transplantation of CTCs from 
three patients, while injection of less than 1,000 CellSearch-evaluated CTCs from 
106 samples did not lead to metastatic growth of human tumour cells within 15 
months after transplantation [303]. Thus, studies on the CTC-derived xenograft 
models have revealed the potential of employing cultured CTCs as tractable 
platforms to study cancer biology, identify pharmacodynamic biomarkers and 
perform drug response tests for individualized medicine. However, the success 
rate remains low and high CTC number is important for developing xenografts. 
 
1.5 Other liquid biopsy 
Liquid biopsy is developed to detect informative tumour-associated components 
from various body fluids. Compared to conventional surgical biopsy, liquid biopsy 
holds several major advantages. Liquid biopsy provides an opportunity to obtain 
tumour-specific information with minimally invasive procedures and could be 
tested at successive time points providing real-time information on disease 
status. Tumours have been acknowledged with dynamic intra-tumour 
heterogeneity with presence of subpopulations of cells with distinct genotypes 
and phenotypes within a primary tumour and its metastases [304].  Liquid biopsy 
may better reflect the dynamic genetic profile of all tumour subclones present in 
a patient, unlike tissue biopsies which are obtained from only one tumour region 
at one fixed time [305, 306]. In addition to blood which has been the main source 
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of material for liquid biopsy, other body fluids have also been used, for example 
urine and salivary fluid [305, 307, 308]. Different circulating molecules have been 
exploited as materials for liquid biopsy. Beyond exosomes and CTCs which have 
been introduced in earlier chapters, there are other circulating molecules, such 
as cell-free nucleic acids and tumour-educated platelets (TEPs), which have 
been shown to contain tumour-derived genetic material. 
CfDNA presents in the blood at very low concentration, mainly containing 
germline DNA from normal cells and a minority of a highly variable fraction of 
DNA from cancer cells, namely circulating tumour DNA (ctDNA). CfDNA has been 
massively investigated in recent decades owing to the technological advances in 
qPCR and next-generation sequencing. Analysis of ctDNA mainly focus on 
detection of gene mutations, structural chromosome rearrangements and 
somatic copy number variations, while some studies targeted on the ctDNA 
methylation patterns [309, 310]. The utility of ctDNA have been implicated at 
different stages of the management of patients with cancer, including 
diagnosis[311-313], prognosis [314-316], detection of residual disease[317-319] 
and treatment decision[315, 320, 321]. The US FDA has approved qPCR-based 
ctDNA test for mutated EGFR in patients with NSCLC target guild targeted 
therapy [322] and DNA methylation-based test of SEPT9 for the detection of 
colorectal cancer [323]. Large trials leading by one company, GRAIL, are 
currently ongoing aiming to develop blood tests of ctDNA for early cancer 
detection [313]. However, current released data showed the clinical use of ctDNA 
is still limited by low sensitivity and specificity, especially for asymptomatic tumour 
detection [324]. Combination of detection of cfDNA and other molecules may help 
to improve the sensitivity and specificity of the test for biomarker. A blood test, 
namely CancerSEEK, has been recently developed to detect eight common 
cancer types including ovary, liver, stomach, pancreas, esophagus, colorectum, 
lung, or breast through assessment of the levels of circulating proteins and 
mutations in cfDNA [325]. Evidence has showed that a large proportion of human 
blood plasma cfDNA is carried in extracellular vesicles [326, 327]. Thus 




Circulating RNAs is another key member of liquid biopsy. Several studies have 
selectively evaluated some mRNAs and showed their potential as biomarkers 
[328]. Most studies were focused on analysing miRNA due to the stability issues 
of mRNA. A large proportion of cell-free RNA data came from analysis of EV 
RNAs [329], as EV could protect RNAs from degradation. However, it is indicated 
that EV-incorporated miRNAs and cell-free miRNAs in whole plasma may provide 
different information [140]. More studies are needed to explore the utility of 
circulating RNAs as biomarkers which may trigger new circulating biomarker 
discovery and functional implication for cancer biology. 
TEPs have been exploited as an important source of circulating biomarker given 
the well-known interaction between blood platelets and tumour cells which could 
have an effect on the tumour-resident cancer cells as well as the cancer cells that 
have disseminated to the bloodstream [330-332]. TEPs are a fundamental 
component of the tumour microenvironment and they contribute to tumour 
initiation, progression, and therapy response [333]. Most recently, exciting 
findings were reported using thromboSeq, an RNA-sequencing-based 
methodology that enables identification of spliced RNA profiles from TEPs RNA 
combined with sophisticated machine learning-based classification algorithms, to 
discriminate patients with localised and metastasised cancer from healthy 
individuals [334]. This method also allowed to pinpoint the organ-of-origin of the 
primary tumour [334]. A follow-up study in large cohorts of NSCLC patients 
showed that TEPs spliced RNA panel could serve as robust biomarker for cancer 
detection [335]. Other studies also demonstrated the potential of evaluating TEPs 
RNA expression for cancer diagnosis and prognosis [336-338]. Although TEPs 
RNA has shown great value as biomarker, the study of TEPs RNA is still at an 
early stage that warrant validation in large scale cohorts with standardised blood 
storage conditions and processing protocol. In addition, further studies on other 
molecules in TEPs, for example, miRNAs and proteins, are needed. 
 
1.6 Aims 
The main aim of my PhD project is to explore the value of two main circulating 
subjects in peripheral blood, exosomes and CTCs, in monitoring PCa progression 
and predicting treatment response.  
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Exosomes will be isolated from the plasma of PCa patients and RNA will be 
extracted from the plasma exosomes. To identify plasma exosomal miRNAs 
associated with PCa castration-resistant acquisition, next-generation sequencing 
of exosomal RNA will be performed in treatment-naive PCa patients and CRPC 
patients. The differentially expressed miRNAs will be evaluated in more samples 
to validate the differential expression and explore the prediction value of 
exosomal miRNAs for CRPC. Some of the differentially expressed miRNAs will 
be selected based on literatures for further studies in vitro to understand the role 
of the miRNAs in CRPC development. The aim is to utilise exosomal miRNAs as 
a tool to monitor PCa progression to CRPC and potentially reveal new 
mechanism of CRPC development. 
Our lab has previously developed CTC enumeration method and demonstrated 
the value of enumeration of CTCs as biomarker for PCa metastasis and 
prognosis [339]. Ongoing projects are aiming at exploring CTC enumeration as 
biomarker for PCa treatment response. Long-term culture of CTC isolated from 
the peripheral blood bears great potential to provide us patient-specific platforms 
to identify the most efficient treatment modality. For PCa, there are only few 
reports with limited cases on the successful in vitro culture of CTCs. Thus, I plan 
to assess different methods of isolating viable CTCs from prostate patients and 
optimise CTC in vitro culture methods. Investigations will be carried out using 




Chapter II  Materials and methods 
2.1 Cell lines 
Five PCa cell lines, 22Rv1, PC3, DU145, LNCaP and VCaP were used in this 
project. Mouse embryonic fibroblasts, STO cells were also used as feeder cells 
for CTC culture. STO cells were sent for x-ray irradiation to inhibit proliferation 
before used as feeder cell. 
Frozen cell stocks were stored in liquid nitrogen in Dulbecco’s MEM 
(DMEM)(Gibco, Life Technologies, USA) or RPMI-1640 (Gibco, Life 
Technologies, USA) with 10% of DMSO and 20% of Foetal Calf Serum (FCS, 
Gibco, Life Technologies, USA). To recover cells from frozen stocks, cells were 
thawed at 37℃ water bath and the cell suspension was diluted in 5 ml of pre-
warmed culture media (DMEM or RPMI-1640 supplemented with 10% FCS and 
1% penicillin/streptomycin). The cells were then pelleted by centrifugation at 1200 
rpm for 5 min and resuspended in culture medium. Cells were then maintained in 
a controlled standard condition (37°C and 5% CO2) and passaged when reaching 
~80% confluence. To passage cells, the old medium was taken out and cells were 
washed with phosphate buffered saline (PBS). Trypsin-EDTA solution (Sigma, 
UK) was added to detach the cells and then quenched by the addition of equal 
volume of culture media. 
 
2.2 Patient samples 
From St Bartholomew’s Hospital, Barts Health NHS, London, UK, blood samples 
from 291 patients were collected with informed consents. Use of patient blood 
samples and clinical data in this study was approved by the London City & East 
Research Ethics Committee with a Research Ethics Committee reference of 
09/H0704/4+5. From Department of Pathology and Cancer Centre, Medical 
College of Wisconsin (MCW), US, blood samples from 60 patients were collected 
by Dr. Manish Kohli, Dr. Jing jia and Professor Liang Wang with informed patients’ 
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consents. Use of patients’ blood samples and clinical data there was approved 
Institutional Review Board of Medical College of Wisconsin (PRO00017780). 
 
2.3 Exosome isolation 
 Exosome isolation from cell culture media 
Cells were seeded in T175 flasks with culture medium. When the cells reached 
80% confluency, the cells were wash with PBS and 20 ml plain medium was 
added to each flask.  The medium was collected after 24 h and centrifuged 
sequentially as following: the culture medium was firstly centrifuge at 2000 g for 
15 min at room temperature (RT) and supernatant was collected into thin-wall, 
ultra-clear ultracentrifuge tubes (Beckman Coulter, US). The medium was then 
centrifuged at 10000 g for 40 min at 4 °C The supernatant was collected and 
transferred to new ultracentrifuge tubes and centrifuged at 100000 g for 2 h at 
4 °C. Then the supernatant was taken out. PBS was added to repsuspend the 
pellet. Another centrifugation at 100000 g for 2 h at 4 °C was performed. The 
supernatant was taken out and the pellet was resuspended in PBS and filtered 
through 0.22 μm filter and stored at -20 °C. 
 
 Exosome isolation from plasma 
Two kits were used for exosome isolation from plasma in Barts Cancer Institute, 
the total Exosome Isolation Kit (from plasma) (Invitrogen) and ExoEasy Maxi Kit 
(Qiagen). Total Exosome Isolation Kit (from plasma) (Invitrogen) was used to 
isolate exosomes from 200 μl plasma for method test and further clinical 
investigation. The plasma was thaw in RT and centrifuged at 2000 g for 10 min. 
The supernatant plasma to a new tube and centrifuged at 10,000 g for 20 min. 
The supernatant was taken out and mixed with 100 µl of PBS. RNase A was 
added to the plasma to a final concentration of 10 μg/ml. The sample was then 
incubated in 37°C water bath for 60 min. Then 2.25 µl (20 U/µl) RNase inhibitor 
(Applied Biosystems™) and 10 µl of Proteinase K from the Total Exosome 
Isolation Kit (from plasma) (Invitrogen™) were added to the sample. After mixed 
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well, the sample was incubated at 37 °C for 15 min. The sample was quickly 
cooled down on ice and 60 µl of the Exosome Precipitation Reagent (from plasma) 
from the Total Exosome Isolation Kit (from plasma) (Invitrogen) was added to the 
sample and mixed well. Then the sample was incubated at 4 °C for 2 h. Exosomes 
were then pelleted centrifugation at 10,000 g for 10 min and stored at -80 °C. 
ExoEasy Maxi Kit (Qiagen) was used as a test method. 4 ml buffer XBP was 
added to 4 ml plasma and mixed inverting the tube for 5 times. The sample was 
then loaded onto the exoEasy spin column and centrifuged at 500 g for 1 min. 
The flow-through was discarded and the column was centrifuged at 5000 g for 1 
min. After discarded the flow-through, 10 ml buffer XWP was added to the column 
and centrifuged at 5000 g for 5 min to remove residual buffer from the column. 
Then the spin column was transferred to a new collection tube. 400 μl Buffer XE 
was added to the membrane and incubated at RT for 1 min. The column was 
centrifuged at 500 g for 5 min. The eluate was collected and re-applied to the 
exoEasy spin column membrane and incubated at RT for 1 min. The column was 
then centrifuged at 5000 g for 5 min to and the eluate was collected as enriched 
EVs. 
Validation work in Department of Pathology and Cancer Centre, Medical College 
of Wisconsin, US was performed by Dr. Jing Jia as following. 250 μl plasma from 
each patient was centrifuge at 500 g for 10 min at 4 °C. The supernatant was 
transferred to a new RNase-free tube and mixed with 2 μl of thrombin to a final 
concentration of 5 U/ml and incubated at RT for 5 min. The mixture was then 
centrifuged at 10000 g for 5 min at 4 °C. The supernatant was then mixed with 
1/4 volume of ExoQuick exosome precipitation reagent (EXOQ5TM-1, SBI) and 
incubated at 4 °C for 1 h. The tube was rotated several times during the 
incubation to mix the sample. After the incubation, the sample was centrifuged at 
1500 g for 15 min at 4 °C. Then the supernatant was aspirated. The sample was 
centrifuged again at 1500 g for 5 min at 4°C to remove residual ExoQuick solution. 
After removing the supernatant, the exosome pellet was resuspend in 100 μl PBS 




2.4 Nanoparticle tracking analysis  
Nanoparticle tracking analysis was performed with some isolated exosome 
samples using NanoSight LM20 (NanoSight Ltd, UK). Exosomes isolated from 
plasma samples or cell culture media were diluted in PBS and loaded on 
NanoSight LM20. After loading the samples to the machine, 60 seconds videos 
were recorded to generate size distribution and concentration data. 
 
2.5 RNA extraction  
2.5.1.1 RNA extraction from plasma exosomes  
30 µl Buffer RLT (Qiagen, UK) with 0.25% v/v Proteinase K (from the Total 
Exosome Isolation Kit (from plasma) (Invitrogen™)) was added to the exosome 
pellet to resuspend the exosomes. Exosomes were incubated at 50 °C for 30 min. 
Then RNA was then extracted with miRNeasy micro kit (Qiagen, UK) according 
to the manufacturer’s protocol. 700 μl of QIAzol Lysis Reagent (Qiagen, UK) was 
added, vortexed and incubated at RT for 10 min. 140 μl of chloroform was added 
and the sample was shaken vigorously then incubated at RT for 5 min. The 
sample was then centrifuged for 15 min at 12,000 g at 4 °C. The upper aqueous 
phase (about 400 μl) was carefully transferred to a new 1.5 ml Eppendorf tube. 
Then 1.5 volumes of 100% ethanol was added to the upper aqueous phase and 
mixed thoroughly. The mixture was then transferred into a RNeasy MinElute spin 
column in a 2 ml collection tube and centrifuged at 8600 g for 15 s. The flow-
through was discarded. 700 μl Buffer RWT from the kit was added to the spin 
column. The column was centrifuged for 15 s at 8600 g and the flow-through was 
discarded. 500 μl Buffer RPE was added to spin column. The column was 
centrifuged for 15 s at 8600 g at RT and the flow-through was discarded. Then 
500 μl of 80% ethanol was added to the spin column. The column was centrifuged 
for 2 min at 8600 g and the flow-through was discarded. The spin column was 
placed in a new 2 ml collection tube (supplied in the kit) and centrifuged at 10000 
g for 5 min with the column lid open. The spin column was then placed in a new 
1.5 ml collection tube (supplied in the kit). 12 μl RNase-free water was added at 
the centre of the spin column membrane. The column was then centrifuged for 3 
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min at 13200 g at RT and RNA was eluted in the collection tube. RNA was stored 
at -80 °C. 
For plasma samples from Department of Pathology and Cancer Centre, Medical 
College of Wisconsin (MCW), US, the RNA extraction was performed by Dr. Jing 
Jia. Plasma exosome sample resuspended in 100 μl PBS was mixed with 500 μl 
QIAzol Lysis Reagent and vortexed and incubated at RT for 5 min. 100 μl 
chloroform was added to the sample and vortexed vigorously for 15 s and then 
incubated at RT for 2 min. After incubation, the sample was centrifuged for 15 
min at 12000 g at 4 °C. The upper aqueous phase was transferred to a new 
collection tube and mixed with 1.5 volumes of 100% ethanol. The sample was 
then loaded in a RNeasy MinElute spin column with a 2 ml collection tube and 
centrifuged at 12000 g for 30 s. 350 μl Buffer RWT (prepared with isopropanol) 
was added into the RNeasy MinElute spin column and centrifuge for 30 s at RT 
at 12000 g to wash. The flow-through was discarded. 80 μl Buffer RDD supplied 
with DNase from the RNase-Free DNase Set (QIAGEN) was added to the column 
and the column was incubated at RT for 15 min. 500 μl Buffer RWT (prepared 
with isopropanol) into the RNeasy MinElute spin column and centrifuge for 30 s 
at 12000 g. The flow-through was reapplied to the column and centrifuged for 30 
s at 12000 g. After discarding the flow-through, the column was loaded with 500 
μl Buffer RPE and centrifuged for 30 s at 12000 g. After discarded the flow-
through, the column was loaded with 500 μl of 80% ethanol and centrifuged for 2 
min at 12000 g. Then column was placed into a new 2 ml collection tube and 
centrifuged at full speed for 5 minutes with the lid open. Then the column was 
place in a new 1.5 ml collection tube. 14 μl RNase-free water was added to the 
column. The column was centrifuged for 1 min at full speed to elute the RNA. 
 
2.5.1.2 RNA extraction from cell line exosomes 
100 µl Buffer RLT (Qiagen, UK) with 0.25% v/v Proteinase K (from the Total 
Exosome Isolation Kit (from plasma) (Invitrogen™)) and 0.1% v/v β-
mercaptoethanol (β-ME) was added to the 200 µl of exosomes. The mixture was 
incubated at 50 °C for 30 min. Then RNA was extracted with miRNeasy micro kit 




2.5.1.3 RNA extraction from cell lines 
Total RNA from cell lines was extracted with miRNeasy micro kit (Qiagen, UK) 
according to the manufacturer’s protocol as described in 2.5.1.1.  
MiRNAs from PC3 cells were extracted using AllPrep® DNA/RNA/Protein Mini kit 
(Qiagen) and miReasy micro kit (Qiagen). 350 µl of RLT buffer (with 1% v/v β-
ME) was added to 106 cells and mixed well by pipetting up and down. The lysate 
was transferred to an ALLPrep DNA spin column placed in a 2 ml collection tube 
and centrifuged at 9000 g for 30 s. The liquid passed through was mixed with 250 
µl of 100% ethanol, mixed well and added to a RNeasy mini spin column placed 
in a 2 ml collection tube. The column was then centrifuged at 9000 g for 15 s. The 
liquid passed through was mixed with 600 µl Buffer APP and incubated at RT for 
10 min. Then the liquid was centrifuged at 13200 g for 10 min to precipitate protein. 
The supernatant was taken out and mixed with 600 µl of ethanol. The sample 
was then added to a RNeasy MinElute spin column placed in a 2 ml collection 
tube and centrifuge at 9000 g for 15 s. The flow-through was discarded and the 
column was washed by 700 µl Buffer RWT and centrifuged at 9000 g for 15 s. 
500 µl Buffer RPE was added to the column and centrifuged at 9000 g for 15 sec. 
After discarding the flow-through, another 500 µl Buffer RPE was added to the 
column and centrifuged at 9000 g for 2 min. Then the column was placed in a 
new 2 ml collection tube and centrifuged at 13200 g for 2 min. The column was 
placed in a 1.5 ml collection tube. 14 µl RNase-free water was added to the 
column and centrifuged at 13200 g for 1 min.  
 
2.6 RNA detection assays 
 Reverse transcription real-time quantitative polymerase chain reaction 
(RT-qPCR) 
2.6.1.1 cDNA synthesis 
The traditional reverse transcription was performed using miScript II RT Kit 
(Qiagen). RNA was thawed on ice. 10× miScript Nucleics Mix, RNase-free water, 
and 5× miScript HiFlex Buffer were thawed at RT. The reverse-transcription 
reaction mix was prepared on ice according to Table 4. The reactions were 
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incubated for 60 min at 37 °C following an incubation at 95 °C for 5 min. The 
reactions were then placed on ice to cool down. The cDNA was then diluted 10 
times with RNase-free water and stored at -20 °C for later use. 
Table 4. Reverse-transcription reaction components for cDNA preparation for RT-
qPCR. 
Components  Volume  
5x miScript HiFlex Buffer  2 μl  
10x miScript Nucleics Mix  1 μl  
miScript Reverse Transcriptase Mix  1 μl  
Template RNA  6 μl 
Total volume  10 μl 
 
2.6.1.2 RT-qPCR 
RT-qPCR was performed with miScript SYBR® Green PCR Kit (Qiagen) and 
miScript Primer Assays (Qiagen). MiScript Primer Assays (Qiagen) were 
reconstituted in 550 μl RNase-free water. The RT-qPCR mix was prepared on ice 
according to Table 5.  
Table 5. RT-qPCR reaction components. 
Components  Volume/reaction(384-well plate) 
2x QuantiTect SYBR Green PCR 
Master Mix 
5 μl  
10x miScript Universal Primer 1 μl  
10x miScript Primer Assay 1 μl  
RNase-free water 2 μl 
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Template cDNA  1 μl  
Total volume 10 ul 
  
Reactions were loaded in optical 384-well reaction plates and run the programme 
(Table 6) on The Applied Biosystems™ QuantStudio™ 7 Flex Real-Time PCR 
System. Water was loaded as negative control. PC3 miRNA sample was loaded 
in every plate as normaliser between plates. All reactions were run as triplicates. 
 
Table 6. Cycling conditions for RT-qPCR. 
Step Time Temperature 
PCR initial activation 
step 
15 min  95 °C 
3-step cycling  
Denaturation 15 s 94 °C 
Annealing 30 s 55 °C 
Extension 30 s 70 °C 
Cycle number 40 cycles 
 
 Fluidigm multiple RT-qPCR 
Samples for Fluidigm multiple RT-qPCR were prepared using the miScript 
Microfluidics PreAMP Kit (Qiagen), miScript Microfluidics PCR Kit (Qiagen), and 
miScript Primer Assays (Qiagen).  
2.6.2.1 cDNA synthesis 
Reverse transcription was performed using miScript II RT Kit (Qiagen). RNA was 
thawed on ice. 10× miScript Nucleics Mix, RNase-free water, and 5× miScript 
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HiSpec Buffer were thawed at RT. The reverse-transcription reaction mix was 
prepared on ice according to Table 7. The reactions were incubated for 60 min at 
37 °C following another incubation at 95 °C for 5 min. The reactions were then 
placed on ice to cool down. The cDNA was then diluted 5 times with RNase-free 
water and store at -20 °C for later use. 
Table 7. Reverse-transcription reaction components for cDNA preparation for 
Fluidigm. 
Components  Volume  
5× miScript HiSpec Buffer  2 μl  
10× miScript Nucleics Mix  1 μl  
miScript Reverse Transcriptase Mix  1 μl  
Template RNA  6 μl 




The pre-amplification was performed using miScript Microfluidics PreAMP Kit 
(Qiagen) and miScript Primer Assays (Qiagen). MiScript Primer Assays (Qiagen) 
were reconstituted with 27.5 μl RNase free water to make a concentration of 100 
μM. List of primer assays is shown in Table 8. To make miScript PreAMP Primer 
Mix, 2.2 μl of each primer assay was taken and mixed together with 1030 μl of 
RNase free water. The pre-amplification reactions were prepared according to 
Table 9. 
 
Table 8. List of primer assays used in Fluidigm multiple RT-qPCR. 
MS00031829 - Hs_miR-375_2 miScript Primer  
MS00008932 - Hs_miR-193a-5p_1 miScript Primer  
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MS00003640 - Hs_miR-184_1 miScript Primer  
MS00010752 - Hs_miR-9_1 miScript Primer  
MS00031703 - Hs_miR-320b_2 miScript Primer  
MS00003738 - Hs_miR-200a_1 miScript Primer  
MS00008372 - Hs_miR-101_3 miScript Primer  
MS00003556 - Hs_miR-148a_1 miScript Primer  
MS00003577 - Hs_miR-150_1 miScript Primer  
MS00032158 - Hs_miR-99a_2 miScript Primer 
MS00004179 - Hs_miR-423_1 miScript Primer  
MS00014707 - Hs_miR-320a_1 miScript Primer  
MS00004242 - Hs_miR-451_1 miScript Primer  
MS00003416 - Hs_miR-122a_1 miScript Primer  
MS00031234 - Hs_miR-100_2 miScript Primer  
MS00031710 - Hs_miR-320d_2 miScript Primer  
MS00009366 - Hs_miR-30c_2 miScript Primer  
MS00006552 - Hs_miR-24_1 miScript Primer  
MS00041867 - Hs_miR-320c_3 miScript Primer  
MS00048510 - Hs_miR-7706_1 miScript Primer  
MS00043491 - Hs_miR-1246_2 miScript Primer  
MS00048538 - Hs_miR-4433b-3p_1 miScript  
MS00009142 - Hs_miR-22*_1 miScript Primer 
MS00003535 - Hs_miR-146a_1 miScript Primer  
MS00003206 - Hs_miR-20b_1 miScript Primer  
MS00010549 - Hs_miR-744_1 miScript Primer  
MS00006629 - Hs_miR-125b_1 miScript Primer  
MS00008554 - Hs_miR-125a-3p_1 miScript 
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MS00008281 - Hs_let-7b*_1 miScript Primer  
MS00009408 - Hs_miR-30e*_1 miScript Primer  
MS00007350 - Hs_miR-30a-5p_1 miScript Primer 
MS00003129 - Hs_let-7c_1 miScript Primer 
 
Table 9. Pre-amplification reaction components for Fluidigm sample preparation. 
Component  Volume per 
sample  
5× miScript PreAMP Buffer  5 μl  
HotStarTaq DNA Polymerase  2 μl  
miScript PreAMP Primer Mix 5 μl  
RNase-free water  7 μl  
miScript Microfluidics Universal Primer  1 μl  
Diluted cDNA 5 μl 
Total volume  25 μl  
 
Pre-amplification was then performed in thermal cycler according to Table 10. 
 
Table 10. Cycling conditions for pre-amplification for Fluidigm sample preparation. 
Step  Time  Temperature  
PCR initial activation step 15 min  95 °C  
2-step cycling:  
Denaturation  30 s 94 °C 
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Annealing/extension  3 min 60 °C 
Cycle number 12 cycles 
 
After the run was finished, 2 μl Side Reaction Reducer was added to each pre-
amplified reaction. The samples were mixed well, and centrifuged briefly to collect 
any liquid on the tube wall.  
 
2.6.2.3 Multiple RT-qPCR 
To perform multiple RT-qPCR, primers were further diluted from 100 μM to 40 
μM by adding 7.5 μl RNase free water to 5 μl primer (100 μM). Pre-amplified 
cDNA samples were used without dilution. Multiple RT-qPCR was performed by 
Barts and the London Genome centre using BioMark HD system (Fluidigm, USA). 
Reactions were assayed in 96.96 Dynamic Array Integrated fluidic circuit. PCR 
was performed with 40 cycles. 
 
 RNA-sequencing  
2.6.3.1 Exosome RNA-sequencing 
Exosome RNA from 24 treatment-naive PCa and 24 CRPC samples were sent 
for RNA-sequencing to the Barts and the London Genome Centre core facility. 
Indexed libraries were prepared from exosomal RNA as instructed by the 
NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England 
Biolabs) according to the manufacturer’s instructions without size selection. RNA-
sequencing was performed on Illumina NextSeq 500 platform and run twice.   
 
2.6.3.2 RNA-sequencing data analysis 
Unaligned reads were trimmed and aligned against mirBase mature miRNA 
(Release 20) within Partek® Genomics Suite®. Low expression miRNAs 
(expressed in less than 25% of samples) were removed. The miRNA read counts 
were then analysed using three methods to identify differentially expressed 
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miRNAs. 1) Linear Models for Microarray and RNA-sequencing Data (Limma) 
[340] was performed using functions implemented in edgeR and limma() in R 
studio. 2) Counts per million (CPM): Read counts were transformed to CPM using 
cpm() function implemented in R package edgeR (version 2.4.0) and then 
Welch’s t-test were performed in SPSS 24. 3) The trimmed mean of M-value 
normalisation (TMM)[341] was performed using functions implemented in the 
edgeR in R studio and ExactTest() function in edgeR was used to find 
differentially expressed miRNAs. 
 
2.7 Transient miR-423-3p over-expression  
Cells were seeded in CellBind 6-well plates (Corning) with phenol red-free RPMI-
1640 (Gibco, US) supplemented with 10% charcoal-depleted FCS (Gibco) and 1% 
penicillin/streptomycin at a density of 2×105 cells per well. After 24 h when the 
cells were 70%-80% confluency, the medium was changed to phenol red-free 
RPMI-1640 (Gibco, US) supplemented with 1% penicillin/streptomycin (plain 
medium). For each well of the 6-well plate, 25 nmol of mirVana miR-423-3p 
mimics (Invitrogen)/ mirVana miRNA mimics Negative Control #1 (Invitrogen) and 
7.5 μl Lipofectamine® RNAiMAX Reagent (Invitrogen) were used. MirVana miR-
423-3p mimics (Invitrogen)/ mirVana miRNA mimics Negative Control #1 
(Invitrogen) and Lipofectamine® RNAiMAX Reagent (Invitrogen) were separately 
diluted in 150 μl plain medium, incubated for 5 min and then mixed together and 
incubated for 20 min at RT. The mixture was then added to the cells. After 6 h of 
transfection, the transfection medium was aspirated and replaced with phenol 
red-free RPMI-1640 (Gibco, US) supplemented with 10% charcoal-depleted FCS 
(Gibco) and 1% penicillin/streptomycin. 
 
2.8 Cell viability assay 
Cell viability assay was performed at 72 h of seeding using the CellTiter 96 
Aqueous Non-radioactive cell proliferation assay (Promega, UK). The assay is 
composed of a tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) and 
an electron coupling reagent (phenazine methosulfate; PMS). MTS is bioreduced 
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by cells into a formazan product that is soluble in tissue culture medium. The 
quantity of formazan product as measured by the amount of 490 nm absorbance 
is directly proportional to the number of living cells in culture. After 24 h of 
transfection, the transfected cells were trypsinised and centrifuged at 1000 rpm 
for 5 min. Cells were then resuspended and seeded in a 24-well plate at a density 
of 2×105 cells per well in same volume of medium. At 72 h of seeding, 200 μl of 
MTS and PMS mixture (1:20) was added to each well and incubated at 37 °C for 
3 h. Absorbance was then measured at 495 nm using SPECTROstar Nano 
Absorbance plate reader (BMG LABTECH).  
 
2.9 Cell migration assay 
Cell migration was assayed by transwell migration assay. After 24 h of 
transfection, the transfected cells were trypsinised and centrifuged at 1000 rpm 
for 5 min. Cells were then resuspended as single cell solution in phenol red-free 
RPMI-1640 medium supplemented with 1% charcoal-depleted FCS and 1% 
penicillin/streptomycin and counted. 24-well plates were filled with 500 μl phenol 
red-free RPMI-1640 medium supplemented with 10% charcoal-depleted FCS 
and 1% penicillin/streptomycin per well and transwell inserts with 8 μm pores 
(Corning, US) were placed on top. A total of 8×104 cells per well were seeded 
into the inserts. Cells were incubated for 24 h to migrate. Depending on the cell 
type, different number of cells will be migrated after 24h. Cells were fixed in cold 
methanol for 20 min and cells in the inner side of the insert membrane were 
removed. The membranes were then stained with 0.057% sulforhodamine B for 
30 min and rinsed in 1% acetic acid. Membranes were cut from the inserts and 
rinsed in xylene and mounted on the glass slides in DPX mounting medium. 
Slides were scanned using Hamamatsu NanoZoomer S210 system. Cell number 
was counted from equal size of each membrane. 
 
2.10 Cell invasion assay 
Cell invasion for non-transfected LNCaP and C4-2 was determined by transwell 
invasion assay using Corning® BioCoat™ Growth Factor Reduced Matrigel 
Invasion Chambers with 8.0 µm PET Membrane as previously described [23]. 
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Cells were seeded at 8×104 cells per well into the invasion chambers in phenol 
red-free RPMI 1640 medium supplemented with 1% charcoal-depleted FCS. 
Phenol red-free RPMI 1640 medium with 10% charcoal-depleted FCS was added 
in the 24-well plates to attract invasion. Depending on the cell type, different 
number of cells will be migrated after 24h. Cells were incubated for 24 h before 
they were fixed, stained and counted using the same method as for migration 
assay.  
Invasion ability of transfected LNCaP cells was assayed by single cell invasion 
assay through collagen type-I/Matrigel matrix. Cells were seeded onto the matrix 
of 1.6 mg/ml collagen type-I (BD Biosciences) and 50% growth factor-reduced 
Matrigel™ (BD Biosciences) as single cell suspension in phenol red-free RPMI 
1640 medium with 10% charcoal-depleted FCS. 24 h later, cells with 
pseudopodia-like extensions were counted as invaded cells. 
 
2.11 WB 
 Protein extraction 
Cells were lysed in lysis buffer (Table 11) on ice for 20 min with vortex every 5 
min. Cell debris were pelleted by centrifugation at 2000 g for 2 min. The 
supernatant was collected and stored at -80 °C until use. For protein extraction 
from exosomes, 50 μl of 10% Triton-100, 71.5 μl of Protease inhibitor cocktail 7×, 
and 2.5 μl of Phosphatase inhibitor were directly added to 376 μl of isolated 
exosomes (which were resuspended in PBS) and incubated on ice for 30 min 
with vortex every 5 min. To concentration the protein, the exosome protein lysate 
was mixed with 4 volumes of cold acetone (-20 °C) and incubated at -20 °C for 2 
h. The mixture was then centrifuged at 12000 g at 4 °C for 10 min. The 
supernatant was discarded. The protein pellet was air-dried and then dissolved 
in PBS.  
Table 11. Cell lysis buffer for protein extraction. 
Reagent Volume (μl) 
50 mM Tris/HCl pH8.0 752 
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10% Triton-100 100 
Protease inhibitor cocktail 7× 143 
Phosphatase inhibitor 5 
Total volume 1000 
 
 Bradford assay 
Cell lysates were defrosted on ice and the concentration of protein was measured 
by Bradford assay. 10 μl of each protein solution or standard solutions (bovine 
serum albumin (BSA) solutions at 100/200/400/500/1000/2000 μg/ml) was added 
to 190 μl of diluted 1×Protein Assay Dye Reagent Concentrate (BioRad, UK) in 
triplicates in 96-well plate. Absorbance at 565 nm was measured on 
SPECTROstar® Omega absorbance microplate reader (BMG LABTECH, 
Germany).  The standard curve was made using the readings of the standard 
solutions and the concentrations of cell lysates were calculated from the standard 
curve. 
 
 Sodium Dodecyl Sulphate-Polyacrylamide gel electrophoresis and 
Polyvinylidene difluoride (PVDF) membrane transfer 
Protein samples (30 μg) were mixed with loading buffer and reducing buffer. 
Samples were denatured at 95°C for 5 min and then loaded on the gel prepared 
according to Table 12. The denatured protein samples were loaded on the gel 
and run in 1× Tris Glysine with SDS at 80 V for 20 min and then 110 V for 80 min. 
PVDF membrane (Immobilon-P Membrane, 0.45 μm, Millipore, UK) was pre-
treated for 1 min in 100% methanol. After electrophoresis, proteins were 
transferred on PVDF membrane for 120 min at 200 mA in using standard transfer 
buffer (10% 10× Tris-Glycine buffer (0.25 M Tris base and 1.92 M glycine, 
National Diagnostics, UK), 20% methanol, 70% water).  
 
Table 12. Sodium Dodecyl Sulphate-polyacrylamide gel preparation. 
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12% resolving gel Stacking gel 
Reagents volume Reagents volume
ProtoFlowgel (Flowgen 
Bioscience, UK) 8 ml 
ProtoFlowgel (Flowgen 
Bioscience, UK) 1.3 ml 
4×ProtoFLOWGel Resolving 







water 6.8 ml water 6.1 ml 
TEMED (Sigma, UK) 20 μl TEMED (Sigma, UK) 10 μl 
10% Amonium persulphate 
(Sigma, UK) 200 μl 
10% Amonium 
persulphate (Sigma, UK) 50 μl 
 
 Antibody incubation and protein detection 
The PVDF membrane with proteins was blocked in 5% BSA in Tris Buffer 
Saline/0.1% Tween-20 (TBST) at RT for 1h. After blocking, the membrane was 
incubated with primary antibody diluted in 3% BSA at 4 °C overnight. Next day, 
the membrane was washed in TBST for 5 min three times. Then the membrane 
was incubated in secondary peroxidase conjugated antibody diluted in 3% BSA 
at RT for 1 h, followed by washes in TBST for 5 min three times. All antibodies 
used are listed in Table 13. 
Table 13. Antibodies and dilutions used for Western-blotting. 







































Protein detection was done with Immobilon Western Chemiluminescent HRP 
Substrate (Millipore, UK). 1 ml of Chemiluminescent HRP Substrate was added 
on the membrane. Protein bands were detected using X-ray film (Fuji Photo Flim, 
Fisher Scientific, UK). 
 
2.12 CTC isolation 
Several CTC isolation methods were used in this project for enumeration and/or 
culture. 
 Ficoll centrifugation 
50 ml LeucoSep tube was filled with 15.3 ml of Ficoll-Paque PLUS (Greiner Bio-
One, Germany), and spun at 1000 g for 30 sec at RT. Whole blood was added to 
the LeucoSep tube with same volume of PBS. The mix was centrifuged at 1000 
g for 15 min with breaks off. After the spin, a layer of peripheral blood 
mononuclear cells (PBMC) was shown above the frit in the LeucoSep tube. All 
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liquid above the frit was moved to a 50 ml conical tube and PBMC was pelleted 
at 200 g for 8 min. 
 
 Parsortix™ 
The Parsortix™ system (ANGLE, UK) is a micro-fluidic CTC isolation platform 
which captures CTCs in cassettes (Figure 6) based on their less deformable 
nature and larger size as compared to other blood components.  
 
2.12.2.1 For CTC enumeration 
7 ml blood was used in the Ficoll centrifugation step. After the Ficoll centrifugation 
step, the cell pellet was resuspended in 4 ml isolation buffer (PBS with 2 mM 
EDTA and 1% BSA) and added back to the original EDTA blood tube containing 
0.5 ml whole blood. 
Sample was then loaded onto Parsortix and cells were separated in the 10 μm-
gap cassette using installed program PX2_S26. The enriched cells in the cassette 
were eluted to a low retention 1.5 ml tube and centrifuged at 1000 g for 3 min. 
Cell pellet was resuspended in 10 μl of 0.075 M KCl and transferred onto poly-L-
lysine coated slides with Supersilk™ surface and wide orfice pipet tips (VWR, 
UK). Another 10 μl of 0.075 M KCl was used to rinse the tube and liquid was 
transferred onto the same slide. Slides were air-dried. Cells were fixed with cold 






2.12.2.2 For CTC culture 
Various volumes of blood were used in the Ficoll centrifugation step. If more than 
10 ml of blood was used, blood was separated into two equal portions and 
processed in two LeucoSep tube during the Ficoll centrifugation step. After the 
Ficoll centrifugation step, the cell pellet was resuspended in a total of 4 ml 
isolation buffer (PBS with 2 mM EDTA and 1% BSA) and added back to the 
original EDTA blood tube containing 0.5 ml of whole blood. 
Figure 6. Parsortix system overview and cassette design. 
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Sample was then loaded onto Parsortix and cells were separated in the 10 μm-
gap cassette using installed program PX2_S26. The enriched cells in the cassette 
were eluted to a low retention 1.5 ml tube and centrifuged at 1000 g for 3 min. 
Cell pellet was then resuspended in cell culture media. 
 
 EasySep™ 
EasySep™ is an immuno-magnetic system for CTC isolation (Figure 7). After the 
Ficoll centrifugation step, the cell pellet was repsupended in 200 µl of EasySep™ 
buffer (PBS containing 2% FCS and 1 mM EDTA) and transferred to a Falcon 5 
ml polystyrene round-bottom tube with Supersilk™ surface and wide orfice pipet 
tips. Conical tube was rinsed with 200 µl of EasySep buffer twice and liquid was 
transferred to the Falcon 5 ml polystyrene round-bottom tube. Then 30 µl of 
EasySep CD45 cocktail antibody (included in EasySep™ Human CD45 Depletion 
kit) (STEMCELL, Canada) was added into the sample, mixed well and incubate 
at RT for 15 min. 60 µl EasySep magnetic nanoparticles (included in EasySep™ 
Human CD45 Depletion kit) was added to the sample, mixed well, and incubated 
at RT for 10 min. EasySep™ buffer was added to top up the sample to a total 
volume of 2.5 ml. Cells were mixed and the tube (without cap) was placed into 
EasySep™ Violet Magnet rack (STEMCELL) and set aside for 10 min. Then the 
sample was poured into a new Falcon 5 ml polystyrene round-bottom tube. 
Remained cells in the old tube were washed with 100 µl of EasySep™ buffer and 
transferred to the new tube. The new tube with cells was placed into the magnet 
and set aside for 10 min. Cells were then poured out and pelleted by 
centrifugation at 1000 g for 3 min. 
 





RosetteSep™ is an immunodensity procedure for the isolation of cells from whole 
blood (Figure 8). By crosslinking unwanted cells to red blood cells (RBCs) present 
in the sample, target cells are purified during standard density gradient 
centrifugation. RosetteSep™ CTC enrichment cocktail containing anti-D56 
(STEMCELL) contains tetrameric antibody complexes recognizing CD3, CD14, 
CD16, CD19, CD38, CD45, CD56, CD61, CD66b and crosslinks cells positive for 
these antigens with red blood cells and deplete them via centrifugation with 
density gradient medium. 50 μl of RosetteSep™ CTC enrichment cocktail 
containing anti-D56 (STEMCELL) was added per 1 ml whole blood and mixed 
well. Sample was then incubated for 20 min at RT. Then the sample was diluted 
with an equal volume of PBS (with 2% FCS). The diluted sample was slowly 
added on top of 15 ml Lymphoprep™ (STEMCELL). The sample was then 
centrifuged at 1200 g for 20 min with the brake off. The enriched cells were taken 
from the density gradient medium/plasma interface and washed with cell culture 
medium twice and pelleted by centrifugation at 1200 rpm for 5 min. 
 
 
Figure 8. Illustration of RossetteSep work flow for CTC enrichment. 
 
2.13 CTC culture 
 Culture media 
Several culture media were used for in vitro culture of CTCs: 
1) RPMI-1640 supplemented with 1% FCS and 1% penicillin/streptomycin (for 




2) Clonetics™ Prostate Epithelial Cell Growth Medium (PrEGM) (Lonza, 
Walkersville, Inc., USA) [342]. 
3) F-medium[343]: 3:1 (v/v) F-12 Nutrient Mixture (Ham)–Dulbecco’s modified 
Eagle’s medium (Invitrogen) containing 5% FCS, 0.4 µg/mL hydrocortisone 
(Sigma-Aldrich), 1ml per liter insulin solution human (Sigma-Aldrich), 8.4 ng/ml 
cholera toxin (Sigma-Aldrich), 10 ng/ml epidermal growth factor (Peprotech), 24 
µg/ml adenine (Sigma-Aldrich),10 µmol/L Y-27632 (Selleckchem), and 
1×antibiotic antimycotic(Sigma-Aldrich). 
4) Organoid culture medium [246]. Advanced DMEM/Ham's F-12 (ADMEM/F-12) 
(Gibco) was used as basal media with supplements listed in Table 14. 
Table 14. Supplements in organoid culture medium. 
Reagents Final concentration Company 
Recombinant human EGF 5 ng/ml Peprotech 
Recombinant Human Noggin 100 ng/ml Peprotech 
Recombinant Human R-
spondin-1 500 ng/ml Peprotech 
A83-01 500 nM Tocris 
Prostaglandin E2 1 µM Tocris 
human FGF10 10 ng/ml Peprotech 
human FGF-basic 5 ng/ml Peprotech 
Nicotinamide 10 mM Sigma 
SB202190 10 µM Sigma 
n-Acetyl-cysteine 1.25 mM Sigma 
Dihydrotestosterone 1 nM Sigma 
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Y-27623 2HCl 10 µM Selleckchem.com 
B-27 1× Life technology 
HEPES 10 mM Sigma 
Glutamax 1× Life technology 
Antibiotic&antimycotic 1× Sigma 
 
5) CTC culture Plating medium and Base medium (Xcell Biosciences, San 
Francisco, US). 
 
 Culture condition 
2D culture was performed in normal cell culture plates.  Spheroid culture was 
performed in ultra-low attachment plate (Corning). For 2.5D culture, 100 μl of 
Matrigel® Growth Factor Reduced (GFR) Basement Membrane Matrix (Corning) 
was added to each well in 96-well plate and incubated in 37 °C for 1 h to solidify. 
Cells were then added on top. When using CTC culture Plating media and Base 
media (Xcell Biosciences, San Francisco, US), cell were cultured in XCM 6-well 
plates (Xcell Biosciences, San Francisco, US) in Avatar system or under hypoxia 
condition (1% O2, 5% CO2, 37 °C). 
 
2.14 Immunofluorescence staining 
Fixed CTC slides were rehydrated with PBS for 3 min. Unspecific background 
was blocked by incubating slides with 10% normal donkey serum (Sigma, UK) for 
10 min. After PBS wash 2× 2 min, slides were stained with rabbit polyclonal PE 
conjugated anti-human CD45 antibody (Miltenyi Biotec) for 15 min. Antibody 
excess was washed with  PBS for 3 min. Cells were then permeabilized with 0.1% 
Triton X-100 for 10 min followed by staining with FITC conjugated anti-CK 
(Miltenyi Biotec) and Alexa Fluor® 647 conjugated anti-Vimentin (Abcam) for 30 
min. Slide were washed in PBS 3× 3 min, dried and mounted in SlowFade® gold 
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antifade mountant with DAPI. All antibodies were diluted in dilution buffer (2% 
BSA, 2 mM EDTA in PBS) as detailed in Table 15. Slides were scanned using 
Ariol image analysis system (Leica Microsystems (Gateshead) Ltd, UK), 
equipped with an Olympus BX61 microscope. For CTC enumeration, the number 
of cells in the following categories were counted: CK+Vim-CD45- (epithelial type), 
CK+Vim+CD45- (EMT type) and CK-Vim+CD45- (mesenchymal type).  
 
Table 15. Antibodies and dilution used in immunofluorescence staining. 
Antibody Clone Dilution 
FITC conjugated anti-CK, 
Miltenyi Biotec, 130-080-101 
CK-6H5 1:30 
PE conjugated anti-CD45, 
Miltenyi Biotec, 130-080-201 
5B1 1:10 




2.15 Fluorescent in situ hybridisation (FISH) 
The cultured CTC slides used previously for IF were incubated in stripping buffer 
(containing 2% SDS, 0.0625 M Tris-HCL pH 6.8 and 0.8% β-ME) at 50 °C for 20 
min to wash off the immunofluorescence signal, following three 5 min PBS 
washes. The slides were then fixed in methanol: acetic acid (3:1) for 10 min and 
stripped of cytoplasm by incubation in 70% acetic acid for 10 min. After 3× 5 min 
PBS washes, slides were dehydrated through 3 min incubation in series of 70%, 
90% and 100% ethanol, and air-dried. AR (RP11-479J1) and PTEN (CTD-
846G17) BAC probes were used for subsequent FISH. FISH probes were 
prepared by Dr Xueying Mao. The AR (red) probe was labelled with 
Tetramethunl-rhodamine-5-dUTP (Roche, US) and PTEN probe (green) was 
labelled with Fluorecein-12-dUTP (Roche, US). Probes labelling was performed 
with BioPrime DNA Labelling System (Invitrogen, Life Technologies, UK) 
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according to the manufacturer’s protocol. For each probe, 300 ng of amplified 
BAC DNA was diluted in water to a final volume of 24 µl and mixed with 20 µl of 
random primers (octamers). The mixture was denatured at 95°C for 5 min and 
cooled on ice for 10 min. Next, the AR DNA solution was mixed with 1.75 µl of 
Tetramethunl-rhodamine -5-dUTP and the PTEN DNA solution was mixed with 
1.75 µl of Fluorescein-12-dUTP.  5 µl of the special 10×dNTP (1mM dATP, dGTP, 
dCTP, 0.65 mM dTTP) and 1 µl of Klenow enzyme (BioPrime DNA Labeling kit) 
were added to both solutions. The labelling was performed at 37 °C for 3 h and 
stopped by adding 5 µl of stop buffer. Labelled probes were cleaned with 
Microspin G50 columns (GE Healthcare, UK). Purified DNA was mixed with 30 µl 
of COT-1 DNA (Roche, UK) and 1 µl of salmon sperm DNA (Sigma, UK). Next, 
DNA was precipitated with 4 M NaCl (1/10 of DNA volume) and 2.5 volumes of 
ethanol at -80 °C for 30 min. The samples were then centrifuged at 13000 rpm 
for 20 min at 4 °C. The DNA pellet was washed with 200 µl of fresh 80% ethanol 
and centrifuged at 13000 rpm for 10 min at 4 °C. The pellet was air-dried and 
resuspended in 20 µl of nuclease-free water. 10 μl of hybridisation buffer (60% 
formamide, 12%w/v dextran sulphate, 2.4×SSC, 0.14 mM EDTA pH 8.0, 400 
μg/ml salmon sperm in water) was mixed with 1 μl of AR probe and 1 μl of PTEN 
probe and applied to each CTC slide. The slides were covered with coverslips, 
sealed with liquid rubber and denatured at 95 °C for 10 min. Finally, the slides 
were put in a humid box and incubated at 37 °C overnight to allow probes 
hybridisation. Next day the coverslips were removed and the excess of probes 
was washed off through series of washes performed at 42 °C: quick rinse in 
2×SSC to remove hybridisation solution, 4 min in 50% formamide/2×SSC twice 
and 5 min in 2×SSC twice. Finally, slides were washed twice in PBS for 5 min, 
dehydrated in 70% ethanol for 2× 20 s, air-dried and mounted in mounting 
medium with DAPI. Slide were then scanned using Ariol image analysis system. 
 
2.16 Mouse engrafting and xenograft cells in vitro culture 
The mouse engrafting and sacrifice were performed by Dr. Marc Yeste-Velasco. 
The NU Foxn1nu nude mouse was housed in the Biological Services Unit of the 
Barts Cancer Institute, Queen Mary University of London according to our 
institutional guidelines, and the United Kingdom Home Office regulations. 
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Procedures were performed under the personal license number: P1EE3ECB4. 
8.8×106 of cultured prostate cancer CTC cells were suspended in PBS, mixed 
with same volume of Matrigel and injected into the flank of nude mouse. Tumour 
was allowed to grow for 11 weeks before the mouse was sacrificed. The tumour 
tissue was then separated into three parts: 
1) Part of the tissue was put in gentleMACS™ C tube (Miltenyi Biotec) containing 
6 ml of 0.33% collagenase (STEMCELL Technologies) diluted in plain RPMI-
1640. Collagenase tissue digestion was performed at 37 °C for 90 min, with shred 
on gentleMACS dissociator system (Miltenyi Biotec) every 30 min. To stop 
enzymatic reaction, 10 ml of RPMI-1640 (supplemented with 10% FCS and 1% 
antibiotic & antimycotic) was added to the cells suspension and mixed well. After 
5 min centrifugation at 1300 rpm, the supernatant containing suspended cells 
was filtered through 70 μl filter. The pass through cells were centrifuged at 1300 
rpm for 5 min. The cell pellet was resuspended in PBS and filtered through 40 μl 
filter. The pass through cells were centrifuged at 1300 rpm for 5 min. The cell 
pellet was resuspended in RPMI-1640 (supplemented with 10% FCS and 1% 
antibiotic & antimycotic) to create single cell suspension and cultured at 37 °C 
and 5% CO2. 
2) Part of the xenograft tissue was cut to small clumps and cultured in RPMI-1640 
(supplemented with 10% FCS and 1% antibiotic & antimycotic) in 6-well plates at 
37 °C and 5% CO2.  
3) Part of xenograft tissue was fixed in 10% formalin at 4 °C overnight. The fixed 
tissue was then moved to 70% ethanol and sent to Barts Cancer Institute 
pathology service, where the tissue was embedded in paraffin and sectioned by 
Mr George Elia. 
2.17 Metaphase spreads preparation 
After reaching 70% confluence, cultured xenograft-derived cells were treated for 
4 h with 0.04 ug/ml of colcemid to arrest cultured cells in metaphase. After 4 h 
treatment of colcemid, cells were trypsinised and pelleted by centrifugation at 
1000 rpm for 3 min. The cell pellet was resuspended in pre-warmed (37 °C) 0.075 
M KCl and incubated at 37 °C for 15 min. 1 ml of fixation solution (methanol: 
acetic acid (v:v)=3:1) was added to 8 ml of cell suspension and mixed. Cells were 
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pelleted by centrifugation at 1000 rpm for 6 min. The supernatant was aspirated 
and cells were resuspended in 10 ml of fixation solution. After 15 min incubation 
at RT, cells were pelleted by centrifugation at 1000 rpm for 6 min. The 
supernatant was then aspirated and cells were resuspended in 200 μl of fixation 
solution. Glass slides used for metaphase spreads preparation were previously 
cleaned with 100% ethanol, treated in 100% acetic acid overnight, washed in 
distilled water and kept in distilled water at 4 °C. The fixed cells were then dropped 
on the glass slides and air-dried. SlowFade® gold antifade mountant with DAPI 
was added on the dried slides and the slides were covered with cover slips. The 
metaphase spreads were checked under Axioplan fluorescent microscope 
(Zeiss). 
 
2.18 Immunohistochemistry (IHC) staining 
IHC on formalin-fixed, paraffin-embedded (FFPE) xenograft sections were 
performed by Dr. Elzbieta Stankiewicz. The tissue slides were dewaxed in xylene 
for 5 min twice. Then the slides were incubated in 100% ethanol for 5 min, 
following 10 min incubation in 3% H2O2 in methanol solution. The slides were 
then washed under running water for 2 min. Next, the slides were sunk in pre-
boiled antigen retrieval solution (Vectastain, H3300) and boiled in a pressure 
cooker for 10 min. After antigen retrieval, slides were rinsed in water, spread onto 
the staining tray and equilibrated in TBST for 5 min. Next, the TBST was removed 
and the slides were incubated with the primary antibodies (diluted in 1% BSA in 
PBS with azide) for 60 min at RT. Antibodies and dilutions used for IHC are listed 
in Table 16. After incubation, the slides were rinsed with TBST for 3 min twice. 
Then the slides were incubated for 30 min at RT with secondary biotinylated 
universal antibody (Vector Lab, Vectastain Universal Elite ABC Kit, PK6200). 
After incubation, the slides were rinsed with TBST buffer for 3 min twice. Then 
complex avidin + biotinylated horseradish peroxidise (Vector Lab, Vectastain 
Universal Elite ABC Kit, PK6200) was applied to the slides and incubated for 20 
min. After incubation, the slides were rinsed with TBST for 3 min twice. The slides 
were then incubated with DAB solution (BioGenex, HK153-5KE) for 10 min. 
Finally, the slides were counterstained in Hematoxylin solution Gill’s No. 2 (Sigma) 
for 3 min, washed in water and dehydrated through series of ethanol solutions: 
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70%, 90% and 100% ethanol for 3 min each. The slides were then cleared in 
xylene for 3 min twice and mounted with xylene based mounting medium (DPX). 
 
Table 16. Primary antibodies used for IHC and their dilutions. 
Primary antibodies Dilution
Anti-AR antibody, monoclonal, mouse, clone 441 (Abcam, ab9474) 1:800 
Anti-Human PSA, Polyclonal, Rabbit (Dako, A0562)  1:8000 
 
 
2.19 Statistical analysis 
For RT-qPCR results, ΔCt value for each mature miRNA profiled was calculated 
using the formula ΔCt = sample (CtmiRNA - average CtNormalisers) - PC3 (CtmiRNA -
average CtNormaliser). 2-ΔCt was used to compare the expression levels of each 
miRNA in different groups of patients. Expression levels were compared by 
Mann-Whitney U tests. Receiver operating characteristic (ROC) curve analysis 
was used to test the performance of predictors in distinguishing CRPC patients. 
Area under the curve (AUC) was used to evaluate the prediction value of 
parameters 
For Fluidigm, results were reported as Ct values and quality threshold was set at 
0.65.  ΔCt value for each mature miRNA profiled was calculated using the formula 
ΔCt = CtmiRNA - average CtNormaliser. 2-ΔCt was used to compare the expression 
levels of each miRNA in different groups of patients. Expression levels were 
compared by Mann-Whitney U tests. Bivariate logistic regression was performed 
to combine several predictors. ROC curve analysis was used to test the 
performance of predictors in distinguishing CRPC patients. AUC was used to 
evaluate the prediction value of parameters. Spearman correlation tests were 
used to evaluate the correlation of miRNA expression levels and PSA levels and 
the correlation of Ct values generated from different methods. Two-tailed 
Student-t-test was used to compare cell proliferation, migration and invasion. 
Statistical analyses were performed in SPSS 24 and GraphPad Prism 5.1.  
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Chapter III  Identification of plasma exosomal miRNA profile 
in PCa and CRPC-associated miRNAs by RNA-
sequencing 
3.1 Introduction 
Exosomes are cell-derived small membrane vesicles (<150 nm) existing in 
various body fluids that are believed to be involved in various biological functions 
including angiogenesis, cell proliferation, tumour cell invasion and metastasis, 
immune response through intercellular transfer of their protein or RNA content 
[344]. Studies have demonstrated their important roles in intercellular 
communication, as well as the potential of using exosomes as vehicles to deliver 
therapeutic agents [195, 345].  
It has been reported that EVs contains a variety of RNA species, the majority 
being small non-coding RNAs [178, 346]. MiRNAs are stably preserved in plasma 
exosomes [347] and can be functionally active, making them an ideal source of 
non-invasive biomarker and good material to study cancer biology. A number of 
studies have been reported investigating exosomal miRNAs as diagnostic 
biomarker for PCa [348]. However, there is currently limited data generated from 
clinical samples, especially comprehensive analysis of plasma exosomal 
miRNAs in CRPC [103, 175, 346]. Plasma exosomal miRNAs associated with 
CRPC development have not been investigated. 
RNA-sequencing has quickly emerged as the preferred platform for studying 
miRNA expression in recent years. The key advantage of RNA-sequencing over 
microarray or qPCR-based miRNA expression profiling techniques is that it 
enables examining the differential expression of all small RNAs in samples 
without target RNA pre-selection. It has been previous reported that RNA-
sequencing can be used to profile the RNA contents in exosomes, and RNAs in 
exosomes bear great value as biomarker [103, 175, 346]. 
This chapter aims to identify the miRNA expression profile of plasma exosomes 
from treatment-naive PCa and CRPC patients and identify the differentially 




 Enrichment of exosomes  
Exosomes from PCa patients’ plasma were firstly isolated by precipitation using 
the commercial kit, the total Exosome Isolation Kit (from plasma) (Invitrogen). To 
check the purity and concentration of enriched exosomes, we sent exosome from 
three samples for nanoparticle tracking analysis. The nanoparticle tracking 
analysis results showed that plasma exosomes isolated with this precipitation 
commercial kit had good purity, with mean sizes and mode sizes from three 
samples were all smaller than 150 nm, though they had slightly different size 
distribution (Figure 9). Most of the particles fell in <150 nm range. Exosomes from 
different patients had varies concentrations, but all three samples had more than 
108 particles obtained from 200 µl plasma (Figure 9).  
In comparison, we used ExoEasy kit, which is a membrane-based affinity binding 
step to isolate exosomes and other EVs from plasma, to enrich exosomes and 
EVs from BCI150. The exosomes and EVs isolated using exoEasy kit showed 
larger particle size than our exosome precipitation kit and the particles sizes 
mainly fell into two ranges, <100 nm and 200-300 nm (Figure 10). Comparing to 
ExoEsy, the total Exosome Isolation Kit (from plasma) (Invitrogen) showed better 
specificity of isolating exosomes (which are of smaller sizes than other EVs). 
Therefore, the total Exosome Isolation Kit (from plasma) (Invitrogen) was used 












 Figure 9. Nanoparticle tracking analysis of exosomes isolated from plasma of 
PCa patients using the Total Exosome Isolation Kit (from plasma) 
(Invitrogen). A. Exosomes from BCI150, mean size=122 nm, mode size=32 
nm, concentration=5.47×108 particles/ml; B. Exosomes from BCI025, mean 
size=73 nm, mode size=28 nm, concentration=19.51×108 particles/ml; C. 
Exosomes from BCI158, mean size=69 nm, mode size=28 nm, 
concentration=13.96×108 particles/ml. X-axis: size (nm), Y-axis: 







Figure 10. Nanoparticle tracking analysis of exosomes and EVs isolated from 
plasma of BCI150 with ExoEasy kit (Qiagen). Mean size=188nm, mode 
size=56nm, concentration= 0.99×108 particles/ml. X-axis: size (nm), Y-axis: 
Concentration (106 particles/ml). 
 
 Analysis of exosomal miRNA by RNA-sequencing 
To profile the plasma exosomal miRNA expression pattern in treatment-naive 
PCa and CRPC, exosomes were isolated from 200 μl plasma of 24 treatment-
naive PCa patients and 24 CRPC patients using the Total Exosome Isolation Kit 
(from plasma) (Invitrogen) and exosomal RNA was extracted from each sample 
(these samples were processed together with Dr. Yang Wang). All treatment-
naive PCa had no metastasis. Most CRPC patients had metastasis that 20 out of 
the 24 CRPC patients had metastasis including regional lymph nodes metastasis 
and metastasis information for 2 patients was unavailable. Patients’ data was 
summarised in Table 17. Detailed information for each patients was listed in 
Appendix I .  
Exosomal RNA samples were sent for bioanalyzer, but the concentration was 
very low that did not show clear bands in bioanalyzer (Figure 11). To determine 
the existence of miRNA, RT-qPCR of miR-17, which was used as miRNA 
endogenous control in previous studies, was performed (performed by Dr. Yang 
Wang), In RT-qPCR, Ct of miR-16 were all less than 27, showing the potential of 









Number of cases 24 24 






Gleason score at diagnose   
6 8 1 
7 16 2 
8 0 5 
>=9 0 9 
unknown 0 7 
Median PSA at sample collection, 
ng/ml (IQR) 
9.9(6.9-12.75) 51(17.75-241.8) 
IQR: interquartile range; Prostate cancer: PCa; CRPC: castration-resistant 





Figure 11. Representative Bioanalyzer results of exosomal RNA. 
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Due to the low amount of RNA that we could obtained from exosomes from small 
volume of plasma, first attempt of library preparation with size selection failed. 
Thus, we later did not perform size selection and RNA-sequencing was run twice 
for each sample and reads from two runs were combined. From the two runs, an 
average of 5-million reads per sample was generated. As no size selection was 
performed during sample preparation, large number of the reads were from other 
RNA species and primer dimers. After alignment and annotation, 0.2% of raw 
reads were aligned to mature miRNAs. A total of 612 plasma exosome miRNAs 
were detected, with 483 detected in treatment-naive PCa and 499 in CRPC. 
Reads of all miRNAs for all samples are provided in Appendix II. 
There were 37 miRNAs which consistently expressed in all samples (Table 18). 
45 miRNAs expressed in all CRPC samples (Table 18) and 45 miRNAs 
expressed in all treatment-naive PCa samples (Table 18). On average, miR-451a 
was the most abundant miRNA in both treatment-naive PCa and CRPC. The top 
ten most abundant miRNAs detected in two groups were same and list in Table 
19. Although the rankings for each miRNAs in two groups are different, in general, 





Table 18. Plasma exosomal miRNAs expressed in all RNA-sequencing samples/ 
all treatment-naive PCa samples/ all CRPC samples. 
All samples treatment-naive PCa CRPC 
let-7a-5p let-7a-5p let-7a-5p 
let-7b-5p let-7b-5p let-7b-5p 
let-7c-5p let-7c-5p let-7c-5p 
let-7f-5p let-7d-5p let-7d-3p 
let-7g-5p let-7f-5p let-7e-5p 
let-7i-5p let-7g-5p let-7f-5p 
miR-10a-5p let-7i-5p let-7g-5p 
miR-10b-5p miR-101-3p let-7i-5p 
miR-122-5p miR-10a-5p miR-10a-5p 
miR-126-3p miR-10b-5p miR-10b-5p 
miR-128-3p miR-122-5p miR-122-5p 
miR-148a-3p miR-126-3p miR-125a-5p 
miR-150-5p miR-128-3p miR-126-3p 
miR-151a-3p miR-148a-3p miR-128-3p 
miR-181a-5p miR-150-5p miR-143-3p 
miR-183-5p miR-151a-3p miR-146a-5p 
miR-191-5p miR-16-5p miR-148a-3p 
miR-192-5p miR-181a-5p miR-150-5p 
miR-21-5p miR-183-5p miR-151a-3p 
miR-22-3p miR-185-5p miR-155-5p 
miR-24-3p miR-191-5p miR-181a-5p 
miR-25-3p miR-192-5p miR-183-5p 
miR-26a-5p miR-21-5p miR-191-5p 
miR-27a-3p miR-22-3p miR-192-5p 
miR-30a-3p miR-24-3p miR-21-5p 
miR-30d-5p miR-25-3p miR-22-3p 
miR-30e-3p miR-26a-5p miR-24-3p 
miR-320a miR-27a-3p miR-25-3p 
miR-320b miR-30a-3p miR-26a-5p 
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miR-423-3p miR-30c-5p miR-27a-3p 
miR-423-5p miR-30d-5p miR-30a-3p 
miR-451a miR-30e-3p miR-30a-5p 
miR-486-5p miR-3168 miR-30d-5p 
miR-532-5p miR-320a miR-30e-3p 
miR-92a-3p miR-320b miR-320a 
miR-99a-5p miR-363-3p miR-320b 










Table 19. The top ten most abundant miRNAs in plasma exosomes from RNA-
sequencing. 
miRNA Read counts 
treatment-naive PCa CRPC 
let-7a-5p 10785 11740 
let-7b-5p 21445 23510 
let-7i-5p 9428 13628 
miR-122-5p 6840 32435 
miR-126-3p 25910 18888 
miR-148a-3p 5696 13845 
miR-423-5p 17712 18064 
miR-451a 65849 59687 
miR-486-5p 32939 30138 




 MiRNAs differential expression analysis 
Three analysis methods (Limma, TMM and CPM) were applied to identify 
differentially expressed exosomal miRNAs in treatment-naive PCa and CRPC 
patients. These three analyses resulted in three different lists of differentially 
expressed miRNAs with 13, 13, and 11 miRNAs with p<0.01 for Limma, TMM 
and CPM respectively (Table 20). There are five miRNAs (miR-423-3p, miR-99a-
5p, miR-320a, miR-200a-3p and miR-193a-5p) showed significant differential 
expression (p< 0.01) between treatment-naive PCa and CRPC patients in three 
analyses (Table 20). These five miRNAs were all higher expressed in CRPC 
exosomes. 
 
Table 20. Significantly differentially expressed plasma exosomal miRNAs with 
p<0.01 between treatment-naive PCa and CRPC identified by RNA-sequencing. 
Limma TMM CPM 
MiRNA p-value* MiRNA p-value* MiRNA p-value* 







1.32×10-5 miR-21-5p 0.00106 
miR-101-
3p 
0.000907 miR-9-5p 1.56×10-5 miR-320a 0.0011 





0.0004 miR-451a 0.00261 


























0.006394 miR-320d 0.0029 miR-22-5p 0.00921 
miR-200a-
3p 










0.00707     
*p-values without multiple test adjustment. MiRNAs showed significant 
difference in all three analyses are in bold. Limma: Linear Models for Microarray 
and RNA-sequencing Data; CPM: counts per million transformation; TMM: the 
trimmed mean of M-value normalisation.  
 
 Prediction value of exosomal miRNA for CRPC 
To evaluate the predictive value of plasma exosomal miRNAs for CRPC, I 
performed ROC curves analysis using the CPM values of the five exosomal 
miRNAs which showed significant difference between treatment-naive PCa and 
CRPC in all three analyses. The AUC values of miRNAs were similar as the AUC 





Figure 12. ROC curves analyses of PSA and miRNAs which showed significant 
difference between treatment-naive PCa and CRPC in all three RNA-
sequencing analyses. This ROC curves analyses of miRNAs were performed 
using the count-per-million values from RNA-sequencing data. Large under the 
curve area indicates good prediction value with high sensitivity and high 
specificity. 
 
Table 21. AUCs and p-values from ROC curves analysis results of PSA level and 
miRNAs which showed significant difference between treatment-naive PCa and 
CRPC in all three RNA-sequencing analyses for CRPC prediction. 
AUC 95% CI p-value 
miR-423-3p 0.7587 0.6185 to 0.8988 0.0021 
miR-99a-5p 0.7257 0.5811 to 0.8703 0.0074 
miR-320a 0.7674 0.6347 to 0.9001 0.0015 
miR-193a-5p 0.8038 0.6791 to 0.9286 0.0003 
miR-200a-3p 0.7292 0.5842 to 0.8742 0.0065 




 In silicon analysis of published publically available plasma exosomal RNA-
sequencing  
To date, exosomal RNA-sequencing data in PCa has mainly come from studies 
from Liang Wang’s group [103, 175, 346]. Huang et al. reported their study of 
plasma exosomal RNA in 2016 using RNA-sequencing, which included samples 
from 50 healthy individuals, 100 colorectal cancer, 15 hormone-sensitive PCa 
(HSPC), 21 CRPC and 6 pancreatic cancer patients [346]. They scaled their 
sequencing data as read counts per million mapped reads (RPM, which is equal 
to CPM). I took the data of their list of the RNA transcripts with average log2 
transformed RPM >5, which were in total 187 human mature miRNAs with 
average log2 RPM>5 (as in their supplementary table 1), and did further analysis 
of the PCa and healthy control data.  
204 human mature miRNAs with average log2 CPM>5 were detected in our study, 
where 113 are shared with the 187 miRNAs detected in Huang’s study. 32 of their 
187 miRNAs were not detected in our mapped reads. The top ten most abundant 
miRNAs detected in Huang’s study are listed in Table 22. Although the rankings 
(by abundance) for each miRNAs in each sample groups are different, in general, 
the top ten most abundant miRNAs were the same within three groups. Let-7i-5p 
was within the top ten most abundant miRNAs in both our study and Huang’s. 
The top ten most abundant exosomal miRNAs detected in our study all present 
in top 65 in Huang’s data. The top ten most abundant exosomal miRNAs detected 
in Huang’s study were all detected in our study, with seven miRNAs ranked in top 
37 most abundant. The other three miRNAs had lower expression as miR-181b-
5p ranked at 111, miR-129-5p ranked at 166, and miR-9-3p ranked at 542 with 
expression in only one sample. 
 
Table 22. Top ten most abundant miRNAs in plasma exosomes in data from 
Huang et al. [346]. 
N HSPC CRPC 
miR-99a-5p miR-99a-5p miR-99a-5p 
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miR-128-3p miR-129-5p miR-129-5p 
miR-129-5p miR-22-3p miR-22-3p 
miR-22-3p hsa-let-7i-5p miR-128-3p 
miR-181a-5p miR-128-3p miR-9-3p 
miR-9-3p miR-181a-5p miR-181a-5p 
miR-100-5p miR-320a miR-100-5p 
miR-181b-5p miR-9-3p miR-181b-5p 
hsa-let-7i-5p miR-181b-5p miR-320a 
miR-320a miR-100-5p hsa-let-7i-5p 
N: healthy individual; HSPC: hormone-sensitive prostate cancer; CRPC: 
castration-resistant prostate cancer. 
 
 
I analysed differentially expressed miRNAs in plasma exosomes between healthy 
individuals and HSPC patients in Huang’s study using the RPM data and Welch’s 
t-test [346]. The top ten most significantly differentially expressed miRNAs are 
listed in Table 23. None of the identified top ten differentially expressed miRNAs 
shown significant difference in our RNA-sequencing data comparing treatment-
naive PCa and CRPC. 
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Table 23. Top ten differentially expressed miRNAs in plasma exosomes 
between healthy individuals and hormone-sensitive PCa patients in data from 













I then identified differentially expressed miRNAs in plasma exosomes between 
HSPC and CRPC patients in Huang’s study using the RPM data and Welch’s t-
test [346]. The top ten most significantly differentially expressed miRNAs are 
listed in Table 24. Six of the top ten most significantly differentially expressed 
miRNAs had low expression in our sequencing (expressed in less than 25% 
samples) and had been filtered out before our differentially expression analyses. 
The remaining four miRNAs were not significantly differentially expressed in our 
CPM analysis (unadjusted p-value for miR-125b-5p, miR-425-5p, miR-99b-3p 
and miR-652-3p was 0.085, 0.150, 0.414, and 0.533, respectively). I identified 11 
miRNAs differentially expressed between treatment-naive PCa and CRPC by 
CPM method in our data, among which miR-193a-5p and miR-320d had low 
expression in Huang’s data and were filtered out before analysis. The remaining 
nine miRNAs did not show difference at p<0.01 in the Huang’s data (unadjusted 
p-value for miR-423-3p, miR-21-5p, miR-320a, miR-451a, miR-24-3p, miR-99a-
5p, miR-146a-5p, miR-200a-3p, and miR-22-5p was 0.1572, 0.5134, 0.2342, 
0.8675, 0.1139, 0.0318, 0.0102, 0.0442, and 0.8801, respectively). 
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Table 24. Top ten most significantly differentially expressed miRNAs in plasma 
exosomes between hormone-sensitive PCa and CRPC patients in data from 

















 Exosomal miRNA profiling 
Exosome is a major member of cell-derived vesicles that has been massively 
investigated in recent years. It has been demonstrated that exosomes play 
important roles for intercellular communication and could serve as potential 
biomarkers for particular disease status. MiRNAs, as important small non-coding 
RNAs, play important roles in post-transcriptional regulation of biological 
processes [349]. The expression profiles of miRNAs vary widely in normal and 
tumour tissues [123-125]. Study of miRNAs carried in exosomes have shown that 
miRNAs are stably protected by exosomes in circulation and can be functionally 
active and transferred between cells [347, 350, 351]. Thus, investigation of 
miRNA contents in exosomes may shed light on discovery of new non-invasive 
biomarkers, as well as providing novel insight into the biological roles mediated 
by exosomes. Up to date, several resources have deposited the RNA contents in 
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exosomes, such as ExoCarta [352] , EVpedia [353], exoRBase [354] and 
EVmiRNA [355], which collect RNA expression data from publications. However, 
the most extensive exosomal RNA profile data in PCa has mainly come from 
RNA-sequencing studies from Wang’s group [103, 175, 346]. In the current study, 
we used RNA-sequencing to generate miRNA expression profile in plasma 
exosomes from treatment-naive PCa and CRPC patients. We generated 
individual libraries from 24 treatment-naive PCa and 24 CRPC patients without 
pooling cases together, thus significantly contributed to the current data for 
exosomal miRNAs in PCa. 
Our data present similar features in terms of the most abundant miRNAs from 
published exosomal RNA-sequencing data from other groups [350, 356, 357], 
which showed the reliability of our RNA-sequencing results. In our cohort, we 
found examples of highly expressed exosomal miRNAs that were previously 
reported as abundant circulating miRNAs in serum/plasma. Among the top ten 
highly expressed exosomal miRNAs, 5 miRNAs (miR-122-5p, miR-148-3p, miR-
423-5p, miR-486-5p, miR-451a) were also identified as top ten highly expressed 
miRNAs in a previous RNA-sequencing study evaluating RNAs in healthy donors’ 
serum [358]. MiR-451a is the most abundant miRNA we detected, and it is also 
reported as the most abundant miRNA in plasma from participants of an on-going 
cardiovascular disease study [359]. As we used RNase to treat our plasma 
samples to degrade RNAs outside exosomes, these shared abundant miRNAs in 
our exosomes and previous reported miRNAs in plasma/serum may suggest that 
most detectable miRNAs in plasma/serum are embedded in exosomes. 
To be noted, our RNA-sequencing profiles present slightly different features in 
terms of most abundant miRNAs as previous published data from Wang’s group 
[103, 175, 346]. We observed that the top ten most abundant miRNAs were all 
the same within different sample groups in each study, but different across two 
studies. As the exosome isolation methods, RNA-sequencing library preparation 
and reads alignment methods used in two studies were totally different. This may 
indicate that the workflow used could significantly influence the miRNA detection 
in RNA-sequencing and may have certain bias on detecting some miRNAs. The 
effects of vesicle isolation methods, RNA extraction, sequencing library 
preparation or gel size selection on RNA profiling using RNA-sequencing have 
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been previously demonstrated by Huang et al. [346]. After RNA-sequencing, the 
software packages and methods for miRNA-sequencing data processing and 
alignment to generate miRNA reads could also affect the final results [360]. The 
different workflows used between studies makes it difficult to compare miRNA 
expression across studies. Thus, it is critical to establish a standardised pipeline 
for studies of exosomal RNAs. 
 
 Differentially expressed miRNAs between treatment-naive PCa and CRPC 
identified by RNA-sequencing 
After generating RNA read counts in RNA-sequencing, RNA read counts are 
normally sent for normalisation to remove variations in the data which were 
caused by non-biological effects. Several normalisation methods for RNA-
sequencing data have been proposed, but no standard method has currently be 
established. We employed three methods, Limma, CPM and TMM, to analyse 
our sequencing data to identify differentially expressed gene. Limma is a 
commonly used package for the analysis of gene expression data arising from 
microarray or RNA-sequencing technologies by using of linear models to assess 
differential expression in the context of multifactor designed experiments [340]. 
CPM is a simple normalisation method to be applied. However some studies have 
shown that it may not be sufficient to account for technical differences across 
samples [360, 361]. The TMM method estimates scale factors between samples 
and assumes that most genes are not differentially expressed. Tam et al. 
assessed several normalisation methods and demonstrated the advantage of 
using of TMM for the miRNA-sequencing normalisation over other methods [360]. 
In our study, we used three methods and the differentially expressed miRNAs 
lists generated from these three methods were different but sharing some 
miRNAs. The difference mainly came from normalisation strategy rather than 
statistical tests. It has been previously demonstrated that different normalisation 
methods for miRNA sequencing data could cause bias [360]. Our results showed 
that different normalisation methods would affect the analyses of differentially 
expression genes with different significance levels (p-values). As there are many 
methods available, it is worth to consider using different methods when analysing 
RNA-sequencing data for a particular study. 
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In our study, there are five miRNAs (miR-423-3p, miR-99a-5p, miR-320a, miR-
200a-3p and miR-193a-5p) showed significant differential expression (p< 0.01) 
between treatment-naive PCa and CRPC patients in three analyses. The 
prediction values of all these miRNAs were similar to PSA for CRPC as 
determined by AUC, though miR-193a-5p showed slightly higher AUC than PSA. 
These data suggested potential biomarker value of exosomal miRNAs for CRPC. 
However, as the sample number is small, further validation in larger cohorts is 
required. 
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Chapter IV  Identification of plasma exosomal miRNAs as 
biomarkers for CRPC  
4.1 Introduction 
Currently, CRPC is usually diagnosed based on biochemical and radiographic 
progression [39]. Radiographic progression is hard to detect in a timely fashion 
and needs frequent bone scans and CT scans. Biochemical progression relies 
on PSA level despite castrate levels of serum testosterone. However, there are 
various reasons for raised PSA level and the serum PSA level is not always 
correlated with the clinical status of CRPC [362]. Studies of CRPC biomarkers 
have been mainly focused on identifying prognostic markers and markers for 
prognosis and therapy response in CRPC [95]. Some studies have investigated 
CRPC-related miRNAs in cell lines [363, 364], but their clinical utility as biomarker 
remain invalidated. Thus, it is important to further identify biomarkers for the 
prediction of CRPC occurrence. 
As described in Chapter III, RNA-sequencing has enabled us to characterise 
exosomal miRNA profiles of treatment-naive PCa and CRPC patients and identify 
differentially expressed exosomal miRNAs between these two groups of patients. 
RNA-sequencing has been commonly used in various biological applications in 
recent years. However, as demonstrated in previous chapter, several aspects 
including technique issues and data analysis methods could affect the results of 
differentially expressed miRNA. In addition, RNA-sequencing is much more 
expensive than other RNA quantification method, which, in most studies, caused 
limited sample number. Currently, it is still difficult to apply RNA-sequencing in 
daily clinic tests. 
RT-qPCR is a commonly used method for quantifying gene expression in clinic. 
It bears several advantages including being fast, accurate, sensitive, high-
throughput in terms of the number of clinical samples that can be analysed, cost-
effective and requiring a small amount of sample [365]. It is the current gold 
standard for the evaluation and validation of miRNA biomarkers. In this chapter, 
we examined candidate miRNAs identified by exosome RNA-sequencing in 
Chapter III in a larger cohort of patients using RT-qPCR and investigated the 




 Fluidigm validation of differentially expressed exosomal miRNAs 
To facilitate the validation of a large number of miRNAs from the RNA-sequencing 
data in a large number of samples, we firstly selected 32 miRNAs including 3 
endogenous control candidates (miR-30e-3p, miR-30a-5p and let-7c-5p) and 
quantified their expression levels with Fluidigm in a cohort of 52 treatment-naive 
PCa and 42 CRPC patients. Most treatment-naive PCa had no metastasis 
(92.3%), with only four patients had N1 disease (7.7%). Most of the CRPC 
patients had metastasis (90.5%), with only two patients without metastasis (4.8%) 
and four patients had no information for metastasis status. Patients’ information 
is summarised in Table 25. The detailed patients’ information is provided in 
Appendix I.  
 
Table 25. Summary of clinical characteristics of patients in the Fluidigm validation 
cohort. 
 Treatment-naive PCa CRPC* 
Number of cases 52 42 
Age at sample 
collection, yr, median 
(IQR) 
65.45 (58.63-69.75) 74.5 (69.02-81.25) 
Gleason score at 
diagnose   
6 27 1 
7 17 2 
8 2 3 
>=9 5 14 
unknown 1 10 (including one NEC)
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Median PSA at sample 
collection, ng/ml (IQR) 
7.5 (5.32-11.93)(missing 
two patients’ data) 
65 (20.5-335)(missing 
one patient’s data) 
IQR: interquartile range; PCa: prostate cancer; CRPC: castration-resistant 
prostate cancer; PSA: prostate-specific antigen; NEC: neuroendocrine 
carcinoma. * including 21 patients used for RNA-sequencing.  
 
Three miRNAs were initially selected as endogenous controls based on their 
stable expression across all samples in RNA-sequencing and previous reports 
[103, 175, 346]. However, in Fluidigm, miR-30e-3p was undetectable in five 
samples (Ct > 40 in two or all three technical replicate wells). Thus, miR-30a-5p 
and let-7c-5p were used as endogenous control. After Bonferroni correction of 
the p-values, there were 13 miRNAs showed significant difference between 
treatment-naive PCa and CRPC with p< 0.05 (Table 26).  
. 
Table 26. List of plasma exosomal miRNAs and their p-values/ corrected p-values 
evaluetd using Fluidigm. 
 MiRNA p-value Corrected p-value 
miR-99a-5p 8.81×10-10 2.55×10-08 
miR-100-5p 2.73×10-09 7.91×10-08 
miR-125b-5p 1.23×10-08 3.55×10-07 
let7b-3p 3.02×10-06 0.00009 
miR-320b 4.36×10-06 0.00013 
miR-320a 0.00001 0.00019 
miR-744-5p 0.00001 0.00039 
miR-200a-3p 0.00001 0.00042 
miR-24-3p 0.00010 0.00277 
miR-193a-5p 0.00013 0.00367 
miR-148a-3p 0.00032 0.00933 
miR-146a-5p 0.00059 0.01703 
miR-4433b-3p 0.00087 0.02509 
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miR-30c-5p 0.00358 0.10390 
miR-150-5p 0.01038 0.30102 
miR-9-5p 0.01133 0.32845 
miR-22-5p 0.01317 0.38181 
miR-184 0.02637 0.76481 
miR-451a 0.02637 0.76481 
miR-122-5p 0.03138 0.91000 
miR-320d 0.05247   
miR-423-3p 0.07148   
miR-1246 0.08990   
miR-125a-3p 0.14011   
miR-101-3p 0.26359   
miR-7706 0.27014   
miR-320c 0.44695   
miR-20b-5p 0.67574   
miR-375 0.91521   
 
I performed ROC analysis of PSA and the plasma exosomal miRNAs, which 
showed Bonferroni corrected p<0.05 from Fluidigm data, for the correlation with 
CRPC. The result showed that many plasma exosomal miRNAs had high AUCs 




Figure 13. ROC analysis of Fluidigm data of plasma exosomal miRNAs and 
PSA for prediction of CRPC from treatment-naive PCa. Large under the curve 
area indicates good prediction value with high sensitivity and high specificity. 
 
Table 27. ROC curves to predict CRPC from treatment by Fluidigm data of 
plasma exosomal miRNAs and PSA level. 
  Area 95% confidence interval p-value 
PSA 0.861 0.7714 to 0.9505 <0.0001 
miR-99a-5p 0.869 0.7989 to 0.9392 <0.0001 
miR-100-5p 0.8581 0.7841 to 0.9320 <0.0001 
miR-125b-5p 0.8429 0.7659 to 0.9200 <0.0001 
let7b-3p 0.7811 0.6852 to 0.8771 <0.0001 
miR-320b 0.7766 0.6803 to 0.8728 <0.0001 
miR-320a 0.7715 0.6769 to 0.8661 <0.0001 
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miR-744-5p 0.7619 0.6614 to 0.8624 <0.0001 
miR-200a-3p 0.761 0.6594 to 0.8626 <0.0001 
miR-24-3p 0.7349 0.6295 to 0.8402 <0.0001 
miR-193a-5p 0.7308 0.6277 to 0.8338 0.0001 
miR-148a-3p 0.7166 0.6103 to 0.8229 0.0003 
miR-146a-5p 0.707 0.5968-0.8171 0.0006 
miR-4433b-3p 0.7005 0.5944-0.8067 0.0009 
 
The Fluidigm results showed plasma miRNAs had great prediction value for 
CRPC. However, within the 13 miRNAs which showed significant (adjusted p< 
0.05) difference between treatment-naive PCa and CRPC in Fluidigm, there are 
four miRNAs which had opposite expression pattern as they were identified in 
RNA-sequencing (Table 28). MiR-100-5p was found expressed higher in CRPC 
in the Fluidigm validation but expressed lower in CRPC in the RNA-sequencing 
data. MiR-320b, miR-320a and miR-744-5p were found expressed lower in 
CRPC in the Fluidigm validation but expressed higher in CRPC in the RNA-
sequencing. These conflict results led to our further validation of plasma 
exosomal miRNA expression using traditional RT-qPCR. 
 
Table 28. Summary of significantly differentially (adjusted p-value <0.01) 
expressed plasma exosomal miRNAs between treatment-naive PCa and CRPC 
identified by Fluidigm and their expression patterns in RNA-sequencing*. 
MiRNA Fluidigm result adjusted p-value RNA-sequencing result 
miR-99a-5p high in CRPC 2.5537×10-08 high in CRPC 
miR-100-5p high in CRPC 7.9124×10-08 low in CRPC 
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miR-125b-5p high in CRPC 3.5530×10-07 high in CRPC 
let-7b-3p high in CRPC 8.7559×10-05 high in CRPC 
miR-320b low in CRPC 1.2643×10-04 high in CRPC 
miR-320a low in CRPC 0.0002 high in CRPC 
miR-744-5p low in CRPC 0.0004 high in CRPC 
miR-200a-3p high in CRPC 0.0004 high in CRPC 
miR-24-3p high in CRPC 0.0028 high in CRPC 
miR-193a-5p high in CRPC 0.0037 high in CRPC 
miR-148a-3p high in CRPC 0.0093 high in CRPC 
miR-146a-5p high in CRPC 0.01703 high in CRPC 
miR-4433b-3p high in CRPC 0.02509 high in CRPC 
*MiRNAs showed opposite expression pattern between Fluidigm and RNA-
sequencing are in bold. 
 
 RT-qPCR confirmation of differentially expressed plasma exosomal 
miRNAs in treatment-naive PCa and CRPC patients 
As the Fluidigm system results are inconsistent to RNA-sequencing data, I used 
the conventional RT-qPCR to investigate the plasma exosomal miRNA 
expression between treatment naive PCa and CRPC patients in a larger cohort 
of cases. MiRNAs were re-selected based on the RNA-sequencing data and 
many of them have been included in the Fluidigm analysis. Plasma samples from 
108 treatment-naive PCa and 42 CRPC patients (including 24 patients whose 
plasma exosomal miRNAs had been analysed both by in RNA-sequencing and 
the Fluidiam) were used. Most treatment-naive PCa patients had no metastasis 
(95.4%), with only five patients bearing metastasis including regional lymph 
nodes metastasis. Most of the CRPC patients had metastasis including regional 
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lymph nodes metastasis (81%), with only two patients without metastasis (4.8%) 
and six patients had no metastasis information. Patients’ data were summarised 
in Table 29 and detailed information is listed in Appendix I.  
 
Table 29. Summary of clinical characteristics of patients in the RT-qPCR 
validation cohort. 
 
 Treatment-naive PCa CRPC* 
Number of cases 108 42 
Age at sample 
collection, yr, 
median (IQR) 
65.90 (57.875-72.1) 72.65 (68.375-80.875) 
Gleason score at 
diagnose   
6 36 1 
7 58 7 
8 6 8 
>=9 8 16 
unknown 0 10 




8.9 (5.75-13) 57 (21.5-192.25) 
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IQR: interquartile range; PCa: prostate cancer; CRPC: castration-resistant 
prostate cancer; PSA: prostate-specific antigen. * including 24 patients used 
for sequencing  
 
 
There are five miRNAs which showed significant difference in three sequencing 
data analyses. Among them, one miRNA, miR-200a-3p expressed at very low 
level which cannot be detected by our RT-qPCR method in many samples. In the 
126 evaluated sample, 76 samples had Ct larger than 35 or undetected of miR-
200a-3p. This is consistent to Fluidigm data, in which 35 out of 94 samples had 
no detection of miR-200a-3p. Out of the remaining four miRNAs, three miRNAs, 
miR-423-3p, miR-320a and miR-99a-5p were significantly differentially 
expressed between treatment-naive PCa patients and CRPC (p= 7.3×10-8, 0.002 
and 0.0186, respectively) (Figure 14A). Consistent to the RNA-sequencing data, 
these three miRNAs expressed at higher levels in CRPC compared to treatment-
naive PCa. MiR-193a-5p did not show significant difference between treatment-
naive PCa and CRPC in the RT-qPCR cohort (Figure 14A). 
We also tested six miRNAs which showed significant difference in two of the three 
analysis methods of RNA-sequencing data. Among these six miRNAs, miR-375 
could not be detected efficiently by our RT-qPCR method, with 118 out of 126 
samples evaluated presented Ct over 30 while Ct of negative control (water) 
presented at 32.9 which was close to the Ct of samples. This problem was also 
observed in Fluidigm, where 41 out of the 94 samples had more than 2 or 3 wells 
of three technical replicates had failed quality score. Of the remaining five 
miRNAs, three miRNAs, miR-320d, miR-320b and miR-150-5p were significantly 
differentially expressed (p= 0.0028, 0.0013 and 0.0058, respectively) (Figure 14B) 
and miR-148a-3p and miR-451a showed no difference between treatment-naive 
PCa and CRPC (p= 0.95 and 0.98 respectively) (Figure 14B).  
Four miRNAs which showed significant difference in one of the three analysis 
methods were also checked. MiR-101-3p, miR-21-5p and miR-24-3p showed no 
difference in the RT-qPCR validation (p= 0.086, 0.17 and 0.075, respectively) 
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(Figure 15). MiR-9 had too low expression to be detected, as 92 out of 126 
evaluated samples had undetected level or Ct>35. 
 
Figure 14. RT-qPCR evaluation of plasma exosomal miRNAs in treatment-naive 
PCa and CRPC. A. MiRNAs identified by three RNA-sequencing analyses; B. 






Figure 15. RT-qPCR evaluation of plasma exosomal miRNAs in treatment-naive 
PCa and CRPC which were identified by one RNA-sequencing analysis. 
 
 
 Independent validation of miR-423-3p in MCW centre 
The most significantly differentially expressed plasma exosomal miRNA, miR-
423-3p, was then evaluated in MCW by Professor Liang Wang’s team. 30 
treatment-naive PCa and 30 CRPC samples were used. The patients’ information 
is summarised in Table 30. Although different exosomal isolation method was 
used, in the MCW cohort, miR-423-3p also showed significant difference in the 
plasma exosomes between treatment-naive PCa and CRPC with p= 0.0163 
(Figure 16A). AUC of miR-423-3p was 0.679 (95% CI= 0.542-0.817, p= 0.017). 
Using the same combination model generated in the Barts cohort of treatment-
naive PCa and CRPC described in 4.2.5(combine model= 
0.026*PSA+0.033*miR-423-3p), miR-423-3p in combination with PSA improves 
the prediction value of PSA alone from AUC = 0.716 (95% CI=0.5822-0.8499, p= 
0.0044) to AUC = 0.729 (95% CI= 0.5963-0.8612, p= 0.0026) for CRPC (Figure 
16B).  
 




 Treatment-naive PCa CRPC 
Number of cases 30 30 
Age at sample collection, yr, 
median(IQR) 67.30 (63.38-80.55) 
71.70 (65.85-
76.58) 
Gleason score at diagnose      
<=6 2 4 
7 14 9 
8 3 4 
>=9 8 10 
unknown 3 3 
Median PSA at sample 
collection, ng/ml (IQR) 
7 (1.75-28.55)(missing one 





Figure 16. RT-qPCR evaluation of miR-423-3p for its CRPC prediction value in 
a MCW cohort. A. Scatter plots of plasma exosomal miR-423-3p expression 
levels; significance is defined by raw p-value (*p< 0.05); B. ROC analysis of the 
123 
 
efficiencies of miR-423-3p (AUC= 0.679, p= 0.017), serum PSA (AUC = 0.716, 
p= 0.0044) and the combination model of PSA and miR-423-3p (AUC = 0.729, p 
= 0.0026) in discriminating CRPC from treatment-naive PCa. Large under the 





 RT-qPCR identified differentially expressed plasma exosomal miRNAs 
between treated non-CRPC and CRPC patients 
For above, we have validated differentially expressed exosomal miRNAs 
between untreated PCa and CRPC. Considering the management of PCa 
patients in clinics where patients receive hormone therapy before diagnosis of 
CRPC, I further checked the miRNAs levels in 36 PCa patients who were 
receiving hormone therapy but had not developed CRPC (non-CRPC). Most 
patients had metastasis including regional lymph nodes metastasis (75%), with 
eight patients (22.2%) had no metastasis and one patient had no metastasis 
information. The six exosomal miRNAs validated by RT-qPCR comparing 
untreated and CRPC patients showed interesting expression patterns within 
treatment-naive PCa, non-CRPC and CRPC (Figure 17). Five of the six miRNAs, 
miR-423-3p (p< 0.0001), miR-320a (p< 0.0001), miR-320b (p< 0.0001), miR-
320d (p< 0.0001) and miR-99a-5p (p< 0.0001) showed significant difference 
between non-CRPC and CRPC. In addition, treatment-naive miR-320a (p= 
0.0047), miR-320b (p< 0.0001), miR-99a-5p (p< 0.0001), miR-320d (p< 0.0001), 
and miR-150-5p (p= 0.0013) showed significant difference between treatment-
naive PCa and non-CRPC, while the expression level of miR-423-3p had no 






Figure 17. RT-qPCR evaluation of plasma exosomal miRNAs in
treatment-naive PCa, non-CRPC and CRPC. 
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I then checked the expression level of five miRNAs which showed no difference 
between treatment-naive PCa and CRPC. Surprisingly, three of them (miR-101-
3p, miR-193a-5p and miR-148a-3p) were significantly differentially expressed 
between treated non-CRPC and CRPC with p<0.001 (Figure 18). 
 
Figure 18. RT-qPCR evaluation of plasma exosomal miRNAs which showed no 
difference in treatment-naive PCa and CRPC.  
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 Evaluation of plasma exosomal miRNAs as potential biomarkers for CRPC 
To evaluate the predictive value of plasma exosomal miRNAs for CRPC, we 
performed ROC curves analysis based on the RT-qPCR results. When 
comparing the treatment-naive PCa and CRPC, miR-423-3p showed best 
prediction value with AUC= 0.7835 (95% CI: 0.707- 0.860, p< 0.0001)(Figure 19A, 
Table 31) among the miRNAs. Any combination of miRNAs did not show better 
performance than miR-423-3p alone. Although its efficiency was lower than PSA 
(AUC= 0.837, 95% CI: 0.740- 0.934, p< 0.0001), when combined with PSA in a 
logistic binominal regression model (combine model= 0.026*PSA+0.033*miR-
423-3p REL), the performance improved to AUC= 0.9076 (95% CI: 0.861- 0.955, 














Figure 19. ROC analyses of exosomal miRNAs for prediction of CRPC from 
treatment-naive PCa using RT-qPCR data. A. MiRNAs showed significant 
different expression between CRPC and treatment-naive PCa; B. MiR-423-3p, 
PSA and miR-423-3p combine PSA. Large under the curve area indicates good 






Table 31. ROC curves to predict CRPC from treatment-naive PCa by exosomal 
miRNAs and PSA level. 
 
AUC 95% CI p-value 
miR-423-3p 0.7835 0.707- 0.8601 <0.0001
miR-320a 0.6627 0.5615- 0.7639 0.002 
miR-320b 0.6695 0.5602- 0.7788 0.0013 
miR-99a-5p 0.6241 0.5144- 0.7339 0.0184 
miR-320d 0.6574 0.5486- 0.7662 0.0028 
miR-150-5p 0.6453 0.5392- 0.7514 0.0058 
PSA 0.8368 0.7401- 0.9334 <0.0001
PSA combine miR-423-3p 0.9076 0.8607 to 0.9545 <0.0001
 
 
When comparing the treated non-CRPC and CRPC, exosomal miRNAs except 
for miR-150-5p showed good AUCs and PSA showed worst prediction value of 
CRPC from non-CRPC with AUC= 0.6521 (95% CI: 0.5282-0.776, p=0.211). Five 
miRNAs showed significant difference between CRPC and treatment-naive also 
had good prediction value for CRPC when comparing CRPC and non-CRPC 
(Table 32, Figure 20A). Three miRNAs which showed no difference between 
CRPC and treatment-naive PCa but showed significant difference between 
CRPC and non-CRPC had high AUCs for CRPC (Table 32, Figure 20B), while 
the best performance comes from miR-148a-3p with AUC= 0.9087 (95% CI: 





Table 32. ROC curves to predict CRPC from non-CRPC by plasma exosomal 
miRNAs and PSA level. 
 
AUC 95% CI P value 
miR-423-3p 0.879 0.7981 to 0.9599 <0.0001 
miR-320a 0.7923 0.6921 to 0.8925 <0.0001 
miR-320b 0.8009 0.6972 to 0.9047 <0.0001 
miR-99a-5p 0.795 0.6937 to 0.8963 <0.0001 
miR-320d 0.8175 0.7205 to 0.9144 <0.0001 
miR-150-5p 0.5192 0.3887 to 0.6496 0.7713 
miR-101-3p 0.8406 0.7457 to 0.9355 <0.0001 
miR-148a-3p 0.9087 0.8383 to 0.9792 <0.0001 
miR-193a-5p 0.8313 0.7361 to 0.9266 <0.0001 

















 Association of exosomal miRNA expression with serum PSA level 
As PSA level is an important parameter in CRPC detection, we analysed the 
correlation of six plasma exosomal miRNA expression levels and serum PSA 
level in all Barts samples. The Spearman’s rank order correlation test showed 
only miR-150-5p had weak reverse correlation with PSA level, while the other five 
miRNAs were not correlated to PSA levels (Figure 21). The Spearman r for miR-
423-3p, miR-320a, miR-320b, miR-320d, miR-150-5p and miR-99a-5p were 
0.1770, 0.1136, 0.1129, 0.1188, -0.2358 and 0.1404, respectively and only miR-
423-3p and miR-150-5p reached p< 0.05. 
Figure 20. ROC analysis of exosomal miRNAs for prediction of CRPC from non-
CRPC using RT-qPCR data. A. MiRNAs showed significant different expression 
between CRPC and treatment-naive PCa also showed significant different 
expression between CRPC and treated non-CRPC; B. MiRNAs showed 
significant different expression only between CRPC and non-CRPC. Large 












 Technical investigation of the reason for inconsistence results between 
techniques used for plasma exosomal miRNA detection 
Fluidigm and traditional RT-qPCR are both RT-qPCR based methods for RNA 
quantification. However, it is found in this study that Fluidigm showed very 
different results from RNA-sequencing that some plasma exosomal miRNAs 
showed opposite expression patterns, while traditional RT-qPCR showed 
consistent results to RNA-sequencing. I then wanted to find the potential reason. 
The main difference between these Fluidigm and traditional RT-qPCR is the 
cDNA preparation process. When preparing cDNA for Fluidigm, pre-amplification 
was performed. I performed traditional RT-qPCR of let-7b in 23 cDNA samples 
used for Fluidigm PCR analysis with and without pre-amplification to compare the 
Cts to data derived from Fluidigm system. cDNA samples with amplification 
showed clearly lower Ct in the RT-qPCR (Figure 22). Cts of amplified cDNA 
correlates better with Cts obtained from Fluidigm run with Spearman r=0.8557 
with the best fit linear regression R2=0.8254, compared to non-amplified DNA 
with Spearman r=0.7826 with the best fit linear regression R2=0.7475 (Figure 22).  
When performing reverse transcription, different types of buffer in the miScript II 
RT Kit (Qiagen) were used: HiFlex buffer was used for RT-qPCR and HiSpec 
buffer was used for Fluidigm. To examine if different buffer used in the reverse 
transcription step affected final miRNA quantification, I performed reverse 
transcription using HiSpec buffer for 26 samples and ran RT-qPCR of miR-320b 
and compared to the results from HiFlex buffer. Spearman correlation analysis 
showed that the Cts generated from the same samples using HiSpec buffer and 
HiFlex buffer for reverse transcription had Spearman r=0.7338 and the best fit 






Figure 23. Correlation of Cts of miR-320b using cDNA sythesized with HiFlex 
buffer and HiSpec buffer. 
 
4.3 Discussion 
 The potential prediction value of plasma exosomal miRNAs for CRPC  
The study was initiated by comparing two distinct groups of PCa patients: 
treatment-naive PCa and CRPC and this strategy was adopted by most studies 
for CRPC-specific genes [366]. Within these two groups of patients, I identified 
several exosomal miRNAs that have prediction value for CRPC. Although none 
Figure 22. Correlation of Cts of let7b-3p from Fluidigm and 
RT-qPCR using pre-amplified and non-amplified cDNA. 
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of them overtook PSA level individually, exosomal miRNA improved prediction 
value of PSA when combined.  
As CRPC developed when patients’ are undergoing hormone therapy, I later 
checked the miRNAs levels in PCa patients who were receiving hormone therapy 
but had not developed CRPC (referring to treated non-CRPC). Five of the six 
exosomal miRNAs which were differentially expressed between treatment-naive 
PCa and CRPC also showed significant difference between treated non-CRPC 
and CRPC. In addition, three out of five miRNAs which were not differentially 
expressed between treatment-naive PCa and CRPC also showed significant 
difference between treated non-CRPC and CRPC. Importantly, all differentially 
expressed exosomal miRNAs had better prediction value for CRPC from treated 
non-CRPC than PSA. In our cohort, PSA had good AUC when comparing 
treatment-naive PCa and CRPC maybe because most (87%) of the treatment-
naive PCa patients were low/intermediate risk who had low PSA level at 8.9 
(5.75-13) ng/ml. In the treated non-CRPC group, the PSA levels fell in a wide 
range 15.5 (6.26-112.65) ng/ml. The expression level of miRNAs in treated non-
CRPC was not consistent to it in treatment-naive PCa, as 9 out 11 miRNAs I 
validated had significant difference between treatment-naive PCa and treated 
non-CRPC. Some miRNAs showed consistent aberrant expression in CRPC 
compared to non-CRPC and treatment-naive PCa, while some miRNAs showed 
fluctuated expression level along treatment-naive PCa, non-CRPC and CRPC. It 
is possible that these miRNAs are involved in different biological processes in the 
development of CRPC. These results showed the importance of evaluating 
plasma exosomal miRNA levels in treated non-CRPC patients for developing 
clinically useful CRPC predictive biomarkers. 
The miRNAs I identified in the current study have been previously reported in 
tissues, plasma/serum and some functional studies. However, the findings were 
not consistent. In my RT-qPCR validation, I found four exosomal miRNAs (miR-
423-3p, miR-320a, miR-320b and miR-320d) that were consistently higher 
expressed in CRPC compared to treatment-naive PCa and treated non-CRPC. 
In line with our finding, miR-423-3p has been previously found highly expressed 
in the plasma of patients with mCRPC compared to localised disease [366]. Mir-
423-3p was also found up-regulated in the serum of lung cancer patients (n=40) 
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compared to the benign pulmonary disease (n=40) and healthy control (n=40) 
[367]. However, in an earlier study analysing one patient’s non-metastatic and 
metastatic xenograft lines, mir-423-3p was not identified as significant 
differentially expressed miRNA [368]. 
Except for miR-423-3p, the other three miRNAs I found consistently higher 
expressed in CRPC compared to treatment-naive PCa and treated non-CRPC 
are all from miR-320 family. Several studies have reported the tumour suppressor 
role of miR-320 family members in PCa [369-371] as well as many other cancer 
types [372-375]. MiR-320a level has been found high in non-cancer prostate 
tissue compared to PCa tissue and CRPC metastasis [371]. In a study of serum 
level of miR-320a/b/c, the healthy control group showed the lowest median levels 
of miR-320a/b/c followed by the PCa group, while the BPH group showed the 
highest median expression levels of these miRNAs [376]. Changes of the levels 
of these miRNAs before and after radical prostatectomy and increased levels of 
these miRNAs after radical prostatectomy were correlated to better PSA-
recurrence-free survival [376]. Based on these findings, miR-320a/b/d are 
expected to be less abundant in plasma exosomes of CRPC patients, which is 
opposite to our findings.  
In our study, miR-193a-5p was significantly higher expressed in plasma 
exosomes of CRPC compared to treated non-CRPC, while there was no 
difference between treatment-naive PCa and CRPC. Different studies have 
shown different expression levels of miR-193-5p in PCa tissues. It has been 
found upregulated in PCa tissues and PCa cell lines, with significant suppression 
of PC3 cell apoptosis induced by oxidative stress [377, 378]. However, in a study 
examining 20 primary PCa tissues and their paired adjacent benign tissues, miR-
193a-5p was found lower expressed in the tumour tissues [379]. 
I also observed that miR-99a-5p, miR-101-3p and miR-148a-3p were expressed 
at significantly lower levels in plasma exosomes of CRPC compared to treated 
non-CRPC. MiR-99a-5p was previously  demonstrated as a tumour suppressor 
[380]. However, miR-99a has been found higher expressed in the plasma of 
mCRPC compared to localised PCa [366]. MiR-101-3p was found downregulated 
in metastatic PCa tissue compared to primary PCa tissue [381]. Tumour 
suppressor role of miR-148a-3p has been reported in many cancer types [382-
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384]. However, in PCa, miR-148a has been reported as an androgen-responsive 
miRNA which could promote LNCaP cell growth by repressing its target CAND1 
expression [385]. I also found miR-150-5p was expressed lower in plasma 
exosomes of CRPC when compared to treatment-naive PCa, but there was no 
difference between treated non-CRPC and CRPC. Both miR-150-3p and mir-
150-5p have been found as tumour suppressor in PCa [386, 387] and other 
cancer types [388]. However, one study reported elevated serum level of miR-
148a-3p and miR-150-3p in PCa patients (n=19) compared to healthy controls 
(n = 19) by RNA-sequencing and RT-qPCR [389].  
The inconsistency of the expression levels of miRNAs found in the same sample 
source, for example in blood or tissue, could be largely caused by the small 
number of samples used and different techniques used to detect miRNAs. 
However, evidence shown there are biological reasons supporting the different 
expression of miRNAs in circulation and tissues. MiRNAs are found to be 
generally downregulated in cancer [390], but in a review of serum/plasma miRNA 
in PCa, most miRNAs were found up-regulated in malignant diseases [391]. 
Studies evaluating miRNAs in tumour tissue and serum/plasma of the same 
patient also found big difference of miRNA expression patterns [138, 392]. One 
potential explanation could be that miRNAs in circulation were originated from 
various cell types. For plasma exosomes, the exosomal miRNA profile in plasma 
represents the collective miRNA contributions from various cell types. It has been 
reported that although miR-320a is highly expressed in the non-small cell lung 
cancer patients and it plays a tumour suppressor role [393, 394]. miR-320a is 
expressed by different cell types of the microenvironment but absent in epithelial 
cells both from normal and tumour lung tissues [395]. It is found that miR-320a is 
higher expressed in activated polymorphonuclear leukocytes and M2 
macrophages and could induced M2-polarization of macrophages [395]. Thus, 
the miRNAs we detected in plasma exosomes may reflect the tumour 
microenvironment and immune response status, resulting in different expression 
levels in tumour cells. Currently, it is difficult to identify the origin of exosomes. 
One potential approach is to selectively pull down EVs derived from specific 
tissues by immuno-capture specific membrane proteins. However, this approach 




 Different techniques influence evaluation of miRNA expression  
In this study, I applied two qPCR-based methods for exosomal miRNA 
quantification: the traditional RT-qPCR and Fluidigm multiple RT-qPCR. The 
main advantage of Fluidigm is that it enables detecting multiple gene targets in a 
large number of samples at one time with little amount of starting RNA material, 
making it an ideal platform for screening genes in large sample sets. However, 
the Fluidigm results are inconsistent to the RNA-sequencing data. Therefore, the 
conventional RT-qPCR method, which is not a good choice for validation of a 
large panel of miRNAs using very limited number of clinical samples, were used 
for the plasma exosomal miRNA validation. Each of the three miRNA analysis 
methods used different reverse transcription methods, with or without cDNA 
amplification step. Hence, certain degree of discorrelation is expected. My data 
showed that the traditional RT-qPCR is generally consistent to RNA sequencing 
data and the invalidated miRNAs are more likely due to false discovery rather 
than technically inconsistence. However, data from the Fluidigm were very 
different from the traditional RT-qPCR. As RT-qPCR and Fluidigm multiple RT-
qPCR should perform similar RT-qPCR reactions, consistent results were 
expected from these two methods. The main difference between these two 
methods is the cDNA preparation process. As Fluidigm used small amount of 
material and the reaction was done in extreme small volume, when preparing 
samples for Fluidigm, additional step of pre-amplification of the cDNA is required. 
When I performed traditional RT-qPCR using the cDNA prepared for Fluidigm 
before and after the pre-amplification, Cts of amplified cDNA correlates better 
with Cts obtained from Fluidigm compared to non-amplified DNA. This indicates 
that traditional RT-qPCR and Fluidigm can generate consistent results when 
using the same starting cDNA samples. However, pre-amplification would slightly 
affect the quantification. When performing reverse transcription, different types of 
buffer in the miScript II RT Kit (Qiagen) were used: HiFlex for RT-qPCR and 
HiSpec for Fluidigm. To examine if different buffer used in the reverse 
transcription step would affect final miRNA quantification, I performed reverse 
transcription using both HiSpec and HiFlex buffers for the same samples and ran 
RT-qPCR. It showed that the correlation between Cts generated from cDNA 
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samples reverse transcribed with HiSpec and HiFlex buffers was poor (Spearman 
R2=0.7503). This indicates the cDNA synthesis methods may affect miRNA 
quantification. In summary, the cDNA preparation process could affect the results 
from Fluidigm and RT-qPCR, especially for detection of differentially expressed 
miRNAs when the expression difference among samples is small. 
 
 Validation of RNA-sequencing data by RT-qPCR 
There are different techniques to quantify RNA expression. RNA-sequencing has 
been intensively used in recent decades for RNA expression profiling, however, 
RT-qPCR validation is often requested to provide evidence from a different 
method as well as to evaluate more samples. In our RT-qPCR validation step, we 
selected a number of differentially expressed miRNAs from our RNA-sequencing 
data and checked their expression in a larger cohort. Despite the miRNAs which 
we were not able to validate due to low-expression issue, the results showed the 
benefit of using different methods for RNA-sequencing data analysis. 75% (3/4) 
miRNAs which showed significant difference in three RNA-sequencing analysis 
methods and 60% (3/5) miRNAs which showed significant difference in two RNA-
sequencing analysis methods were validated in RT-qPCR, while none of the three 
miRNAs which showed significant difference in only one method was validated in 
RT-qPCR. The overall precision of our RNA-sequencing in comparison to RT-
qPCR is 0.5, which is slightly lower than a previous report [396]. Although high 
consistency of the fold changes estimated from RNA-sequencing and from the 
RT-qPCR were reported [396, 397], it was also common observed that some 
genes could not be validated and even had opposite expression direction [220, 
396, 398]. Thus, it is important to recognise the false positive and false negative 
signals from using different techniques and cross validate the target genes using 




Chapter V  Function of miR-423-3p for castration-
resistance acquisition 
5.1 Introduction 
Understanding the mechanisms of resistance that cause hormone-naive prostate 
cancer to progress to castration-resistance is the key to developing future therapy. 
Lots of studies have been done investigating the mechanism under CRPC 
development. Multiple mechanisms have been demonstrated, which can mainly 
be divided into AR-androgen axis-dependent mechanisms and AR-androgen axis 
independent mechanisms [85]. The majority of mechanisms identified leading to 
castration-resistant are mediated by AR or the androgen axis. In CRPC patients, 
low levels of androgen persist despite androgen blockade with ADT. Tumour cells 
can develop resistance either through overexpression of AR protein to cause AR 
hypersensitive to low level of androgen [86], or  AR mutations/variants to increase 
AR transactivation activity and decreased ligand specificity [88]. Amplification of 
the AR gene, overexpression of the AR protein, AR mutation are commonly 
observed among patients with CRPC. In recent years, the role of AR splice 
variants in CRPC have been implicated. For example, the presence of AR-V7 has 
been found associated with more advanced malignance and reduced survival in 
patients with mCRPC [90]. Altered expression and function of AR co-regulators 
are also involved in CRPC development [92]. AR-independent mechanisms 
mainly involves aberrant activation of other pathways such as PI3K-Akt-mTOR 
pathway, Src signalling pathway, growth factor pathways  [85].  
Alterations of miRNAs expression have been reported in CRPC. However, the 
mechanism of how miRNAs regulate CRPC development remain largely 
unknown. Pathway analyses suggested that miR-218, miR-145, miR-197, miR-
149, miR-122, and let-7b may contribute to the development of CRPC through 
the influence of Ras, Rho proteins, and the SCF complex [364], but lack of 
experimental validation. Several miRNAs have been identified as AR regulators 
or AR-regulated miRNAs, thus potentially involved in the development of CRPC 
[399]. 
MiR-423 gene is located in chromosome 17q11.2 and can produce two mature 
sequences: miR-423-3p and miR-423-5p. As described in previous chapters, 
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miR-423-3p expressed at significantly higher level in the plasma exosomes of 
CRPC compared to treatment-naive-PCa and treated hormone-sensitive PCa 
patients. MiR-423-3p has been found overexpressed in PCa tissue compared to 
non-malignant tissue [400]. It has also been found upregulated in the plasma of 
metastatic CRPC (mCRPC) compared to localised PCa and associated with 
higher Gleason score, metastasis and poorer outcome [366]. Functional studies 
have demonstrated the tumour promoting role of miR-423-3p by targeting 
different genes in different cancer types. For example, miR-423-3p was found to 
promote cell proliferation, migration, and invasion in gastric cell lines by targeting 
Bcl-2-interacting mediator of cell death [401]. It has been reported that miR-423-
3p could promote tumour progression via modulation of AdipoR2 in laryngeal 
carcinoma [402]. In glioma, miR-423-3p was found enhancing cell growth through 
inhibition of PANX2 [403]. However, its functional role in PCa has not been 
elucidated. Thus, we sought to study the potential function of miR-423-3p in 
CRPC development in this chapter.  
 
5.2 Results 
 Overexpression of miR-423-3p did not affect LNCaP cell proliferation in 
hormone-depleted medium 
To study the potential function of miR-423-3p in CRPC development, I transiently 
transfected miR-423-3p mimics in hormone-dependent PCa cell line, LNCaP, and 
cultured the cells in hormone-depleted medium. RT-qPCR showed that 
transfection of miR-423-3p mimics significantly increased the miRNA level in 
LNCaP cells compared to negative control and the high level of miR-423-3p could 




To evaluate the effect of miR-423-3p on cell proliferation, MTS assays were 
performed on the LNCaP cells transfected with miR-423-3p or negative control 
miRNA. The MTS assay results showed that overexpression of miR-423-3p did 
not affect LNCaP cell viability (Figure 25) in hormone-depleted medium. 
 
Figure 25. The effect of miR-423-3p overexpression of LNCaP cell proliferation. 
Cell viability measured by MTS assay at 96 h post transfection showed that the 
proliferation of LNCaP cells transfected with miR-423-3p mimics and negative 
control (NC) were not different. Relative cell viability was normalised to NC. Data 
Figure 24. Transient overexpression of miR-423-3p in LNCaP cells. MiR-423-3p 
level was measured at different time points after transfection. NC, negative
control. Expression of miR-423-3p was normalised to U6. 
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were obtained from three experiments and triplicate wells were used in each 
experiment. 
 
 Overexpression of miR-423-3p leads to increased cell migration and 
invasion 
I then evaluated the effect of overexpression miR-423-3p on cell migration using 
transwell assay. Overexpression of miR-423-3p led to significantly (p= 0.023) 
increased cell migration (Figure 26) (1.5 fold) of LNCaP cells in hormone-
depleted medium. On the migration membrane, more round cells sitting on the 
membrane were observed in the control group, while migrated cells in the miR-





I then attempted to evaluate the effect of miR-423-3p on cell invasion. Invasion 
Figure 26. Overexpression of miR-423-3p leads to increased LNCaP cell 
migration in hormone-depleted medium. A.  Transwell migration assay showed
1.5 fold increased cell migration in LNCaP transfected with miR-423-3p mimics 
compared to negative control (NC); B. Representative images of transwell 
membranes to show increased cell number in LNCaP transfected with miR-423-
3p mimics compared to NC; C. Morphology difference was observed between
LNCaP cells overexpressing miR-423-3p and LNCaP cells transfected with 
negative control, that LNCaP cells overexpressing miR-423-3p had more 
stretched morphology. Cells were incubated for 24 h to migrate. Photos were 
taken using Hamamatsu NanoZoomer S210 system under 200× magnification. 
Data were obtained from three experiments and triplicate wells were used in




chambers with Matrigel-coated membranes were firstly used, but LNCaP cells 
were easy to float after transfection and the invasion ability of LNCaP after 
transfection was extremely poor that it is difficult to be examined by invasion 
chambers. Thus, I performed single cell invasion assay through collagen/Matrigel 
matrix and determined 1.6 fold increased (p= 0.0134) invasion ability of LNCaP 





Figure 27. Overexpression of miR-423-3p leads to increased LNCaP cell invasion
in hormone-depleted medium. A. Single cell invasion assay showed increased
cell invasion (1.6 fold) in LNCaP transfected with miR-423-3p mimics compared
to negative control (NC); data were obtained from three experiments and triplicate
wells were used in each experiment; *p<0.05. B. Representative images of single
cell invasion assay showing increased invading cells (arrow) after LNCaP cell
overexpressing miR-423-3p.  Cells were incubated for 24 h to invade. Photos
were taken under 400× magnification. 
145 
 
 MiR-423-3p expressed at higher level in the C4-2 cells and C4-2 cells have 
better migration and invasion ability 
C4-2 is an androgen-independent isolated from LNCaP cell subcutaneous 
xenograft tumour of castrated mouse [404]. I checked the expression level of 
miR-423-3p in LNCaP and C4-2 cells and found that C4-2 cells have 1.6 fold 
higher expression of miR-423-3p (p= 0.019) than LNCaP cells (Figure 28). 
I then compared the migration and invasion ability of LNCaP and C4-2 cells in 
hormone-depleted environment and C4-2 cells showed significant better 
migration (p= 1.3×10-04) which was 3.8 folds better than LNCaP cells. C4-2 cell 
also showed 3.7 folds better invasion (p= 0.0005) ability compared to LNCaP 
cells (Figure 29). 
 
 
Figure 28. Expression level of miR-423-3p in LNCaP and C4-2 cells 
evaluated by RT-qPCR showed C4-2 cells have 1.6 fold higher expression 
of miR-423-3p than LNCaP cells. Expression of miR-423-3p was 




Figure 29. C4-2 cells have better migration and invasion ability compared to 
LNCaP cells in hormone-depleted medium. A. Transwell migration assay showed 
better migration ability of C4-2 (3.8 folds) compared to LNCaP; B. Representative 
images of transwell membranes to show better migration ability of C4-2 compared 
to LNCaP cells; C. Matrigel invasion chamber assay showed better invasion 
ability of C4-2 (3.7 folds) compared to LNCaP cells; D. Representative images of 
Matrigel invasion chamber membranes, showing C4-2 has more cells invaded 
than LNCaP. Data were obtained from three experiments and triplicate wells were 
used in each experiment. Cells were incubated for 24 h to migrate/invade. Photos 
were taken using Hamamatsu NanoZoomer S210 system under 200× 





 Investigation of potential MiR-423-3p targets 
In silicon analysis of miR-423-3p target genes were performed using TargetScan 
7.1 (http://www.targetscan.org/vert_71/) and miRDB (http://mirdb.org/). By 
TargetScan 7.1 analysis, there are several hundreds of target predicted genes. 
However, there are only 18 target genes of miR-423-3p with conserved sites 
(which tends to be more effective)(Table 33). There are 30 targets predicted in 
miRDB, with four shared genes with Targetscan 7.1, PABPC1, RAP2C, BCORL1, 
and LGALSL. However, the literature on the role of PABPC1 in PCa against our 
observation and the other three genes have not been reported for their 
involvement in PCa.  
MEIS1 is ranked third of the predicted miR-423-3p targets by TargetScan 7.1 with 
one predicted target site. It has been identified as an AR negative regulator [413] 
and found with decreased expression in metastatic tissue. However, there is no 
experimentally confirmation if MEIS1 is a miR-423-3p target. As I found miR-423-
3p could induce PCa cell migration and invasion, it is interesting to investigate if 
overexpression of miR-423-3p contribute to CRPC development through down-
regulation of MEIS1. I checked if miR-423-3p overexpression affects MEIS1 
protein expression level by WB. Biological replicates of WB analysis were carried 
out in LNCaP cells cultured in hormone-depleted medium with and without miR-
423-3p overexpression. WB showed that overexpression of miR-423-3p 
decreased MEIS1 protein expression when normalised to β-actin, though the 
degree of this effect varied in the biological replicates. WB images were shown 




Table 33. Predicted targets of miR-423-3p with conserved sites in TargetScan 7.1*. 
Orthologue of 














FAM222B family with sequence similarity 222, member B  1 1 0 0 -1.23 
RAP2C RAP2C, member of RAS oncogene family  1 1 0 0 -0.85 
MEIS1 Meis homeobox 1  1 1 0 0 -0.78 
PABPC1 poly(A) binding protein, cytoplasmic 1  1 1 0 0 -0.72 
BCORL1 BCL6 corepressor-like 1  1 1 0 0 -0.61 
GBX2 gastrulation brain homeobox 2  1 0 1 0 -0.54 
KCTD2 potassium channel tetramerization domain containing 2  1 0 1 0 -0.52 
LGALSL lectin, galactoside-binding-like  1 0 1 0 -0.51 
CINP cyclin-dependent kinase 2 interacting protein  1 0 1 0 -0.42 
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AC007375.1 Uncharacterized protein; cDNA FLJ43210 fis, clone FEBRA2020582   1 0 1 0 -0.29 
VLDLR very low density lipoprotein receptor  1 0 1 0 -0.29 
WTIP Wilms tumour 1 interacting protein  1 0 1 0 -0.28 
MYO9A myosin IXA  1 0 1 0 -0.26 
ARFGAP1 ADP-ribosylation factor GTPase activating protein 1  1 0 0 1 -0.26 
ZXDC ZXD family zinc finger C  1 0 1 0 -0.25 
RNF19B ring finger protein 19B  1 0 1 0 -0.15 
ZBTB7A zinc finger and BTB domain containing 7A  1 0 1 0 -0.14 
WDR91 WD repeat domain 91  1 0 1 0 -0.13 






 Technical development for functional evaluation of exosome miRNAs in 
vitro 
I found different expression levels of miR-423-3p in plasma exosomes of CRPC 
and non-CRPC patients, indicating that PCa may release miR-423-3p through 
exosomes into the cancer microenvironment to facilitate their castration resistant 
growth. Therefore, it is logical to explore the potential role of exosomal miR-423-
3p in CRPC development. For the preparation of this study, I attempted to 
establish and evaluate the efficiency of the exosome isolation method from cell 
culture media in our laboratory together with Dr. Yang Wang. Exosomes from cell 
culture media of PC3 and DU145 cells have been isolated by ultracentrifugation. 
Figure 30. Images of two WB showing that overexpression of miR-423-3p
slightly down-regulated MEIS1 protein expression in LNCaP cells in
hormone-depleted medium. Band density was measured using ImageJ.
The relative expression of MEIS1 in each sample is firstly normalised to β-
actin and expression in cells transfected with miR-423-3p mimic was further
normalised to negative control (NC).  
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I further confirmed the purity of exosomes by Nanosight nanoparticle tracking 
analysis, which showed exosomes isolated from cell culture media has high purity 
(Figure 31). Exosomes isolated from PC3 cell culture media presented mean 
exosome isolated from DU145 cell culture media presented mean size=52 nm, 
mode size=32 nm, size=71 nm, mode size=35 nm, concentration=13.81×108 







Figure 31. Nanosight nanoparticle tracking analysis of exosomes isolated from 
cell culture media by ultracentrifugation. A. Exosome isolated from PC3 cell
culture media, with mean size=71 nm, mode size=35 nm, 
concentration=13.81×108 particles per ml; B. Exosome isolated from DU145 
cell culture media, with mean size=52 nm, mode size=32 nm,
concentration=9.3×108 particles per ml. X-axis: size (nm), Y-axis: 
Concentration (106 particles/ml). 
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Protein was extracted from exosomes from DU145 and PC3 cells. WB detected 
ALIX expression in the isolated DU145 and PC3 exosomes (Figure 32) (Protein 
extraction and WB were done by Dr Yang Wang). ALIX is a member of exosome 
proteome, which plays important role in exosome biogenesis. It is frequently used 
as a marker for exosomes. The detection of ALIX by WB indicated success 




RNA was extracted from exosomes from PC3 cells and DU145 cells. Bioanalyzer 
showed existence of small RNAs in the exosomes from the cell culture media 
(Figure 33). From the Bioanalyser, tRNA was enriched in the exosomes (~60nt). 
I then performed RT-qPCR and detected two endogenous controls miR-30a-5p 
and let-7c-5p expression in the cell line exosomes with Ct<30. 
Figure 32. WB detection of ALIX in exosomes from DU145 and 




The method of isolating high purity exosomes from cell cultures has been 
established to facilitate further study of the miRNAs packaged in exosomes and 
the study of miRNAs delivery via exosome in the future, but I ran out of time to 
fully investigate the role of exosomal miR-423-3p in CRPC. 
 
5.3 Discussion 
Higher level of miR-423-3p in CRPC exosomes suggested that miR-423-3p could 
potentially promote tumour progression. To evaluate the function of miR-423-3p 
prostate cancer cells in relation to CRPC development, I overexpressed miR-423-
3p in hormone-dependent PCa cell line, LNCaP, and evaluated the cell 
proliferation, migration and invasion under the hormone-depleted environment. 
The increased migration and invasion ability of LNCaP cells overexpressing miR-
423-3p indicated that miR-423-3p could induce hormone-independent migration 
and invasion of LNCaP cells. The higher expression of miR-423-3p in C4-2 cells 
and higher migration and invasion ability of C4-2 cells compared to LNCaP cells 
also supported CRPC development is associated with increased cancer cell 
migration/invasion ability and miR-423-3p could promote CRPC via promoting 
hormone-independent migration and invasion. 
Figure 33. Bioanalyzer evaluation of RNA extracted from PC3 cell




MiR-423-3p has been reported to act as an oncogene via promoting cell 
proliferation, cell migration and invasion [402, 405, 406]. However, I did not 
observe changes in cell proliferation when I overexpressed miR-423-3p in LNCaP 
cells in hormone-depleted medium. My data indicated that miR-423-3p is mainly 
associated with cell migration and invasion in castration environment. Some 
studies have revealed that miR-423-3p is involved in cancer metastasis. In lung 
adenocarcinoma, miR-423-3p was found highly expressed in patients with brain 
metastasis [406] and overexpression of miR-423-3p promoted lung cancer cell 
migration [407]. CRPC is highly related to metastasis, as only small proportion of 
CRPC patients have non-metastatic disease when diagnosed with CRPC and 
about half of the non-metastatic CRPC patients would develop metastasis within 
3 years of diagnosis [408]. Thus, it is potential that miR-423-3p promoted CRPC 
development by inducing cell migration and invasion. Further study is warranted 
to understand the role of miR-423-3p in CRPC and the association of cancer cell 
invasion with CRPC development. 
MiRNAs downregulate gene expression through incorporation into the RISC, 
which then binds to partially complementary sites mainly in the 3′UTR (also can 
be in 5’ UTR) of their mRNA targets. According to TargetScan 7.1, there are in 
total 18 predicted target genes of miR-423-3p with conserved sites and MEIS1 is 
the top third target. Although it is not predicted by other prediction tool, this lower 
expression of this gene has shown positive association with PCa progression, 
while there is limited information of other predicted targets based on literatures. 
MEIS1 is a homeodomain transcription factor. In PCa, MEIS1 level exhibits a 
stepwise decrease in from benign epithelia, to primary tumour, and then to 
metastatic tissues and low expression of MEIS1 is associated with poor prognosis 
[409, 410]. MEIS1 has been identified as an AR negative regulator, which could 
inhibit the AR transcriptional activity and reduced the expression of AR target 
gene as well as disrupt the cytoplasm to nucleus translocation of AR in response 
to androgen [411]. Thus, I decided to explore if miR-423-3p could function as a 
regulator of MEIS1 in PCa cells. My WB results showed that over-expression of 
miR-423-3p decreased the protein level of MEIS1, but the effect was not big. This 
result cannot rule out the potential that MEIS1 is a miR-423-3p target. Further 
studies will be done to investigate if MEIS1 is a direct target of miR-423-3p.  
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Other genes may also be involved in the development of CRPC via regulation by 
miR-423-3p. In hepatocellular carcinoma [412], lung adenocarcinoma[406], and  
colorectal cancer [405], it has been demonstrated that miR-423-3p induces cell 
proliferation and invasion by directly targeting p21 (WAF1/CIP1), a cyclin 
dependent kinase inhibitor, although p21 (WAF1/CIP1) is not predicted as target 
of miR-423-3p either by Targetscan or miRDB. Previous reports of p21 
(WAF1/CIP1) function in PCa progression are controversial. Early studies found 
p21 (WAF1/CIP1) is highly expressed in androgen-independent tumours and 
correlates with poor prognosis [413, 414], while other studies showed  increased 
p21(WAF1/CIP1) production directly suppresses proliferation of PCa cells 
regardless of androgen sensitivity [415] and downregulation of both 
p21(WAF1/CIP1) and p27/Kip1 could produces a more aggressive prostate 
cancer phenotype[416]. Further studies should be done to determine the 
interaction of miR-423-3p and p21(WAF1/CIP1) and their role in PCa progression. 
As I found different expression levels of miR-423-3p in plasma exosomes of 
CRPC and non-CRPC patients, it would be interesting to explore the potential 
role of exosomal miR-423-3p. The exosomes in plasma may come from various 
cell types. Currently we do not have evidence of the source of the exosomes. 
However, we observed higher levels of miR-423-3p in C4-2 cells compared to 
LNCaP cells, indicating that plasma exosomes miR-423-3p expression potentially 
resembles that in the tumour tissue. It has been demonstrated that exosomes 
from malignant cells could deliver miRNAs to recipient cells and induce their 
change from non-malignant to malignant [197, 417]. Due to short of time, the role 
of exosome-derived miRNAs in CRPC development have not been elucidated in 
the present study. However, I have tested method of ultracentrifugation to enrich 
exosomes from cell culture medium, which may facilitate further studies exploring 
the mechanism of miR-423-3p packaging in exosomes, and investigation of 
whether exosomes can deliver exogenous miR-423-3p to LNCaP cells and 
mediate its hormone-sensitivity. Exosomal miRNAs have also been 
demonstrated to playing important roles in regulating cancer microenvironment 
and promoting metastasis [203, 418, 419]. The effect of exosomal miRNAs on 
other cells, for example cancer-associated fibroblast and immune cells may also 
be explored.  
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Chapter VI  In vitro propagation of PCa CTCs 
6.1 Introduction 
Patient-derived in vitro models will enable the investigation of the biology and 
genetics of PCa progression, in particular the mechanism under therapy 
response and drug resistance. Consequently, it will facilitate the identification of 
new biomarkers and the improvement of PCa clinical management. Expanding 
CTCs has offered the opportunity to establish patient-specific tumour models for 
individualised therapeutic prediction where tissue samples are not available. In 
the past decades, many research teams have attempted to establish CTC 
cultures, however limited achievements have been made.  
There is only one case report on long-term culture of CTCs from PCa which 
cultured CTCs from peripheral blood of a mCRPC patient in organoid condition 
in vitro [246]. The CTC-derived cell line could facilitate detection of gene 
mutations and aberrant gene expression. It was also amenable to drug testing 
[246]. Attempts for short-term culture of CTCs have also been reported. Using an 
in-situ size-based capture and culture method, MetaCell®, CTCs from PCa 
patients could be cultured for over two weeks [257, 292]. The limited number of 
CTCs in blood has been the main issue that hampered CTC culture. Recently, 
CTC isolation method using mononuclear cells from apheresis has been 
developed that showed promises of high yield of CTCs [296, 297], which enable 
the formation of organoids and culture for over 4-6 weeks [297].  
Our laboratory has explored a size-based CTC isolation system, Parsortix and 
demonstrated its high efficiency in capture CTCs [261] and the value of 
enumeration of CTCs as biomarker for PCa metastasis and prognosis [339]. 
Ongoing projects are aiming at exploring CTC enumeration as biomarker for PCa 
treatment response, especially for CRPC development and docetaxel response. 
My project was focused on CTC culture. This chapter aims to develop the method 
for PCa CTC culture in order to explore the value of CTC propagation for the 





 CTC enumeration using Parsortix 
For each clinical sample used for CTC culture, parallel assessment of CTC 
number using 7.5 ml blood was done using Ficoll-Parsortix and 
immunofluorescence staining as described in the method Chapter II. From the 
immunofluorescence staining, we detected different populations of CTCs: 
CK+Vim-CD45-(epithelial type), CK+Vim+CD45-(EMT type) and CK-Vim+CD45-
(mesenchymal type). Representative images of each population of cells are 
shown in Figure 34. The CTC enumeration for each sample is presented in later 
section together with CTC culture results. 
 
 
Figure 34. Representative immunofluorescence images for different types of cells 
in PCa patients. A. A representative CK+Vim-CD45- cell (arrow); B. A 
representative CK-Vim+CD45- cell (arrow); C. Two representative cells with 
CK+Vim+CD45- (arrow). Photos were taken using Ariol under 200× magnification. 
Part of this image has been published [339]. 
 
 Initial test of CTC culture from clinical samples 
To culture CTCs, I initially tried several samples with different isolation methods 
and culture media. Previously our group has shown Parsortix is an efficient CTC 
isolation platform with >50 harvest rate when testing with PCa cell lines [261]. 
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Thus, it was used as one of the CTC isolation methods for initial test for CTC 
culture from clinical samples. EasySep is a negative selection method for CTC 
enrichment, which has been tested by Dr. Lei Xu in our group to further purify 
CTCs enriched from Parsortix. To shorten processing time and avoid cell loss, I 
used Ficoll-EasySep for CTC culture instead of Ficoll-Parsortix-EasySep. PrEGM 
media is designed for primary prostate cell culture and feeder cells are commonly 
used for primary prostate cell culture [343, 420]. Organoid culture medium and 
Matrigel has previously been used for PCa cells primary culture and PCa CTC 
culture [246]. I therefore tested three culture conditions 1) PrEGM medium with 
5% Matrigel; 2) PrEGM with STO cells as feeder cells seeded at the bottom of 
the culture plate; 3) Organoid culture medium in Matrigel-coated plates (Figure 
35). Three cases were isolated with Ficoll-Parsortix. However, all three cases got 
bacteria contamination shortly in culture. Eight samples were isolated by Ficoll-
EasySep and no bacteria contamination was observed in these samples.  
 
Figure 35. Illustration of three cell culture conditions for initial test of CTC culture 
from clinical samples.  
 
When PrEGM medium is mixed with 25 % Matrigel, the medium is semisolid and 
cells remain in their position. White blood cell and red blood cell contamination 
severely affected the growth and observation of CTCs in culture in PrEGM 
medium mixed with 25 % Matrigel.  Thus I gave up this culture condition as I 
tested it in only one sample. In the three samples which I PrEGM with feeder cells, 
it was difficult to distinguish CTC cells from feeder cells. All cells died out after 
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two weeks including the feeder cells, indicating the failure of CTC expansion. In 
the four samples which I used organoid culture medium with Matrigel, attached 
cells were observed at the first 3-5 days. However, there was no live cells 
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 Test of CTC isolation methods and culture conditions 
Following the failure of the initial test of CTC culture, PCa cell lines were used to 
test different CTC isolation methods and culture media and conditions. 
6.2.3.1 Test of CTC isolation methods 
Although Ficoll-Parsortix and Fioll-EasySep did not work in initial test of CTC 
culture from clinical samples, there may be various reasons for the failure. Thus, 
there two methods were further tested using PCa cells lines. In addition, another 
negative-selection method which has been previously reported for CTC culture, 
RossetteSep [246], was also tested.  
2400 VCaP cells, which are difficult to culture at low cell density, were spiked in 
7.5 ml healthy donors’ blood for each method. VCaP cells were then isolated by 
Ficoll-Parsortix, Ficoll-EasySep or RossetteSep. Harvested cells were 
resuspended in RPMI-1640 and equally aliquoted and used for culture in four 
different conditions: 2D culture in normal 96-well plate, 2.5D culture on Matrigel-
coated 96-well plate, organoid culture mixed with Matrigel and suspension culture 
in low-attachment 96-well plate. Cells ran through Parsortix were quickly 
contaminated with bacteria within one week under all culture conditions. Viable 
cells could be isolated by EasySep and RossetteSep, but only limited cells 
survived at the beginning of culture and the cells gradually died off. This is mainly 
because VCaP cells are too difficult to be expanded when start with small number 
of cells (Figure 36). It is difficult to draw a conclusion of which isolation method 






I then used PC3 cells for spiking test using different isolation methods and culture 
conditions. 240 PC3 cells were spiked in 7.5 ml healthy donors’ blood and then 
isolated by Parsortix, EasySep or RossetteSep. Harvested cells were 
resuspended in RPMI-1640 (supplemented with 10% FCS and 
1×antibiotic&antimycotic) and equally aliquoted and used for culture in four 
different conditions. Parsortix still had contamination problem but viable cells 
were isolated and could proliferate well (Figure 37). PC3 cells enriched by 
EasySep grown better than the other two isolation methods. Normal culture plates 
and Matrigel-coated plates were both good for cell proliferation (Figure 37). 
 
 
Figure 36. Image of VCaP cells harvested from different CTC isolation methods
and cultured in four different conditions. No image shown for VCaP cells harvested
from Parsortix as the cells were contaminated. White arrows indicate spheres;




Figure 37. Image of PC3 cells harvested from three different CTC isolation 
methods and cultured in four different conditions. Photos were taken uder 40× 
magnification. 
 
6.2.3.2 Test of culture media and conditions 
VCaP cells were used to model CTC culture as VCaP cells are difficult to grow 
when starting with low number of cells. 200 VCaP cells were counted and directly 
seeded in each well of 96-well plates of three conditions and with four different 
culture media. After culturing for two weeks, cells were checked under 
microscope. It showed that RPMI-1640 (supplemented with 10% FCS and 
1×antibiotic&antimycotic) was the most suitable medium for VCaP cells that cells 
formed large colonies in normal plate and low-attachment plate (Figure 38). VCaP 
cells grown well in organoid culture medium in Matrigel-coated plates, but only 
as single cells in normal plate and low-attachment plate (Figure 38). PrEGM and 
F-medium were not as good as RPMI-1640 (supplemented with 10% FCS and 




Figure 38. VCaP cells cultured in different media and conditions. Three replicates 
were done for each condition. White arrows indicate colonies; yellow arrows 
indicate single cells. White arrows indicate spheres; yellow arrows indicate single 
cells. Photos were taken uder 40× magnification. 
 
To test if the culture conditions have the same effect to other PCa cell lines, 
similar tests were also performed using DU145 and 22Rv1 cells. As DU145 and 
22Rv1 cells are easier to expand compared to VCaP cells, in addition to testing 
using 200 cells per well, another group using 30 DU145/22Rv1 cells per well was 
tested. 
In normal plates, DU145 grown best in RPMI-1640 that the wells were confluent 
(Figure 39A). DU145 cells did not grown well in low-attachment plate and there 
was no difference between three media (Figure 39B). In Matrigel-coated plate, 
DU145 cells grew well in RPMI-1640 and organoid culture medium and formed 
more colonies (Figure 39C) than in F-medium. Least colonies formed in PrEGM 
(Figure 39C). 
For 22Rv1, in normal plates, cells grown well in RPMI-1640 and F-medium as the 
wells were confluent (Figure 40A). Cells formed small spheroids in organoid 
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culture medium, but the total live cell number was low (Figure 40A). In low-
attachment plate, 22Rv1 formed large spheres in RPMI-1640 and F-medium. 
Small spheroids were observed in organoid culture medium while very few live 
cells found in PrEGM (Figure 40B). In Matrigel-coated plates, 22Rv1 cells grew 
well in RPMI-1640 and organoid culture medium and formed more colonies than 
in F-medium (Figure 40C). Very few single live cells were observed in PrEGM 







Figure 39. Test of different culture media and conditions using DU145 cells. A.
Cells grown in normal plates; B. Cells grown in low-attachment plates; C. Cells 
grown in Matrigel-coated plates. Three replicates were done for each condition.








Figure 40. Test of different culture media and conditions using 22Rv1 cells. A. 
Cells grown in normal plates; B. Cells grown in low-attachment plates; C. Cells 
grown in Matrigel-coated plates. Three replicates were done for each condition.
Photos were taken uder 40× magnification. 
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I also tried an rotary cell culture system (SYNTHECON, US) (Figure 41) which 
could help 3D cell culture.  20000 VCaP cells were seeded in the 10 ml vessel. 
The cells formed large spheres. However, the cell count after one-week culture 
was even lower than the seeded count. Considering the system requires large 
number of cells to start and did not help VCaP cell expansion, I later did not apply 




 CTC culture using Avatar system and Xcell liquid biopsy kit 
Avatar system is a cell culture incubator which could provide hypoxia and 
pressure condition similar to that in the blood circulation. At this stage, a CTC 
isolation and culture workflow developed by Xcell bioscience (US) using Xcell 
liquid biopsy kit and Avatar cell incubator system was introduced to me. Thus I 
tested Xcell liquid biopsy kit and Avatar system with modifications on the 




Figure 41. The rotary cell culture system. 
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As RPMI-1640 had best performance for cell culture in my previous tests, I firstly 
tested five samples isolated by Ficoll-Parsortix, EasySep or Ficoll only and 
cultured the cells in RPMI-1640 in Avatar incubator (Table 35). The sample 
isolated by Ficoll-Parsortix was not contaminated by bacteria, but no cells live 
after 3 weeks of culture. The sample isolated by Ficoll-Easysep had attached 
cells in culture but the cell morphology showed the cells were unhealthy and cells 
gradually died off (Figure 42). Three samples were isolated by Ficoll and cultured 
in RPMI-1640 in Avatar system. One sample had no attached cells at day 4 of 
culture and the attached cells from other two samples died off within 3 weeks of 
culture. In summary, using RPMI-1640 and Avatar system could not facilitate 
CTC culture when I tested with clinical samples. 
Figure 42. Cells from BCI255 isolated by Ficoll-Easysep 
and cultured in RPMI-1640 in Avatar system at day 4.
Photos were taken uder 100× magnification. 
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Table 35. Summary of samples used for CTC culture with RPMI-1640 in Avatar system and the CTC counts. 





















Avatar 0 5 0 
BCI255 8.5 RPMI-1640 EDTA normal Ficoll-
Easysep 
Avatar 2 0 0 
BCI256 15 RPMI-1640 EDTA normal Ficoll Avatar 0 2 0 
BCI257 15 RPMI-1640 ACD normal Ficoll Avatar 0 0 0 




Xcell liquid biopsy kit was designed for CTC culture which includes seeding 
medium, culture medium, and 6-well plates which are coated-specially for CTC 
culture. Thus, I decided to try Xcell media and plates for CTC culture. According 
to the Xcell bioscience suggestion, CTCs were enriched by Ficoll only to reduce 
processing time and avoid further cell loss during the process.  As Avatar system 
broke down and we had limited time for the demo machine, hypoxia incubator 
was used later instead of Avatar. I employed Avatar system/hypoxia incubator 
and Xcell liquid biopsy kit to culture CTCs from 27 PCa patients’ blood. For each 
sample, we also did parallel CTC enumeration using 7.5 ml blood. Table 33 
shows the CTC isolation method, culture method used for CTC culture of each 

























BCI173 15 XCR ACD XCR  Ficoll Avatar 0 2 0 
BCI243 15 XCR ACD XCR Ficoll Avatar 0 3 0 
BCI262 18 XCR ACD XCR Ficoll Avatar 2 1 0 
BCI263 18 XCR ACD XCR Ficoll Avatar 0 2 1 
BCI244 18 XCR ACD XCR Ficoll Avatar 0 6 0 
BCI265 18 XCR ACD XCR Ficoll Avatar 2 0 1 
BCI266 18 XCR ACD XCR Ficoll Avatar 0 0 0 




coated 24-well plate 
BCI174 18 XCR ACD Half in XCR 
Half in Matrigel-
coated 24-well plate 
Ficoll Avatar 0 1 0 
BCI125 16.5 XCR ACD XCR Ficoll Avatar 0 9 0 
BCI270 8 XCR ACD XCR Ficoll Avatar 0 9 2 
BCI271 18 XCR ACD XCR Ficoll Avatar 0 0 0 
BCI159 18 XCR ACD XCR Ficoll hypoxia 1 3 0 
BCI273 18 XCR ACD XCR Ficoll hypoxia 0 2 0 
BCI274 18 XCR ACD XCR Ficoll hypoxia 0 2 0 
BCI275 17 XCR ACD XCR Ficoll hypoxia 1 3 0 
BCI276 17 XCR ACD XCR Ficoll hypoxia not countatble 
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BCI277 18 XCR ACD XCR Ficoll hypoxia 0 0 0 
BCI278 18 XCR ACD XCR Ficoll Avatar 
moved to 
hypoxia 
0 0 0 
BCI279 16.5 XCR ACD XCR Ficoll Avatar 
moved to 
hypoxia 
0 0 0 
BCI245 17 XCR ACD XCR Ficoll Avatar-
hypoxia 
3 0 0 
BCI281 18 XCR ACD XCR Ficoll hypoxia 0 0 0 
BCI282 18 XCR ACD XCR Ficoll hypoxia 3 0 0 
BCI283 18 XCR ACD XCR Ficoll hypoxia 5 0 1 
BCI290 18 XCR ACD XCR Ficoll  hypoxia 0 0 0 
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BCI291 18 XCR ACD XCR Ficoll hypoxia 2 3 1 
BCI287 17 XCR ACD XCR+Matrigel-
coated plate 
Ficoll hypoxia 0 1 0 
BCI246 17 XCR ACD Matrigel-coated 24-
well plate 
Ficoll hypoxia 0 4 0 




hypoxia 0 0 0 
BCI175 17 XCR ACD Matrigel-coated 24-
well plate 
Ficoll hypoxia 0 0 0 
BCI288 18 XCR ACD low-attachment 96-
well plate 
Ficoll hypoxia 0 0 0 
BCI289 18 XCR ACD low-attachment 96-
well plate 




Cultured CTCs in XCR 6-well plate were attached to the plates as single cells or 
colonies, exhibiting different morphologies (Figure 43). Some attached cells 
exhibited cell membrane ruffling and some exhibit elongated morphology (Figure 
43). In 26 samples which we used Xcell liquid biopsy kit and Avatar/hypoxia 
incubator, we managed to culture 15 samples for over one month, and I froze 
cells from another two samples within one-month culture. The longest culture I 
kept reached five month.  
 
 
Figure 43. Representative images of cultured CTCs in XCR 6-well plate with 
different morphologies. A. Culture cells from BCI263 at day 14; B. Cultured cells 
from BCI125 at day 18; C. Cultured cells from BCI267 at day 25. Photos were 
taken uder 100× magnification. 
 
Enriched CTCs from BCI267 and BCI174 were split into two portions and cultured 
in XCR 6-well plate and Matrigel-coated plate separately (Table 33). Cells in XCR 
6-well plate were attached to the plate as mono layers. In Matrigel-coated plate, 





Figure 44. Representative image of culture CTCs in XCR 6-well plates and 
Matrigel-coated plates. A. BCI267 cells cultured in XCR 6-well plate at day 25; B. 
BCI267 cells cultured in Matrigel-coated plate at day 28; C. BCI174 cells cultured 
in XCR 6-well plate; D. BCI174 cells cultured in Matrigel-coated plate at day 28. 
Photos were taken uder 100× magnification. 
 
 
Three samples were used to culture in Matrigel-coated plates using Xcell media, 
but cells gradually died off. Two samples were used to culture in low-attachment 
plate using Xcell media, but no spheres formed and cells could be easily removed 





 Immunofluorescence-staining and FISH analysis of cultured CTCs 
In certain cases, the enriched CTCs were able to be propagated using XCR CTC 
culture medium in hypoxia incubator for over 3 weeks. However, the cells 
exhibited different morphologies which were not typical epithelial cell morphology. 
We then sought to identify the cell type of living cells in the culture by 
immunofluorescence-staining and FISH. Cells of BCI267 cultured in XCR 6-well 
plate were harvested, dropped and fixed on glass slides. Then the cells were 
fixed and stained with CK, Vim, CD45 and DAPI. Most of the cells showed strong 
Vim stain and different levels of CD45 expression. No or very weak CK 
expression was observed. Some cells shown multiple nucleus (Figure 45). 
 
 
Figure 45. Immunoflorescence-staning of cultued CTCs from BCI267 that 
dropped on slide. Photos were taken using Ariol under 200× magnification. Blue: 
DAPI; Yellow: Vimentin; Green: CK, Red: CD45. 
 
 
To clearly observe the cell morphology at culture condition, I harvested cells of 
BCI278 cultured in XCR 6-well and cultured them on the glass coverslip. 24 h 
after the cells were attached, cells were fixed and stained with CK, Vim, CD45 
and DAPI. Similar as cells from BCI267, most of the cells shown strong Vim stain 
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and different levels of CD45 expression. No or very weak CK expression was 
observed. Some cells shown multiple nucleus (Figure 46). Most cells showed 
elongated morphology, while small portion of cells were round (Figure 46). 
 
PTEN is one of the most frequently deleted tumour suppressor gene in PCa. 
Monoallelic loss of PTEN is present in up to 60% of localised prostate cancers 
and complete loss of PTEN in PCa has been found linked to metastasis and 
androgen-independent progression [76]. AR amplification were reported in 20-30% 
of CRPC and has been suggested to develop during hormone deprivation therapy. 
Thus, I decided to perform FISH to detect AR and PTEN in the cultured CTCs to 
identify potential tumour cells. The immunofluorescence signal was washed off 
and FISH of AR and PTEN was applied on the slide of BCI267. The cell nuclei 
morphology changed potentially during FISH, but the cells could be located 
between FISH image and immunofluorescence image based on the relative cell 
position. 
Figure 46. Immunoflorescence-staining of cultured CTCs from 
BCI278 that grown on slide. A big multi-nucleus cell is indicated 
by arrow. Photos were taken using Ariol under 200× magnification.
Blue: DAPI; Yellow: Vimentin; Green: CK, Red: CD45. 
DAPI VIM CK CD45 
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Most of the cells present normal AR (one copy per cell) and PTEN (two copies 
per cell) copy number. However, I also observed cells with AR gain or PTEN loss 
genotype (Figure 47). In 211 cells examnined, nine cells were found to bear copy 
number changes.  
 
Figure 47. FISH images (left) and corresponded immunofluorescence-staining 
(right) of cultured CTC cells from BCI267. A. White arrow indicates a cell with AR 
gain; B. Two cells with PTEN loss. Immunofluorescence-staining images were 
taken using Ariol under 200× magnification and FISH images were taken using 
Ariol under 400× magnification. 
 
 Xenografts of cultured CTCs 
Cultured CTCs were also obtained from Dr. Lei Xu. These CTCs were initial 
cultured with mitomycin treated mouse fibroblast cell NIH/3T3 in F medium. 
However, NIH/3T3 cells maintained proliferation ability. Initial 
immunofluorescence staining performed by Dr Lei Xu showed that only small 
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portion of the cultured cells expressed CK, indicating the cultured CTCs are 
mixed with NIH/3T3 cells with the later as dominant.  
I recovered the cultured CTCs from Dr. Lei Xu’s frozen stock and performed 
immunofluorescence staining of the cultured CTCs and NIH/3T3 cells. 
Immunofluorescence staining showed both cultured CTCs and NIH/3T3 cells 
expressed Vim. However, only in cultured CTCs, CK expression was observed 
and cells presented different intensity of CK staining (Figure 48). 
 
Figure 48. Immunofluorescence staining of NIH/3T3 cells and mixed population 
of cultured CTCs. Immunofluorescence-staining images were taken using Ariol 
under 200× magnification.  
To enrich the tumour cells from the mixed population, the cultured CTCs were 
engrafted into the nude mouse flank (the mouse engrafting and sacrifice was 
Figure 49. Nude mouse engrafted with cultured CTCs in the flank formed
tumour (red circle) after 11 weeks. 
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performed by Dr. Marc Yeste-Velasco). Injected cells formed tumour after 11 
weeks (Figure 49).  
 
The xenograft tumour was taken out and part of the tumour tissue was cut to 
small clumps or digested and shredded into single cells. The clumps and singles 
cells were cultured in vitro. The left tissue was formalin-fixed paraffin-embedded. 
After 3 days of culture, cells climbed out the clumps (Figure 50A). From the 
shredded tumour tissue, attached cells were observed in the culture (Figure 50B). 
The cells could be passaged and proliferated quickly. However, from the cell 
morphology, it is difficult to determine the cells were tumour cells or fibroblast 
cells. 
 
Figure 50. In vitro culture of cells from CTC xenograft. A. Cells climbed out of 
tissue clump; B. Some cells attached in the shredded tissue culture. Photos were 
taken under 40× magnification. 
 
To examine the cell type, we prepared the metaphase chromosome spread slides 
of the cultured cells. The metaphase spreads showed that most of the 
chromosomes were telocentric but metacentric chromosomes were also present 
(Figure 51), indicating potential hybrid human and mouse cells. Two karyotypes 
with 61 and 125 chromosomes were observed (Figure 51). The karyotypes 
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present different chromosome numbers to NIH/3T3 cells which were reported 
having 52 to 82 chromosomes[421].  
 
Figure 51. Metaphase spread analysis of cultured cells from CTC xenograft. The 
cells presented two karyotypes with 61 chromosomes (A) and 125 chromosomes 
(B). Red circles label metacentric chromosomes. Images were taken under 600× 
magnification. 
 
We then performed IHC on the FFPE sections of the CTC derived tumour tissue 
(Dr. Elzbieta Stankiewicz helped to perform the IHC). The CTC-derive xenograft 
present cytoplasmic AR stain (Figure 52). IHC for PSA showed the xenograft had 
moderate PSA expression (Figure 53). 
 
Figure 52. Detection of AR expression in FFPE sections by IHC. A. Human BPH 
section as positive control where AR present nuclear stain; B. CTC-derived 
xenograft tissue section where AR present cytoplasmic stain; C. Human BPH 








Figure 53. Detection of PSA expression in FFPE sections by IHC. A. Human BPH 
section as positive control; B. CTC-derived xenograft tissue section; C. Human 




 CTC isolation methods for CTC culture 
Isolation and analysis of CTCs from blood have provided significant implications 
in diagnosis and therapeutic treatment of cancers. There are various techniques 
have been developed to isolate CTCs. However, isolation of CTCs remains a 
technological challenge due to their rarity and low recovery rate. The 
requirements for CTC isolation methods are different for different purposes. CTC 
isolation for CTC culture may require preservation of the cell viability and high 
harvest rate, while the demand on purity is not strict. To find a CTC isolation 
method suitable for prostate CTC in vitro culture, in this study, I tested several 
CTC isolation methods which enrich CTCs based on different principles. Ficoll-
Paque PLUS is a density gradient medium that has been recognised standard in 
laboratories worldwide for the isolation of mononuclear cells. Ficoll centrifugation 
provides a quick process to enrich mononuclear cells from whole blood. Using 
red blood cell lysis buffer to deplete red blood cells is another commonly used 
method to enrich nucleated cells. Parsortix is a size-based microfluidic system 
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that could enrich CTCs and keep cell viability [261]. Our lab has developed the 
method using Ficoll-Parsortix for CTC enumeration [261]. EasySep and 
RossetteSep used in this study are immuno-based methods to deplete white 
blood cells. EasySep depletes unwanted cells by first incubating samples with the 
magnetic nanoparticles and tetrameric antibody complexes targeting CD45. Then 
the magnetically labelled cells are separated from unlabelled cells by placing the 
sample-containing tube into the EasySep magnet, which creates a magnetic field 
that holds labelled cells on the tube wall that unlabelled cells can be poured out. 
RossetteSep crosslinks red blood cells and white blood cells that can deplete red 
blood cells and white blood cells at the same time by density centrifugation of 
Ficoll. Several studies of CTC culture have used RossetteSep to enrich CTCs 
[246, 247, 300]. I tested Ficoll-Parsortix, Ficoll-EasySep and RossetteSep using 
VCaP and PC3 cells. When using PC3 cells, viable cells could be harvested from 
Ficoll-Parsortix and cultured in vitro. However, using Parsortix had high bacteria 
contamination risk as Parsortix is an open system that samples would be exposed 
to the outside environment at several steps during the process. Both my CTC 
culture attempts using spiking and clinical blood samples all showed that cells 
isolated from Parsortix were easy to be contaminated by bacteria. Both Ficoll-
EasySep and RossetteSep enabled viable cells isolation. However, when testing 
with PC3 cells using RossetteSep, the cells in culture showed different 
morphology compared to them in routine culture. The morphology of PC3 cells 
isolated using RossetteSep indicates the reagents used in RossetteSep may 
affect cell property or induce blood cell growth. Thus, Ficoll-EasySep is the best 
CTC enrichment method among our tests to deplete white blood cells for in vitro 
culture. However, EasySep has its drawbacks including long processing time and 
potential influence of remaining magnetic beads on cell proliferation. As blood 
cells can be depleted during cell culture and additional step would inevitably 
reduce harvest rate, Ficoll centrifugation alone may be sufficient to preliminary 
enrich CTCs from whole blood.  
 
 Culture media and conditions for CTC culture 
In the published articles of CTC in vitro culture, various culture media and culture 
conditions were used without sufficient comparison to other culture methods. For 
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PCa CTC culture, limited reports have been published. For short-term culture, 
RPMI-1640 supplemented with FCS were used [257, 292]. Organoid culture 
medium was used to establish long term culture of PCa cells from CTCs and 
specimens [246]. In a recent study, organoid culture medium was used to culture 
PCa CTCs from one mCRPC patient. The spheroids were maintained for 4 to 6 
weeks [297]. PrEGM is a serum-free medium designed for prostate epithelial cell 
primary culture. I also included a modified medium, F-medium which has been 
previously reported [343] and used by Dr. Lei Xu for CTC culture. In addition to 
different media, we also included several culture conditions for test. 2D adherent 
condition is most commonly used for in vitro culture. However, it is claimed that 
non-adherent conditions are important for long-term expansion of CTCs, as CTCs 
would senesce after a few cell divisions in adherent monolayer culture [422]. A 
growing body of evidence has suggested that 3D culture represents more 
accurately the actual microenvironment where cells reside in tissues [423]. Thus, 
I also used Matrigel to provide extracellular matrix condition for CTC culture. 
Ultra-low attachment culture dish and rotary cell culture system, which force cells 
to stay in unattached conditions to minic the blood circulation situation for cancer 
cells, were also tested. When I tested different culture media and conditions with 
cell lines, we observed different cell proliferation pattern in different media and 
conditions. Different cells lines also suited differently.  
In general, all cell lines tested maintained in good condition in RPMI-1640, but 
did not survive well in PrEGM. Organoid media worked specifically in Matrigel-
coated condition that supported cells to form organoids. Cells in F-medium had 
slightly poorer organoid-forming ability as in organoid medium, but had better 
proliferation in 2D condition. RPMI-1640 was initially used as a control condition 
in our test, but turned out to be the most efficient culture medium for cell 
proliferation in the low cell density PCa cell line culture test. The limitation of this 
culture test is that the cells used are from established cell lines which are get 
used to cell culture condition and were maintained in RPMI-1640, which may bias 
the culture ability towards this culture medium. In a previously study which 
successfully established long-cultures of breast CTCs, several media were also 
tried but only RPMI-1640 with serum-free supplements achieved success CTC 
culture from 6 patients out of 36 patients [299]. In my CTC culture test using the 
Avatar system, RPMI-1640 supplemented with FCS was not successful for long-
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term propagation of CTCs, which was potentially due to the use of FCS. Our tests 
indicated that these existing media and conditions I tested may not be sufficient 
to achieve the best CTC culture condition. The composition of cell culture media 
is complicated and each study used different media and condition. Further 
development of specific cell culture media is needed and more comprehensive 
comparison of different conditions is warranted.  
 
 In vitro culture of prostate CTCs 
I used several conditions to isolate and culture CTCs from PCa patients. When I 
used EasySep or Parsortix to further enrich CTCs after Ficoll centrifugation and 
cultured the cells in different conditions, I observed attached live cells in culture 
in 7 out of 11 samples. However, no cell survived over two weeks. Thus, I 
changed strategy that I enriched CTCs by Ficoll centrifugation only and cultured 
CTCs using Avatar system and Xcell liquid biopsy kit. 
Avatar is a high pressure and hypoxia system for cell culture. Hypoxia is a 
common feature of solid tumours [424] and it had been demonstrated that solid 
tumours present an increased interstitial fluid pressure[425]. The Avatar system 
provided an environment that mimics the environment in solid tumour, in order to 
help tumour cell in vitro propagation. As we have limited volume of blood for each 
clinical samples, it is difficult to compare Avatar and hypoxia incubator using the 
same clinical sample. However, using Avatar did not helped us to expand CTCs 
with different CTC isolation and culture media. In addition, I did not observe clear 
different of cell morphology and success culturing rate when using Avatar and 
hypoxia incubator to culture CTCs. Although previous studies showed that 
increased pressure has shown benefit for tumour cell proliferation in vitro [426, 
427], the effect of pressure for CTC or primary cell culture needs further 
investment.  
I tried low-attachment plate, Matrigel-coated plate and XCR plate to culture CTCs 
with XCR media. In low-attachment plate, cells could form clusters. However it is 
difficult to deplete blood cells. The clusters were easy to be broke when I change 
the medium, indicating the clusters were of loose structure and were not 
organoids or spheroids formed via cell proliferation. In addition, media change 
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caused cell loss that in short term no live cells left. In Matrigel-coated plate, cells 
could form colonies but did not form spheroids. Only when using XCR plate and 
media, I was able to culture enriched CTCs for over 2 weeks in vitro. Although 
we were not able to establish CTC cell line, the cultured CTCs could be used for 
further genetic analysis, such as immunofluorescence-staining, FISH and 
potentially transcriptional analysis. 
The propagation of CTCs in our study was not related to CTC counts isolated by 
Parsortix. The longest culture of CTCs were achieved in BCI267 and BCI174. 
However, there was only one CTC/7.5 ml blood detected in these two samples 
respectively in the parallel CTC enumeration. The CTC enumeration method may 
selectively detect some subpopulations of the CTCs and the CTC enumeration 
results may not represent the viable CTC counts in blood circulation. Previous 
report also found it is possible to establish CTCs-derived colonies in samples with 
undetectable levels of CTC detected in parallel analysis by CellSearch [294]. 
Another study showed none of the CK+ CTCs they detected express proliferation 
marker Ki-67, indicating most CTC were apoptotic [428]. Thus, CTC culture may 
add great values to current analysis of CTC enumeration in terms of detecting 
viable CTCs and understanding CTC heterogeneity. 
It is difficult to identify the cell types in my CTC cultures from clinical samples 
according to their morphology. Most cells were macrophage-like. Later 
immunofluorescence-staining also indicated that most cells expressed Vim and 
CD45, which are expressed in macrophage cells. However, macrophage cells 
normally die off within one month in vitro culture, while we have cells culture over 
one month and much longer. In a previous study which cultured CTCs from breast 
cancer patients, the cultured CTCs also present similar morphology as we 
observed in our study that the attached cells exhibited cell membrane ruffling 
[429]. The authors explained that the presence of cell membrane ruffling 
demonstrated the selective expansion of epithelial cells and improved cell motility 
and they identified the cultured cells as EpCAM positive [429]. Although we 
observed very weak or no CK expression in our cultured cells, it may because of 
the CTCs underwent EMT that present mesenchymal features. Our FISH analysis 
showed the existence of potential tumour cells in culture that exhibit abnormal AR 
and PTEN copy number change. This also demonstrate that using cultured CTCs, 
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we may be able to detect the genetic characteristics which are similar to those 
detected in the primary tumour tissues. However, it is very likely that many 
cultured cells are not CTCs, but they have long-term survival in this specific cell 
culture medium. 
Among the cultured CTCs using Xcell kit, I observed some multinucleated cells. 
The multinucleated cells we observed may be the multinucleated giant cells that 
have been previously demonstrated originate from fusion of monocytes or 
macrophages [430]. Another potential is that tumour cells may fuse with 
macrophage cells. Powell et al. demonstrated in vivo that macrophages could 
fuse with intestinal tumour epithelial cells during the tumourigenesis [431]. The 
fusion cell could exhibit both epithelial and macrophage markers [431]. Similar 
tumour cell-macrophage fusion was also proposed in cultured melanoma CTCs 
[432]. Charles E. Gast et al. reported evidence of fusion hybrids harbouring 
hematopoietic and epithelial properties existence in cell culture, tumour-bearing 
mice and in the peripheral blood of human cancer patients [433]. The tumour cell-
macrophage fusion may contribute to the CTC heterogeneity and may be one of 
the mechanisms of how tumour cells gain the physical macrophage-attributed 
properties, which may facilitate tumour metastasis in extravasation, migration and 
immune evasion. Using cultured CTCs, we may potentially demonstrate the 
tumour cell-macrophage fusion in PCa and explore the correlation of tumour cell-
macrophage fusion in tumour metastasis and treatment response in the future. 
Feeder cells are commonly used for primary cell culture to support target cells. 
Mitomycin C and irradiation treatments are commonly used to prepare 
nonproliferating feeder cells. However, in our study, mitomycin C treatment was 
not sufficient to supress NIH/3T3 cell proliferation, which resulted in mixed 
population of NIH/3T3 cells and cultured CTCs. As the effect of mitomycin C 
treatment may be affect by cell concentration and condition, and it is practically 
difficult to test for the efficiency of mitomycin C treatment, special attention should 
be paid when using this method. Some studies also showed mitomycin C treated 
feeder cells are less preferable to support the target cell proliferation [434]. Thus, 
irradiation may be used for feeder cell preparation when applicable. 
We generated xenografts using the mixed cells of NIH/3T3 cells and CTCs, 
aiming to enrich cancer cells during this process, as NIH/3T3 cell was not 
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supposed to form tumour in nude mice. However, our analysis on the ex vivo 
cultured cells from the xenograft and on the xenograft itself could not confirm the 
cell origin. The metaphase spreads showed majority mouse chromosomes which 
were telocentric, indicating the xenograft was largely mouse cell originated. 
However, metacentric chromosomes also present and the chromosome numbers 
were not representative for NIH/3T3 cells. IHC of AR and human PSA on the 
xenograft section shown untypical staining patterns, which could not help us to 
discriminate the cell type. One explanation for these observations may be that 
cultured CTCs could fuse with mouse fibroblast cells, generating a type of hybrid 
cells which bear contents from both human and murine genomes. Mouse 
embryonic fibroblast and melanoma cell fusion has been observed in co-culturue 
system [435]. It has also been reported that androgen-dependent LNCaP cells 
could fuse with stromal cells in in vitro culture, forming a hybrid cell with type 
androgen-independent phenotype [436]. The mechanism under the cell-cell 
fusion remain further investigation. However, this phenomenon may bring about 
problems of using feeder cells for cell culture and establishing mouse xenografts, 




Chapter VII  Final discussion and future research 
7.1 Final discussion 
PCa is estimated as the most frequently diagnosed male cancer and the second-
leading cause of male oncological mortality in 2019 in the US [437]. While the 
prognosis for localised or locally spread disease is very good, the prognosis for 
locally advanced and metastatic PCa disease is poor. ADT is the standard of care 
for initial management of locally advanced and metastatic PCa. However, the 
progression of PCa remains a major issue of PCa management as patients 
inevitably progress, leading to a lethal stage of disease, CRPC [44]. PSA level is 
not only one of the main factors to guide risk stratification and treatment decisions 
for men with newly diagnosed PCa, it is also the only widely used blood-based 
biomarker for routine monitoring of disease progression in patients receiving 
treatment. In metastatic settings, PSA level at the seventh month of ADT initiation 
[438] and time to PSA nadir after ADT initiation [439] have shown prognostic 
value for patients’ OS. It is also an important parameter for CRPC diagnosis. 
However, the PSA test has its limitations in assessing disease progression [440]. 
PSA level may not always reflect the disease burden. PCa patients with wide-
spread metastatic disease who have poorly differentiated tumour or 
neuroendocrine differentiation on histology may present low levels of PSA [441-
443]. Progression of PCa may also occur despite undetectable or low PSA levels 
[443, 444]. Imaging methods have been widely implemented in confirmation of 
PCa progression. However, imaging procedures are difficult to be conducted 
frequently due to high cost and expertise required for image analysis, thus 
delayed detection of progression may occur resulting in early metastasis being 
missed. Therefore, studies of new biomarkers for PCa progression and 
monitoring are needed to identify non-invasive markers with high sensitivity and 
specificity to routinely monitor PCa progression and guide clinical decisions. 
These studies will also help to identify novel biological mechanisms of PCa 
progression, facilitating discovery of new treatment strategies. Therefore, in the 
present study, I explored the value of two main circulating elements in peripheral 
blood, exosomes and CTCs, in monitoring PCa progression and predicting 
treatment response. There are other research groups working on plasma 
exosomes and CTCs in PCa progression and treatment response. However, 
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none of them investigated their role and biomarker potential in CRPC 
development. Due to time limitation, my plasma exosomal miRNA studies were 
mainly focused on CRPC development and prediction biomarkers as there are 
no previous studies in this area; and my CTC study was focused on CTC cultures 
to facilitate the establishment of patient specific molecular characteristics and 
patient drug sensitivity test, which is critical for patient treatment 
decision/selection making. 
Exosomes, a type of small vesicle that carries varieties of biologically active 
molecules, have been investigated in different cancer types. Biomarker mining 
from exosomes has emerged as an attractive research area. MiRNAs in 
exosomes has been a main focus of research as they bear several advantages: 
1) miRNAs are enriched in exosomes thus facilitate biomarker detection using 
only a small volume of sample [350]; 2) miRNAs are stably protected in exosomes 
upon RNase treatment [350] and are minimally affected by storage conditions 
[347], providing an ideal source of biomarkers; 3) miRNAs in exosomes are 
functionally active, thus can be transferred from donor cells to the receiver cells 
and play important functional roles [351]. 
In PCa, exosomal miRNAs have demonstrated their biomarker potential under 
several pathological conditions. However, only limited data has been reported for 
comprehensive analysis of the exosomal miRNA profile and no study has focused 
on miRNAs correlated to CRPC development. In this study, we generated a 
plasma exosomal miRNA profile in treatment-naive PCa and CRPC patients in 
order to identify novel biomarkers for CRPC via extensive, unbiased screening. 
Although the case number is still limited especially for CRPC, we identified 
several exosomal miRNAs correlated with CRPC which were validated by RT-
qPCR for discriminating CRPC from treatment-naive PCa. Among those 
differentially expressed miRNA, miR-423-3p showed great CRPC prediction 
value (high AUC value), in particular when combined with PSA level. This data 
remained true with different exosome isolation methods, as the differential 
expression level of miR-423-3p in plasma exosomes was validated between 
treatment-naive PCa and CRPC in another centre.  
While differential expression of plasma miRNAs have been correlated to CRPC, 
the expression level of plasma exosomal miRNAs may be affected by the 
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treatment given to the patients. As patients receive hormone therapy before 
diagnosis of CRPC, I included a group of patients with early hormonal therapy 
without progression to minimise the effect of treatments on discovery of plasma 
exosomal miRNA biomarker. MiR-423-3p also showed significant differential 
expression between treated non-CRPC and CRPC and over-performed PSA in 
predicting CRPC, but showed no difference between treatment-naive PCa and 
treated non-CRPC. These results indicate that change of plasma exosomal miR-
423-3p level is not a response of ADT treatment, but is associated with the 
occurrence of CRPC. These data together strongly support the hypothesis that 
plasma exosomal miR-423-3p could be used as a predictive biomarker for CRPC. 
In addition, the in vitro study showed that miR-423-3p is expressed at a higher 
level in castration-resistant cells (C4-2) compared to hormone-sensitive cells 
(LNCaP) and its upregulation in LNCaP cells induce cancer cell 
migration/invasion under castration culture condition, further support that miR-
423-3p is associated with CRPC development and plasma exosomal miR-423-
3p may be released from cancer cells instead of the environmental cells in 
response to PCa progression.  
One problem in the study of CRPC monitoring biomarkers is that it is difficult to 
determine if the differentially expressed miRNAs are metastatic-related or CRPC 
related when comparing treatment-naive PCa vs CRPC. Indeed, CRPC is highly 
correlated with metastasis as a large proportion of patients treated with ADT are 
diagnosed with metastatic disease and metastasis is the common sign of CRPC 
development for patients starting with ADT for locally advanced PCa. CRPC is a 
therapeutic resistance issue, presenting with a distinct mechanism of disease 
progression to cancer metastasis. The link between them has rarely been 
investigated. My in vitro data of miR-423-3p expression changes in LNCaP and 
C4-2 cells indicate that cancer metastasis and CRPC may be linked in cancer 
progression process that miR-423-3p overexpression may induce both cancer 
metastasis and castration-resistance by promoting cancer invasion under 
castration condition. In addition to miR-423-3p in cancer cells, cancer cell 
secreted exosomal miR-423-3p might also play a role in the promotion of mCRPC. 
It has been demonstrated that exosomes from metastatic cells can induce non-
metastatic cells to undergo EMT [445, 446]. Tumour cells can also secret 
exosome carrying miRNAs and transport them to distant sites, regulating the 
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microenvironment and promoting metastasis [203, 418, 419]. My data suggests 
that PCa cells may secret exosomes acting as delivery vesicles that shuttle miR-
423-3p to other cells, even at distant sites, and induce metastasis under 
castration environment. However, currently our functional data is limited and the 
underlying mechanism should be further investigated. 
In this study, I included three groups of patients, treatment-naive PCa, treated 
non-CRPC and CRPC, and evaluated the plasma exosomal miRNA expression. 
To our knowledge, this is the first study that report data from these three groups 
of patients, as most studies only recruited treatment-naive localised PCa and 
CRPC. Interestingly, we observed novel expression patterns of plasma exosomal 
miRNAs between these three groups of patients. MiR-423-3p was the only 
miRNA that showed significant difference when comparing treatment-naive PCa 
vs CRPC and treated non-CRPC vs CRPC, but no difference between treatment-
naive PCa and treated non-CRPC. This may suggest exosomal miR-423-3p is a 
true CRPC development related miRNA. MiR-150-5p showed significant 
difference when comparing treatment-naive PCa vs CRPC and treatment-naive 
PCa vs treated non-CRPC, but no difference between treated non-CRPC vs 
CRPC, suggesting miR-150-5p may be a metastasis-related marker, supported 
by other studies [15, 447]. We also identified seven miRNAs (miR-320a, miR-
320b, miR-320d, miR-99a-5p, miR-101-3p, miR-193a-5p, miR-148a-3p) that 
showed fluctuated expression levels among treatment-naive PCa, treated non-
CRPC and CRPC. One explanation of the fluctuated expression may be that 
these plasma exosomal miRNA levels change are reflective of the tumour burden. 
In the treated non-CRPC group, when the disease was under control, fluctuations 
across these miRNAs were observed in comparison to the treatment-naive PCa 
group. When the disease progressed, these miRNAs underwent expression 
changes respective to the untreated stage. Our study demonstrated that plasma 
exosomal miRNAs could serve as biomarkers for CRPC with some also having 
potential value as biomarkers for metastatic disease. Further studies will be 
needed to evaluate these miRNAs in larger cohorts, and potentially in serial blood 
collection in the same patients, to investigate their utility for disease progression.  
CTCs has been intensively investigated in recent years owing to the development 
of CTC detection methods. CTC enumeration has shown promising value as a 
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biomarker for PCa prognosis. Recent molecular analysis of CTCs, for example 
the detection of AR-V7 in CTCs [448, 449], further elucidated the value of CTCs 
as a biomarker and for study of tumour biology. However, limited number of CTCs 
remains a problem and has hindered comprehensive studies. Propagation of 
CTCs has aroused research interests as a novel approach to non-invasively 
obtain tumour cells and study their molecular features and to establish patient-
specific models to test drug sensitivity. As plasma exosomal miRNAs provide 
systematic information of disease status and we have investigated the potential 
of using plasma exosomal miRNA as biomarkers to detect PCa progression, CTC 
culture may enable us to obtain tumour specific molecular information and 
establish patient-specific models for precision medicine. 
PCa cell primary culture is difficult, and there are very limited reports on 
successful culture of PCa CTCs [246, 297]. In this study, I tested different CTC 
isolation methods, culture media and culture conditions for PCa CTC in vitro 
propagation. We demonstrated that for CTC culture, one-step enrichment of 
mononuclear cells via Ficoll centrifugation without further purification of CTCs 
may be adequate for CTC culture. Although I tried several culture media and 
conditions, we found they were not efficient enough to propagate PCa CTCs 
when using clinical samples. Eventually, I used Xcell liquid biopsy kit, composing 
of special cell culture media and collagen-based pre-coated cell culture plate, and 
hypoxia incubator to culture PCa CTCs. This protocol enabled us to culture CTCs 
for over one month in 15 out of 27 samples with the longest culture reaching five 
months. Although I was not able to establish a CTC cell line, my data showed 
good success rate for short-term CTC culture. In addition, I managed to perform 
immunofluorescence-staining and FISH on the cultured CTCs and I froze some 
cells down for future analysis. AR-gain and PTEN-loss in the cultured CTCs were 
identified by FISH analysis, indicating the presence of viable tumour cells in our 
culture. Unfortunately, we did not have access to the patient’s parallel tissue 
sample. Thus, we were not able to confirm these genetic changes in the patient’s 
tissue.  
In parallel to CTC culture, we performed CTC enumeration using the Parsortix 
system [339]. I did not observe correlation of CTC number and CTC culture 
outcome. In a previous study of short-term culture of CTCs as clusters, it was 
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also found that CTC cluster formation was not always correlated with the detected 
CTC counts [294]. Park et al. showed that CTCs from CRPC patients were similar 
in size to leukocytes (around 8 m) with significant shape variability and many cells 
having an elongated shaped [450]. As very few CTCs were detected, it is possible 
that our size-based CTC enumeration method may have missed some small 
CTCs. It has also been demonstrated that CTCs bear high heterogeneity with 
different proliferative capacity [451, 452]. Thus, it is difficult to link CTC culture 
outcomes with CTC enumeration directly. However, it is commonly accepted that 
more CTCs raises higher chance to establish culture and thus isolating CTCs 
from an apheresis product may provide an access to more starting material for 
CTC culture [296, 297].   
It is confirmed by FISH that there were tumour cells existent in our cultured cells. 
However, most cultured cells presented normal AR and PTEN copy numbers. 
The cells also displayed different morphologies and heterogeneous CK, Vim and 
CD45 expression. Thus, we could assume that our cultured cells were a mixed 
population of different cell types. Further identification of the cell types may be 
conducted using the frozen cells we have. Notably, we observed extremely weak 
or no CK expression in our cultured CTCs. In line with our observation, Zhang et 
al. reported their success in establishing EpCAM- CTC lines from breast cancer 
patients with undetectable CTC level using CellSearch, while the EpCAM+ CTCs 
were not able to be expanded [298].  
Our data showed the possibility to culture PCa CTCs and to perform molecular 
analysis using cultured CTCs. However, the study is still at an early stage and 
the CTCs did not grow vigorously to allow drug sensitivity testing. More thorough 
investigations are needed. Our CTC culture conditions should be further 
improved to facilitate long-term CTC propagation in order to perform drug 
sensitivity tests. 
 
7.2 Future plans 
 Further evaluation of plasma exosomal miRNAs as biomarkers 
In this study, we have evaluated the expression levels of several plasma 
exosomal miRNAs in three groups of patients: treatment-naive PCa, treated non-
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CRPC and CRPC. We identified plasma exosomal miRNAs that could potentially 
be used as biomarkers for CRPC. However, the sample number is still small, 
especially for non-CRPC and CRPC groups. Further validation of our miRNAs is 
needed in a larger cohort of treated non-CRPC and CRPC patients. In addition, 
the prognostic value of the identified exosomal miRNAs in treated non-CRPC 
may be evaluated when follow-up data is obtained. 
To further evaluate the potential of using plasma exosomal miRNAs to monitor 
disease progression, exosomal miRNAs may be evaluated in serial collection of 
blood in patients starting hormone therapy. Our lab have started sample 
collection in patients with recurrent disease or newly diagnosed advanced 
disease, who are assigned for hormonal therapies or hormone combined with 
docetaxel chemotherapy. Plasma exosomes will be isolated from the serial 
collection of samples and the expression levels of exosomal miRNAs in serial 
blood collections in these patients will be evaluated by RT-qPCR. The exosomal 
miRNA levels will be compared with other clinical parameters and follow-up data 
for disease progression such as PSA level and imaging information, to investigate 
if plasma exosomal miRNAs can detect early disease progression.  
Plasma exosomal miRNAs significantly differentially expressed between treated 
non-CRPC and CRPC but not between untreated and CRPC cases were 
observed in this study. RNA-sequencing of plasma exosomal RNA will be 
performed in the treated non-CRPC and CRPC, to comprehensively evaluate the 
differentially expressed plasma exosomal miRNAs between treated non-CRPC 
and CRPC. This may help us identity important biomarkers for CRPC. 
In this study, we identified several miRNAs associated with CRPC using RNA-
sequencing. RT-qPCR enabled us to further validate some of them in larger 
cohorts. However, there are some miRNAs that may have significant CRPC 
biomarker potential which were not able to be evaluated due to technique issues. 
For example, miR-375, miR-200 and miR-9 have previously been demonstrated 
for their correlation with PCa development and progression and bear biomarker 
value [151, 453]. Further evaluation of these miRNAs using more sensitive 




While evaluating miRNAs expression using different methods, I found 
inconsistent results generated from traditional RT-qPCR and Fluidigm. Although 
I found different cDNA preparation procedures may be responsible, this technical 
issue may be further elucidated in future research. Nevertheless, for a biomarker, 
as long as it is clinically useful if detected using a specific measurement method, 
it will be valuable biomarker. The plasma exosomal miRNAs correlated to CRPC 
as detected by Fluidigm, although were not consistent to RNA sequencing and 
RT-qPCR results, achieved better AUCs than those detected by RT-qPCR. They 
should be further validated in a large cohort of patient blood samples for their 
CRPC predictive biomarker potential using the Fluidigm system. 
 
 Investigation of exosomal miRNAs function 
In this study, I explored potential functional role of miR-423-3p. I showed that 
overexpression of miR-423-3p induced cell migration and invasion in a hormone-
depleted condition without affecting cell proliferation. Future studies will be done 
to determine if down-regulation of miR-423-3p would reduce cell proliferation, 
migration and invasion ability, which may reveal a novel PCa treatment strategy. 
MiR-423-3p inhibitors will be transfected to down-regulate the miRNA in LNCaP 
and C4-2 cells. Cell proliferation, migration and invasion ability will be examined 
using the methods described in Chapter VI. 
The mechanism of miR-423-3p induced cell migration and invasion remain to be 
studied. I observed the effect of miR-423-3p on MEIS1 protein expression and 
the changes of MEIS1 mRNA level will be evaluated and whether MEIS1 is a 
direct target of miR-423-3p should be confirmed later by luciferase-reporter assay. 
Further studies will be done to determine the interaction of miR-423-3p and 
p21(WAF1/CIP1) and their role in PCa progression. WB will be performed to 
check if over-expression or inhibition of miR-423-3p will affect protein level of P21 
in PCa cells. MRNA level will be checked by RT-qPCR. 
As overexpression of miR-423-3p induced cell migration and invasion, it is 
possible that it induced EMT in the cells. Thus, EMT-related markers such as Vim 
and N-cadherin will also be investigated in normal and charcoal-striped media by 
manipulating miR-423-3p expression level. 
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Whether miR-423-3p can be transferred via exosomes and be biologically active 
in the recipient cells will be investigated. The expression level of miR-423-3p in 
secreted exosomes of LNCaP, C4-2, and other PCa will be evaluated by RT-
qPCR. Exosomes from LNCaP over-expressing miR-423-3p will be collected and 
the exosomal miR-423-3p expression level will be compared with wild type 
LNCaP exosomes. Different methods including using co-culture system, culturing 
in conditioned media and directly adding exosomes will be performed to evaluate 
if exosomes overexpressing miR-423-3p could increase PCa cell proliferation, 
migration and invasion under cell culture conditions with and without androgen.   
 
 Other plasma exosomal RNA in PCa 
By aligning the RNA-sequencing data to mirBase mature miRNA, we have 
generated a plasma exosomal miRNA expression profile in treatment-naive PCa 
and CRPC by RNA-sequencing. Further analysis of RNA-sequencing data may 
be applied to identify other RNA species that could be related to CRPC. It has 
been demonstrated by RNA-sequencing that exosomes contain several RNA 
species such as tRNA, rRNA, small nuclear, small nucleolar and piwi-interacting 
RNA, lncRNA and mRNA [103, 175, 346, 350]. The value of these exosomal 
RNAs in PCa is largely unknown. Our RNA-sequencing data, without size 
selection, could be used to explore the expression profile of these RNAs and 
reveal potential biomarker value in future studies. The RNA-sequencing raw 
reads will be re-analysed mapping to Ensembl Release to identify other RNA 
species. The differentially expressed RNAs will be identified which may be 
associated to CRPC development. 
 
 CTC culture, molecular analysis and drug test 
Although we were not able to establish CTC cell lines, the high success rate of 
short-term CTC culture may enable us to perform molecular analysis and 
potentially drug testing. The previous study was focused on the long-term 
expansion of CTCs. Future studies will be focused on the molecular 
characterisation of the cultured cells and investigation of the application of 
cultured CTCs. We will utilise cells frozen from previous cultured samples. The 
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cells will be recovered and further immunofluorescence staining will be performed 
to identify the cell type. Epithelial makers such as CK and EpCam, mescenchymal 
marker Vim, and macrophage markers such as CD68 and CD163 will be used. 
Patients with chemo-naive progressed disease may be recruited to test if cultured 
CTCs could be used to test therapy response. The CTCs will be cultured for short-
term (approximately one month) and will be treated with drugs such as docetaxel, 
abiraterone and enzalutamide to test the cell sensitivity to these drugs, which may 
provide information guiding clinical decisions. Single cell RNA and exome 
sequencing of the CTCs may be performed to uncover markers that may help 
further validation of the cell origins in culture and uncover tumour-specific 
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Appendix 1. Clinical characteristics of patients for exosome study. 




Fluidigm Age(year) Gleason Score PSA at 
collection(ng/ml)
Metastasis 
BCI001 treatment-naive  √  74.8 3+3, 1/12 10 None 
BCI002 treatment-naive  √  57.8 4+4, 13/13 22 None 
BCI003 treatment-naive  √  56.0 4+3, 12/13 15 None 
BCI004 treatment-naive  √  58.1 3+3, 3/13 5 None 
BCI005 treatment-naive  √  57.7 3+3, 2/14 5 None 
BCI006 treatment-naive  √  58.1 3+3, 1/27 1 None 
BCI007 treatment-naive  √  67.2 3+4, 5/15 12 None 
BCI008 treatment-naive  √  63.0 3+3, 4/13 5 None 
BCI009 treatment-naive  √  62.3 4+5, 12/12 26 None 
BCI010 treatment-naive √ √  65.8 3+3, 1/12 6 None 
BCI011 treatment-naive  √  56.0 3+3, 1/59 45 None 
BCI012 treatment-naive √ √  69.3 3+3, 1/45 7.5 None 
BCI013 treatment-naive √ √  34.1 3+3, 4/14 4 None 
BCI014 treatment-naive √ √  74.8 4+3, 5/17 8 None 
BCI015 treatment-naive  √  77.2 4+3, 6/12 9.12 None 
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BCI016 treatment-naive  √  76.3 4+3, 11/12 10 None 
BCI017 treatment-naive  √  69.5 3+4, 7/12 3.2 None 
BCI018 treatment-naive √ √  71.2 3+4, 5/12 9.49 None 
BCI019 treatment-naive √ √  50.0 3+3, 3/12 5.42 None 
BCI020 treatment-naive √ √  72.8 4+3, 7/13 6.8 None 
BCI021 treatment-naive √ √  72.2 3+4, 3/16 13 None 
BCI022 treatment-naive √ √  54.6 4+3, 2/14 5.32 None 
BCI023 treatment-naive √ √  66.9 4+3, 3/13 20 None 
BCI024 treatment-naive  √  69.1 3+4, 8/12 7.8 None 
BCI025 treatment-naive √ √  56.2 3+4, 6/12 9.8 None 
BCI026 treatment-naive √ √  59.8 4+3, 7/13 11 None 
BCI027 treatment-naive √ √  73.5 3+4, 8/20 7.9 None 
BCI028 treatment-naive  √  65.3 3+4, 3/50 7.81 None 
BCI029 treatment-naive √ √  66.5 3+3, 1/19 12 None 
BCI030 treatment-naive √ √  51.7 3+4, 7/12 16 None 
BCI031 treatment-naive √ √  64.5 4+3, 6/12 18 None 
BCI032 treatment-naive √ √  55.7 3+4, 9/12 7.2 None 
BCI033 treatment-naive √ √  60.5 3+3,1/15 10 None 
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BCI034 treatment-naive √ √  56.9 4+3, 7/12 19 None 
BCI035 treatment-naive  √  68.6 4+3,10/16 23 None 
BCI036 treatment-naive √ √  58.6 3+4, 7/16 12 None 
BCI037 treatment-naive √ √  66.3 3+3, 4/17 12 None 
BCI038 treatment-naive  √  51.3 3+4, 2/14 9.66 None 
BCI039 treatment-naive  √  67.8 3+3, 3/15 11 None 
BCI040 treatment-naive  √  64.5 3+4, 4/12 7.19 None 
BCI041 treatment-naive  √  55.4 3+3, 5/14 5.5 None 
BCI042 treatment-naive  √  79.8 3+4, 2/13 13 None 
BCI043 treatment-naive  √  57.7 3+4, 4/12 5.13 None 
BCI044 treatment-naive  √  71.2 4+3, 8/19 6.4 None 
BCI045 treatment-naive  √  68.2 4+4, 7/14 9 None 
BCI046 treatment-naive  √  66.3 3+3, 1/33 6.46 None 
BCI047 treatment-naive  √  54.3 3+3, 2/12 6.9 None 
BCI048 treatment-naive  √  76.5 3+4, 4/14 12 None 
BCI049 treatment-naive  √  73.2 3+3, 4/11 9.92 None 
BCI050 treatment-naive  √  64.8 4+5, 6/6 310 T3bN1M0 
BCI051 treatment-naive  √  83.5 4+4, 5/14 21 None 
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BCI052 treatment-naive  √  81.1 4+5, 12/14 23 None 
BCI053 treatment-naive  √  78.6 3+3, 1/22 18 None 
BCI054 treatment-naive √ √  56.1 3+3, 3/12 6.27 None 
BCI055 treatment-naive √ √  72.5 3+4,13/15 83 None 
BCI056 treatment-naive  √  68.2 3+4, 1/36 5.9 None 
BCI057 treatment-naive √ √  68.2 3+4,  3/16 12 None 
BCI058 treatment-naive  √  63.0 3+4, 8/12 9.28 None 
BCI059 treatment-naive  √  67.3 5+5, all cores 26 regional LYM 
BCI060 treatment-naive  √  69.4 3+4, 11/13 17 None 
BCI061 treatment-naive  √  66.2 3+4, 15/23 18 None 
BCI062 treatment-naive  √  62.8 3+3, 3/14 12 None 
BCI063 treatment-naive  √  78.8 4+5, 3/45 17.6 None 
BCI064 treatment-naive  √  78.1 3+4, 4/12 9.69 None 
BCI065 treatment-naive  √  66.9 4+4, 2/12 7.5 None 
BCI066 treatment-naive  √  55.8 3+4, 8/52 13 None 
BCI067 treatment-naive  √  71.8 3+3, 13/29 17 None 
BCI068 treatment-naive  √  65.6 3+4, 6/12 5.6 None 
BCI069 treatment-naive  √  58.3 3+4, 3/11 4.57 None 
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BCI070 treatment-naive  √  72.3 3+4, 5/18 5.54 None 
BCI071 treatment-naive  √  53.8 3+4, 8/12 8.29 None 
BCI072 treatment-naive  √  53.3 4+3 7.7 None 
BCI073 treatment-naive  √  76.0 4+4, 8/17 7.21 None 
BCI074 treatment-naive  √  58.6 3+4, 1/12 4.3 None 
BCI075 treatment-naive  √  74.6 3+4, 2/16 10 None 
BCI076 treatment-naive  √  61.8 3+3, 9/74 5 None 
BCI077 treatment-naive  √  70.0 3+4, 3/24 8.33 None 
BCI078 treatment-naive  √  62.8 4+3, 1/17 11 None 
BCI079 treatment-naive  √  50.9 3+3, 8/12 6.5 None 
BCI080 treatment-naive  √  48.8 3+3, 2/12 4.2 None 
BCI081 treatment-naive  √  43.0 3+3, 3/15 2.4 None 
BCI082 treatment-naive  √  58.6 3+4, 4/13 5.7 None 
BCI083 treatment-naive  √  72.9 4+4, 6/11 13 T2N0M1, bone 
BCI084 treatment-naive  √  59.2 3+3, 1/53 4.34 None 
BCI085 treatment-naive  √  66.0 3+4, 1/13 5.27 None 
BCI086 treatment-naive  √  58.5 3+4, 8/14 4.8 None 
BCI087 treatment-naive  √  76.0 4+3, 7/14 19.71 None 
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BCI088 treatment-naive  √  64.5 4+3,18/26 6 None 
BCI089 treatment-naive  √  69.3 3+4, 4/43 6.56 None 
BCI090 treatment-naive  √  76.2 3+4, 8/12 5.41 None 
BCI091 treatment-naive  √  65.3 3+3, 5/12 5.09 None 
BCI092 treatment-naive  √  60.3 3+3, 7/12 7.96 None 
BCI093 treatment-naive  √  79.9 4+3, 14/14 13 None 
BCI094 treatment-naive  √  68.2 3+4, 7/15 15.9 None 
BCI095 treatment-naive  √  63.8 4+3, 11/15 26.8 None 
BCI096 CRPC   √ 60.1 4+5 399 LYM 
BCI097 treatment-naive  √  71.0 3+3, 2/12 8.73 None 
BCI098 treatment-naive  √  58.8 3+3, 4/18 4.3 None 
BCI099 treatment-naive  √  43.6 3+3, 1/13 3.3 None 
BCI100 treatment-naive  √  69.4 4+5 21.1 None 
BCI101 treatment-naive  √  51.3 3+3, 7/17 7.87 None 
BCI102 treatment-naive  √  74.4 3+4, 8/14 11 None 
BCI103 treatment-naive  √  48.8 4+3, 2/13 8.8 None 
BCI104 treatment-naive  √  55.4 3+3, 7/11 20 None 
BCI105 treatment-naive  √  57.3 3+3, 2/12 4.81 None 
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BCI106 treatment-naive  √  66.1 3+4, 5/13 6.5 None 
BCI107 treatment-naive  √  76.8 right 5+4, 6/6; left 
4+5, 3/3 
131 bone 
BCI108 treatment-naive  √  73.0 4+5,7/7 4.52 T4N1M1 
BCI109 CRPC √ √  72.8 5+4 255 LYM, multiple bone 
BCI110 CRPC   √ 65.8 3+4 204 multiple bone 
BCI111 CRPC   √ 79.5 3+5 250 LYM, multiple bone 
BCI112 CRPC √ √  68.7 4+4 66 bone 
BCI113 CRPC  √  70.2 4+5 1574 LYM, multiple bone 
BCI114 CRPC   √ 81.2 3+3 2781 multiple bone 
BCI115 CRPC √ √ √ 81.6   525 LYM, multiple bone 
BCI116 CRPC  √ √ 70.9 3+4 609 from lymphadenopathy 
BCI117 CRPC √ √  80.7 4+4 52 None 
BCI118 CRPC √ √ √ 81.8   2 multiple bone 
BCI119 CRPC √ √ √ 60.2 5+5 39 LYM, multiple bone 
BCI120 CRPC   √ 74.0 NEC 53 bladder, LYM 
BCI121 CRPC √ √ √ 68.9 5+4 900 multiple bone 
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BCI122 CRPC   √ 79.9 4+5 260 Liver, LYM, multiple 
bone 
BCI123 CRPC   √ 80.4 3+4 12 single bone 
BCI124 CRPC √ √ √ 83.9   119 LYM 
BCI125 CRPC √ √ √ 63.5 4+3 16 LYM 
BCI126 CRPC √ √ √ 83.9 3+3 1 LYM, multiple bone 
BCI127 CRPC √ √ √ 76.2 4+4 2 multiple bone 
BCI128 CRPC √ √ √ 87.8 4+3 1027 multiple bone 
BCI129 CRPC  √  66.7 5+5 4 LYM 
BCI130 CRPC √ √ √ 67.4 43 multiple bone 
BCI131 CRPC √ √ √ 81.4 77 multiple bone 
BCI132 CRPC √ √ √ 86.5 5+3 29 LYM, multiple bone 
BCI133 CRPC √ √ √ 62.5 5+5 9 multiple bone 
BCI134 CRPC √ √ √ 60.1 4+4 202 multiple bone 
BCI135 CRPC  √  54.3 4+5  176 bone and lymph nodes 
BCI136 CRPC  √  61.4 9 168.2 T2bN1M1 
BCI137 CRPC   √ 69.4 4+4 60 multiple bone 
BCI138 CRPC  √  70.2 4+4 123 M1b 
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BCI139 CRPC   √ 77.0 4+4 11 multiple bone 
BCI140 CRPC √ √ √ 74.4 550 multiple bone, LYM 
BCI141 CRPC  √  76.4 4+3 56 M1b 
BCI142 CRPC  √  54.8 4+5 52 M1b 
BCI143 CRPC  √  71.2 3+4 58 N1 
BCI144 CRPC √ √ √ 74.2 4+5 23 multiple bone, lung, 
regional LYM 
BCI145 CRPC  √  84.0 3+5 18 M1b 
BCI146 CRPC  √  71.3 4+5 58 T3bN1M1 
BCI147 CRPC  √  71.9   22 M1b 
BCI148 CRPC  √  73.8   514 N/A 
BCI149 CRPC  √  59.8 4+4 24 N/A 
BCI150 CRPC √ √ √ 72.5 5+5 50 multiple bone, LYM 
BCI151 treated non-
CRPC 
 √  72.4 4+5 9 multiple bone, LYM 
BCI152 treated non-
CRPC 





 √  79.3 4+5 11 single bone 
BCI154 treated non-
CRPC 
 √  59.9 5 multiple bone 
BCI155 treated non-
CRPC 
 √  60.9 4+4 153 multiple bone, lung 
BCI156 treated non-
CRPC 
 √  62.2 4+5 60 multiple bone, LYM 
BCI157 treated non-
CRPC 
 √  60.0 Adenocarcinoma 
from LYM 
204 multiple bone, LYM 
BCI158 treated non-
CRPC 




 √  80.6 152 multiple bone, LYM 
BCI160 treated non-
CRPC 
 √  63.7 4+3 9.4 multiple bone 
BCI161 treated non-
CRPC 





 √  63.9 5+5 15 multiple bone 
BCI163 treated non-
CRPC 
 √  65.9 3+4 367 None 
BCI164 treated non-
CRPC 
 √  78.9 5+5 6.09 N1 
BCI165 treated non-
CRPC 
 √  66.1 4+3,4/11  13.4 None 
BCI166 treated non-
CRPC 
 √  70.1 5+4,3/4 343 multiple bone 
BCI167 treated non-
CRPC 
 √  74.0 5+4, 12/12 22 None 
BCI168 treated non-
CRPC 
 √  53.8 4+5 138 N/A 
BCI169 treated non-
CRPC 
 √  77.0 4+4, 6/8 51 T3bN1M1 
BCI170 treated non-
CRPC 





 √  68.3 4+3, 6/6 126.6 None 
BCI172 treated non-
CRPC 
 √  65.6 4+3, 13/15 2.69 T3a/T3bN1M1a 
BCI173 treated non-
CRPC 
 √  76.6 1913 T3bN1M1c, lung 
BCI174 treated non-
CRPC 
 √  63.0 4+5 9 T4N2M1 
BCI175 treated non-
CRPC 
 √  61.3 4+5,14/14 57.39 bone 
BCI176 treated non-
CRPC 
 √  57.0 4+5 90.61 T3bN1M1 
BCI177 treated non-
CRPC 
 √  65.9 4+4 31.4 T3aN1M1, bone 
BCI178 treated non-
CRPC 
 √  64.7 4+5 0.74 M1b 
BCI179 treated non-
CRPC 





 √  53.1 4+3 6.75 T3N1M1b 
BCI181 treated non-
CRPC 
 √  63.3 4+4 5.7 M1b 
BCI182 treated non-
CRPC 
 √  71.4 3.4 M1b 
BCI183 treated non-
CRPC 
 √  67.0 4+4,19/19 2.79 N1M1b 
BCI184 treated non-
CRPC 
 √  73.1 4+3,7/10 3.46 (10/01/18) M1b 
BCI185 treated non-
CRPC 
 √  83.8 4+3 30 None 
BCI186 treated non-
CRPC 
 √  57.7 4+5 120 T3bM1b 
BCI187 CRPC √ √ √ 81.9 4+5 4 N/A 
BCI188 CRPC   √ 70.9 4+5 49 multiple bone, T4N2M1 
BCI189 CRPC √ √ √ 84.2 4+5 189 lung, liver 
BCI190 CRPC √ √ √ 77.2   346 N/A 
BCI191 treatment-naive   √ 61.8 4+5, 9/22 11 None 
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BCI192 treatment-naive   √ 75.8 3+4, 4/35 12 None 
BCI193 treatment-naive   √ 68.9 3+3, 1/13 15 None 
BCI194 treatment-naive   √ 71.7 3+4, 6/14 7.05 None 
BCI195 treatment-naive   √ 53.5 3+3, 5/12 4.86 None 
BCI196 treatment-naive   √ 80.8 3+3, 1/13 8.4 None 
BCI197 treatment-naive   √ 63.9 4+5, 12/12 23 N1 
BCI198 treatment-naive   √ 68.7 4+5, 12/12 40 N1 
BCI199 treatment-naive   √ 66.9 3+3,1/15 6.7 None 
BCI200 treatment-naive  √ √ 73.8 3+4, 5/15 19.1 None 
BCI201 treatment-naive   √ 57.1 3+3, 1/16 8.03 None 
BCI202 treatment-naive   √ 57.8 4+3,12/12 12 N1 
BCI203 treatment-naive   √ 60.1 4+3, 8/12 5.93 None 
BCI204 treatment-naive   √ 58.3 4+3 29 None 
BCI205 treatment-naive   √ 69.6 3+4, 8/15 6.15 None 
BCI206 treatment-naive   √ 61.2 3+4, 8/15 18 None 
BCI207 treatment-naive   √ 66.5 3+4, 10/13 7.34 None 
BCI208 treatment-naive   √ 71.2 4+3 2 None 
BCI209 treatment-naive   √ 57.0 3+3 4.84 None 
245 
 
BCI210 treatment-naive   √ 83.3 52.4 None 
BCI211 treatment-naive   √ 68.8 3+3, 7/30 NA None 
BCI212 treatment-naive   √ 65.2 3+4, 7/20 7.5 None 
BCI213 treatment-naive   √ 66.5 3+4, 5/14 7.33 None 
BCI214 treatment-naive   √ 49.2 3+3, 6/13 3.15 None 
BCI215 treatment-naive   √ 61.1 5+4, all cores 127 N1 
BCI216 treatment-naive   √ 69.1 3+4, 2/13 11 None 
BCI217 treatment-naive   √ 82.3 3+3, 2/14 1.37 None 
BCI218 treatment-naive   √ 56.5 3+3 7.64 None 
BCI219 treatment-naive   √ 52.1 3+3, 3/14   None 
BCI220 treatment-naive   √ 59.6 3+3, 1/16 6.73 None 
BCI221 treatment-naive   √ 68.4 4+4, 11/22 8.2 None 
BCI222 treatment-naive   √ 61.2 3+3, 3/28 5.38 None 
BCI223 treatment-naive   √ 75.8 3+3, 3/17 9.2 None 
BCI224 treatment-naive   √ 67.0 3+4, 5/12 6.4 None 
BCI225 treatment-naive   √ 58.2 3+3, 3/41 11.9 None 
BCI226 treatment-naive   √ 70.0 4+4, 1/12 8.7 None 
BCI227 treatment-naive   √ 55.7 3+4, 5/37 5.09 None 
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BCI228 treatment-naive   √ 55.3 3+3 9.77 None 
BCI229 treatment-naive   √ 65.7 3+3, 6/28 6 None 
BCI230 treatment-naive   √ 54.3 3+3, 1/12 6.5 None 
BCI231 treatment-naive   √ 74.1 3+4, 3/17 17 None 
BCI232 treatment-naive   √ 73.7 3+3, 2/14 9.06 None 
BCI233 treatment-naive   √ 51.9 3+3, 1/14 6.6 None 
BCI234 treatment-naive   √ 77.2 3+3, 6/14 7.5 None 
BCI235 treatment-naive   √ 60.9 3+3 0.45 None 
BCI236 treatment-naive   √ 61.2 3+3, 1/13 5.14 None 
BCI237 treatment-naive   √ 61.0 3+3, 2/13 5.1 None 
BCI238 treatment-naive   √ 68.7 3+3, 2/15 11 None 
BCI239 treatment-naive   √ 69.8 3+4, 2/13 24.4 None 
BCI240 treatment-naive   √ 60.8 3+3, 2/14 3.68 None 
BCI241 treatment-naive   √ 66.8 3+3, 8/13 5.14 None 
BCI242 treatment-naive   √ 61.3 4+5 4.99 None 
BCI243 CRPC   √ 78.5 4+4 387 bone 
BCI244 CRPC   √ 78.8 4+5 17 bone 
BCI245 CRPC   √ 49.5 4+4, 7/14 307 bone 
247 
 
BCI246 CRPC   √ 60.8 5+4 392.8 bone 
BCI247 CRPC  √ √ 74.6 4+5 65 N/A 
BCI248 CRPC  √ √ 69.5   20 M1b 
BCI249 CRPC  √ √ 73.9 3+4 134 N1M1b 
BCI250 CRPC √ √ √ 74.9 4+5 29 None 
BCI251 CRPC  √ √ 69.1 4+3 14 N/A 
BCI252 CRPC   √ 72.0 4+3 21 None 
BCI253 CRPC   √ 83.0 324 bone 
CRPC: castration-resistant prostate cancer; NEC: neuroendocrine carcinoma; LYM: lymph nodes metastasis.
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3p  0  0  1  0  0  5  0  0  0  1  6  0  0  2  0  1  0  4  2  1  0  0  0  0 
let‐7a‐
5p  201  134  253  266 
128
3  658  144  164  170  879 
174
6  586  171  764  205 
154
5  418  684  49  289  517  490  124  783 
let‐7b‐
3p  2  0  0  2  8  3  2  0  5  8  11  1  1  4  0  21  0  2  2  3  0  0  0  3 
let‐7b‐
5p  240  149  802  369  813  846  256  372  359  465 
123
18  511  255  387  343  927  363 
141
9  271  479  870  451  245  618 
let‐7c‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
let‐7c‐
5p  23  18  27  23  77  47  24  16  16  57  161  55  19  53  7  86  37  58  8  28  59  44  15  65 
let‐7d‐




5p  20  4  13  7  66  53  7  4  10  29  186  18  7  75  14  107  16  33  0  14  13  35  10  61 
let‐7e‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
let‐7e‐
5p  14  8  9  13  64  39  3  5  20  19  15  9  5  24  7  43  7  15  1  10  24  40  5  31 
let‐7f‐1‐
3p  0  0  0  0  0  2  0  0  0  0  2  1  0  0  0  0  0  0  0  0  0  0  0  0 
let‐7f‐
5p  77  52  128  73  407  372  65  59  65  323  858  199  78  377  87  745  160  261  26  119  189  186  37  355 
let‐7g‐
5p  36  12  69  38  130  158  23  32  30  75  842  72  30  127  47  267  82  180  5  28  69  54  19  114 
let‐7i‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0 
let‐7i‐
5p  134  97  289  140  409 
114
8  128  108  140  281 
629
8  273  198  395  172 
118
8  221  694  81  323  407  396  108  492 
miR‐1  0  1  0  1  2  0  1  0  0  6  8  3  3  11  1  6  2  0  0  1  0  7  0  2 
miR‐




101‐3p  6  8  18  7  12  19  6  5  10  13  171  5  16  10  17  16  4  68  0  4  22  2  3  15 
miR‐
103a‐3p  4  2  5  1  15  11  3  2  0  10  64  5  0  18  4  30  7  16  2  4  1  6  3  14 
miR‐
105‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
106a‐5p  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  2  0  0  0  0  0  0  0  1 
miR‐
106b‐3p  2  3  4  3  13  19  0  3  1  9  79  9  6  6  6  31  3  22  2  8  6  5  3  6 
miR‐
106b‐5p  1  0  3  0  0  0  0  0  0  0  18  1  0  3  0  1  0  4  0  1  0  0  0  1 
miR‐
107  1  0  1  2  6  2  0  0  1  0  18  0  0  1  1  4  3  6  0  3  1  0  0  1 
miR‐
10a‐3p  0  0  0  0  1  0  0  0  0  0  2  0  0  0  0  0  0  1  0  0  0  0  0  1 
miR‐




10b‐3p  0  0  0  0  2  0  0  0  1  1  1  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
10b‐5p  30  24  20  38  134  52  14  25  52  61  157  72  34  59  20  127  36  155  24  62  17  24  16  75 
miR‐
1180‐3p  1  3  6  0  12  5  0  1  4  4  42  9  0  7  1  5  2  11  1  1  1  2  1  3 
miR‐




0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0 
miR‐
1193  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1224‐5p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
1225‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




3  119  112  34 
187




1226‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  3  0  0  0  0  0  0  0  0 
miR‐
1228‐5p  1  0  0  1  0  0  2  0  0  0  3  1  0  1  1  0  0  0  0  0  0  1  0  1 
miR‐
1229‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  1  0  0  0  0  0  0  0  1 
miR‐
124‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1246  2  2  0  0  11  1  1  0  1  6  0  0  0  5  0  4  0  0  0  0  0  2  0  3 
miR‐
1248  0  4  1  0  0  0  0  0  0  0  0  0  0  0  0  0  1  1  0  0  0  0  0  0 
miR‐
1249  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
1254  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐






0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
125a‐3p  1  0  0  0  1  1  0  1  0  3  2  0  0  0  0  2  1  2  0  1  1  3  1  0 
miR‐








0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
125b‐5p  2  1  1  1  21  2  0  1  0  7  14  10  0  2  0  29  0  11  2  0  1  3  2  1 
miR‐
1261  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




2  345  228  602  502 
226












126‐5p  3  2  3  1  15  9  1  1  1  2  12  3  2  11  1  2  2  11  0  3  0  6  0  3 
miR‐
1270  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
127‐3p  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  1  0  0  0  1  0 
miR‐
1277‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1278  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
128‐3p  9  6  15  14  41  96  7  12  7  15  189  19  10  40  15  137  12  127  9  21  16  20  2  54 
miR‐




1287‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1288‐3p  0  0  0  0  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1292‐5p  0  0  0  0  0  2  0  0  0  0  1  1  0  0  0  1  1  2  0  0  0  0  0  0 
miR‐
1293  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1294  0  0  0  0  1  0  0  0  0  0  0  0  0  0  1  1  0  0  0  0  1  0  0  0 
miR‐
1295a  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
129‐5p  0  0  0  0  0  0  0  0  2  2  3  0  0  0  0  1  0  7  0  1  0  0  0  0 
miR‐
1299  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




1304‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1306‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1306‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  1  0  1  0  1  0  2  0  0 
miR‐
1307‐3p  0  2  2  1  9  8  1  1  1  4  28  4  1  12  1  24  3  20  0  4  2  4  0  11 
miR‐
1307‐5p  0  0  0  0  2  1  0  1  1  0  2  0  0  0  0  3  0  1  0  0  0  0  0  1 
miR‐
130a‐3p  0  0  2  0  1  1  2  0  0  0  2  0  0  0  0  1  0  0  0  0  0  1  0  0 
miR‐
130b‐3p  1  0  0  1  0  0  0  0  0  2  0  0  0  0  0  5  0  0  0  0  0  0  0  0 
miR‐
130b‐5p  0  0  1  0  0  3  0  0  0  1  4  0  0  1  1  4  0  4  0  0  1  0  0  0 
miR‐




132‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
132‐5p  0  0  0  0  0  1  0  0  1  0  2  0  0  0  0  0  0  2  0  0  0  0  0  0 
miR‐
1343‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
134‐5p  0  1  2  0  0  11  0  0  0  0  3  0  0  2  0  4  1  0  0  1  0  1  0  2 
miR‐
135a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
136‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
136‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
138‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐




139‐5p  5  3  3  13  36  19  2  9  14  18  52  20  6  18  15  31  12  34  9  34  3  14  0  32 
miR‐
140‐3p  2  0  5  0  6  5  0  2  2  4  22  2  1  0  5  1  2  9  0  2  2  0  0  4 
miR‐
140‐5p  1  0  1  0  2  3  0  0  0  2  10  1  3  2  0  5  1  6  0  0  1  1  0  5 
miR‐
141‐3p  0  1  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  3  0  0  0  0  0  0 
miR‐
142‐3p  2  0  4  1  10  10  4  2  2  1  16  3  1  6  2  9  9  10  0  6  3  6  3  16 
miR‐
142‐5p  1  0  2  3  7  5  0  3  2  1  24  5  0  1  2  1  5  6  0  4  0  3  1  1 
miR‐
143‐3p  4  14  5  4  20  32  4  4  10  22  112  2  6  12  3  29  10  94  4  7  12  5  5  31 
miR‐
144‐3p  1  0  3  1  4  2  0  1  3  0  52  0  0  5  0  1  1  4  1  1  2  1  0  6 
miR‐




145‐3p  0  0  0  1  0  0  0  2  3  0  3  3  0  1  0  4  0  0  0  0  0  0  0  0 
miR‐
145‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1468‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
146a‐5p  4  1  7  2  17  56  5  4  12  7  88  5  4  22  5  104  5  27  5  17  3  10  3  17 
miR‐
146b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  1 
miR‐
146b‐5p  0  3  4  1  2  11  5  0  2  2  43  5  2  16  0  10  4  8  1  10  2  1  1  18 
miR‐
147b  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
148a‐3p  90  675  129  151  737 
102








0  67  254  363  373  117  322 
miR‐




148b‐3p  2  6  9  5  18  44  2  2  6  6  76  11  4  15  7  33  4  33  0  5  9  5  0  8 
miR‐
149‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  1 
miR‐
150‐3p  0  0  0  1  11  4  0  1  0  1  11  3  3  1  1  2  0  6  0  0  0  1  0  3 
miR‐
150‐5p  2  1  9  7  34  11  5  7  5  10  47  6  5  17  2  23  6  24  1  11  7  3  2  29 
miR‐
151a‐3p  11  16  25  13  55  141  8  8  23  37  146  31  24  28  16  236  13  91  14  36  55  45  15  34 
miR‐
151a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐
152‐3p  0  0  0  0  0  0  0  0  0  1  1  0  1  0  0  3  0  2  0  0  2  0  0  0 
miR‐
152‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐




155‐5p  8  4  6  8  36  9  6  3  13  10  18  17  2  12  7  27  12  12  7  20  2  7  2  3 
miR‐
15a‐5p  0  0  0  0  0  0  0  0  0  0  4  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
15b‐3p  1  0  0  0  1  0  0  0  0  0  7  0  0  0  1  0  0  5  0  0  1  0  0  2 
miR‐
15b‐5p  0  0  4  2  3  0  1  2  1  2  19  0  0  4  3  1  1  8  1  0  0  0  2  1 
miR‐16‐
2‐3p  4  0  9  4  8  2  2  8  4  1  71  5  0  7  11  5  3  27  0  3  3  1  2  8 
miR‐16‐
5p  7  0  30  5  27  17  3  4  9  7  345  22  5  35  14  21  9  88  1  5  5  7  1  27 
miR‐17‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0 
miR‐17‐








181a‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
181a‐5p  11  8  6  9  44  31  10  3  17  17  146  9  8  32  8  42  12  58  8  28  5  14  2  25 
miR‐
181b‐5p  1  1  0  2  9  5  1  0  1  2  11  2  0  3  1  7  1  6  2  1  2  0  2  6 
miR‐
181c‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
181c‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
181d‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  3  0  0  0  1  0  0  0  0  0  0 
miR‐
182‐5p  8  8  14  6  24  8  6  7  1  12  119  9  5  11  7  18  9  28  0  12  23  5  0  16 
miR‐
183‐5p  4  6  18  1  31  9  7  11  10  10  145  20  6  13  12  17  8  16  2  7  24  8  1  20 
miR‐




185‐3p  0  0  0  0  0  2  0  0  0  0  4  0  0  2  0  0  0  0  0  0  0  0  0  0 
miR‐
185‐5p  9  8  19  9  125  56  9  14  7  53  175  21  3  98  39  194  22  150  0  3  9  20  2  42 
miR‐
186‐5p  5  2  15  2  34  11  2  4  4  9  138  13  2  15  5  11  3  38  1  5  5  2  0  8 
miR‐
188‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
188‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
18a‐3p  0  0  0  0  0  0  0  0  0  1  1  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
18a‐5p  1  0  0  0  1  1  0  0  0  1  1  2  0  0  0  0  0  1  0  0  1  1  0  1 
miR‐
18b‐5p  0  0  0  0  0  2  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0 
miR‐




190a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
191‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0  0  0  0  0 
miR‐
1914‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
191‐5p  15  5  18  8  66  139  6  4  6  32  114  20  18  80  10  162  24  62  2  28  9  43  2  71 
miR‐
192‐5p  1  2  11  6  18  7  2  1  3  7  110  46  2  5  7  134  5  68  1  4  7  2  1  11 
miR‐
193a‐5p  1  4  2  9  15  1  0  1  0  9  6  11  2  15  1  140  2  9  1  2  0  7  2  2 
miR‐
193b‐5p  0  2  0  2  0  0  0  0  1  4  3  4  0  0  0  15  0  1  0  1  0  2  0  0 
miR‐
194‐3p  0  0  0  0  0  0  0  0  0  0  0  4  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




195‐3p  0  0  0  0  5  0  0  0  0  0  0  0  0  0  0  1  0  3  0  0  0  0  0  0 
miR‐
195‐5p  0  0  0  0  0  1  1  0  0  0  1  0  0  0  0  1  0  1  0  0  0  0  0  0 
miR‐
196a‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
196b‐5p  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  1  0  2  0  0  0  0  0  0 
miR‐
197‐3p  0  0  0  1  5  5  0  0  1  0  2  0  1  2  0  9  0  1  0  0  0  2  0  5 
miR‐
197‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1976  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
199a‐3p  2  0  1  1  12  13  3  0  1  2  12  6  1  4  0  14  1  8  0  2  0  5  0  4 
miR‐




199b‐3p  0  0  2  0  4  3  0  0  1  2  8  1  0  0  0  4  1  4  0  2  0  2  0  1 
miR‐
199b‐5p  0  0  0  1  0  0  0  0  0  0  2  0  1  0  0  0  0  1  0  0  0  0  0  1 
miR‐




0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
19b‐3p  0  0  4  0  2  2  0  0  0  0  20  0  0  2  0  1  0  8  0  0  1  0  0  1 
miR‐
200a‐3p  1  0  0  1  5  1  2  1  0  10  4  3  0  0  1  1  1  29  0  0  8  1  0  4 
miR‐
200a‐5p  0  0  0  0  0  0  0  0  0  1  0  0  0  2  0  0  0  0  0  0  5  0  0  0 
miR‐
200b‐3p  0  0  0  0  2  0  0  0  0  7  0  0  0  3  0  0  0  4  0  0  3  0  0  0 
miR‐




200c‐3p  0  0  0  0  3  0  1  0  1  6  1  0  0  3  0  0  2  4  0  0  3  1  0  1 
miR‐
202‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
203a  1  0  1  0  4  1  0  0  1  0  1  0  2  0  0  3  0  0  3  1  0  3  0  3 
miR‐
204‐3p  0  5  0  0  1  1  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  2 
miR‐
204‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
206  0  0  0  1  1  0  4  0  3  0  1  0  0  0  0  0  0  7  0  0  0  0  0  1 
miR‐
20a‐5p  1  0  1  0  11  3  0  3  0  1  42  4  0  9  0  5  1  6  0  0  2  3  1  4 
miR‐
20b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




210‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
2110  2  3  3  4  1  1  0  2  0  4  39  3  0  2  1  16  3  13  0  1  4  1  2  4 
miR‐
2115‐5p  0  1  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐21‐
3p  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
214‐3p  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
214‐5p  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
215‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
215‐5p  0  0  0  0  0  0  0  0  1  1  12  0  0  1  0  4  0  43  0  0  0  0  0  0 
miR‐21‐




216a‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
216b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐








0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
221‐3p  1  0  2  1  11  10  0  2  0  5  19  1  2  4  1  16  1  5  0  1  2  1  0  8 
miR‐
221‐5p  0  0  0  0  0  0  0  0  0  0  2  0  0  1  0  0  0  1  0  0  0  1  0  0 
miR‐




222‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
223‐3p  0  0  0  0  1  3  0  0  2  1  2  0  0  4  1  0  0  0  0  0  0  0  0  2 
miR‐
223‐5p  2  0  0  4  0  2  1  0  1  3  9  2  1  1  1  6  1  8  1  1  1  2  0  3 
miR‐22‐
3p  34  14  76  31  159  131  24  26  35  73  769  64  11  90  48  384  29  386  27  76  29  52  5  70 
miR‐
224‐5p  0  0  0  2  2  1  0  0  0  0  1  3  0  0  0  13  0  1  0  0  0  0  0  0 
miR‐22‐
5p  0  0  3  0  9  4  0  0  0  6  12  3  0  5  0  12  0  6  1  1  1  2  0  3 
miR‐
2278  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
2355‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




23a‐5p  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
23b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0 
miR‐
23b‐5p  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  0  0  1 
miR‐24‐
3p  21  24  30  22  110  162  14  12  24  51  312  49  26  77  11  361  32  128  11  42  14  36  7  106 
miR‐25‐
3p  50  29  175  26  253  183  36  54  48  55 
186
0  139  20  184  142  200  47  676  17  62  113  37  18  116 
miR‐25‐




0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0 
miR‐
26a‐5p  51  28  54  44  263  411  23  37  58  62  287  84  38  211  47  341  83  146  35  198  19  229  17  265 
miR‐




26b‐5p  1  0  3  1  12  6  2  2  8  3  75  7  0  14  3  11  5  8  1  2  0  3  1  8 
miR‐
27a‐3p  18  4  11  10  76  29  4  4  12  20  178  22  5  15  11  70  25  92  6  33  6  32  5  47 
miR‐
27a‐5p  0  2  1  2  3  4  0  1  0  3  3  2  1  4  0  7  3  2  3  1  2  0  1  0 
miR‐
27b‐3p  9  8  6  6  25  21  2  5  10  10  76  26  6  11  0  95  11  48  6  12  5  6  1  29 
miR‐
27b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  1  0  0  0  0 
miR‐28‐
3p  0  0  0  1  7  19  0  0  1  7  13  0  2  6  0  21  1  3  0  2  0  1  0  1 
miR‐28‐
5p  0  0  0  0  2  0  0  0  0  0  4  1  2  2  0  5  0  1  0  2  0  1  0  0 
miR‐
296‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐








0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
29b‐3p  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  1  0  1  0  0  0  0  0  0 
miR‐
29c‐3p  2  0  0  0  1  0  0  0  0  0  2  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
29c‐5p  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
301a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
301b  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
30a‐3p  5  7  1  2  20  10  3  1  4  12  17  14  5  8  3  20  9  15  4  8  7  5  2  10 
miR‐




30b‐3p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐








1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1  0 
miR‐
30c‐5p  3  1  3  6  21  15  2  4  1  6  16  6  2  13  3  10  3  9  0  9  4  6  4  17 
miR‐
30d‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0  0  0  0 
miR‐
30d‐5p  38  50  49  41  286  106  21  33  38  120  601  58  14  114  35  223  22  257  7  33  53  37  3  87 
miR‐




30e‐5p  1  1  2  3  4  1  0  0  1  2  30  4  0  1  1  11  1  16  0  0  1  0  2  3 
miR‐
3122  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3127‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0 
miR‐
3127‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
3128  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3136‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3138  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐










0  0  0  0  1  0  0  0  0  0  0  2  0  0  0  1  1  0  0  0  0  0  0  0 
miR‐
3157‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3158‐3p  3  0  6  1  0  4  2  2  1  1  27  6  1  2  4  6  2  3  0  0  0  0  0  2 
miR‐
3168  13  4  4  2  6  8  6  4  9  4  23  11  5  6  3  13  2  9  5  3  4  0  1  6 
miR‐
3173‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3174  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
3179  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  1  0  0  0  0  0  0 
miR‐
3180‐3p  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  2  0  0  0  0  0  0  0  0 
miR‐




3191‐3p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3197  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3200‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
320a  68  117  67  85  384  201  42  39  50  268  763  134  46  320  72 
107
1  93  601  16  55  88  161  33  192 
miR‐
320b  6  48  13  15  80  19  11  7  18  74  93  14  7  67  11  257  6  80  5  8  19  36  3  29 
miR‐
320c  0  22  0  3  39  1  1  2  1  26  20  5  3  16  1  90  2  19  2  1  5  11  3  13 
miR‐
320d  0  5  3  1  11  1  1  0  0  5  3  2  1  5  0  30  1  7  1  0  1  2  3  7 
miR‐
320e  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐




323a‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
323b‐3p  0  0  0  0  0  4  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0 
miR‐
324‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  0  0  1 
miR‐32‐
5p  0  0  2  2  1  5  0  1  1  1  16  0  0  1  0  5  0  6  0  2  0  1  1  0 
miR‐
326  0  0  0  0  0  2  0  0  0  0  4  0  1  0  0  3  0  1  0  0  0  0  0  0 
miR‐
328‐3p  2  1  3  1  6  40  2  0  1  3  17  4  5  12  1  55  2  5  0  10  1  13  0  11 
miR‐
330‐3p  0  0  0  0  0  1  0  0  0  2  0  0  0  0  0  0  0  0  0  1  0  1  0  0 
miR‐
330‐5p  0  0  0  0  0  3  0  0  0  0  2  0  1  0  0  0  0  0  0  0  0  0  0  0 
miR‐




335‐3p  0  0  0  0  0  3  0  0  0  0  2  0  1  1  0  6  0  3  0  1  0  0  0  4 
miR‐
335‐5p  0  0  0  0  2  2  0  0  0  0  2  0  0  0  0  4  0  2  0  1  1  0  0  0 
miR‐
337‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
337‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
338‐5p  0  0  0  0  0  1  0  0  0  1  3  0  0  0  0  1  0  2  0  0  1  0  0  1 
miR‐
339‐3p  0  0  0  0  0  1  0  0  1  0  11  0  0  0  1  8  0  5  0  0  0  1  0  0 
miR‐
339‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
340‐3p  0  0  0  0  1  1  0  0  0  0  0  0  0  1  0  1  2  0  0  0  0  0  0  0 
miR‐




342‐3p  0  0  0  1  2  4  0  0  0  0  2  2  1  0  0  0  0  2  0  2  0  2  0  2 
miR‐
342‐5p  1  1  1  3  5  8  2  0  1  0  49  0  0  0  2  8  2  13  2  3  6  1  0  2 
miR‐
345‐5p  0  0  0  1  1  1  2  0  0  0  1  2  0  1  0  2  0  0  0  0  0  0  0  0 
miR‐
34a‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3591‐5p  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3605‐3p  2  0  1  0  8  1  1  0  0  0  6  0  0  1  0  3  0  0  0  0  0  1  1  0 
miR‐
3605‐5p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  1  1 
miR‐
3613‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




361‐3p  0  0  0  0  1  0  0  0  0  0  3  0  1  1  1  0  0  1  0  3  0  0  0  0 
miR‐
3614‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
3615  5  4  1  0  6  0  0  3  0  2  19  0  1  7  1  21  1  7  0  0  2  1  0  3 
miR‐
361‐5p  0  0  0  0  4  1  0  0  0  0  2  1  0  3  0  7  1  1  0  2  0  4  0  0 
miR‐
3621  0  0  0  0  0  0  0  0  0  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐
362‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
363‐3p  16  4  25  4  48  25  2  4  9  9  371  22  6  30  14  20  7  78  4  14  36  13  0  23 
miR‐
363‐5p  0  0  0  0  1  0  0  0  1  0  7  0  0  0  0  0  0  2  0  0  0  0  0  1 
miR‐




365a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
365a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
365b‐3p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3663‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3675‐5p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3682‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3688‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3690  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




369‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
370‐3p  0  0  0  1  0  12  0  0  0  2  9  1  4  6  0  9  1  0  5  0  0  1  3  6 
miR‐
370‐5p  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
372‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
374a‐3p  0  0  0  0  1  1  0  0  1  0  8  0  0  0  0  2  0  1  0  0  0  0  1  1 
miR‐
374a‐5p  1  1  1  0  1  4  0  0  1  1  12  2  0  4  0  3  0  4  0  2  1  1  0  2 
miR‐
374b‐5p  0  0  0  0  0  1  0  0  0  0  4  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
375  7  219  6  2  25  3  3  0  3  578  58  11  5  67  8  124  7  861  1  0  29  4  0  0 
miR‐




378a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
378c  0  0  1  0  1  1  0  0  0  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0 
miR‐
378d  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
379‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
379‐5p  0  0  1  0  0  11  0  0  0  0  2  1  2  2  0  1  2  0  0  1  0  0  1  1 
miR‐
381‐3p  0  0  0  0  0  19  0  0  0  0  8  0  1  4  0  3  0  4  0  0  1  1  2  1 
miR‐
381‐5p  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
382‐5p  0  0  0  0  0  10  0  0  0  1  3  2  0  1  0  4  0  1  1  0  0  0  0  1 
miR‐




3911  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3912‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0 
miR‐
3913‐5p  0  0  0  0  0  0  0  1  0  0  1  0  0  0  2  0  0  1  0  0  1  0  0  0 
miR‐
3928‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
3934‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3936  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3940‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
409‐3p  0  0  2  0  0  20  0  0  0  0  25  0  7  5  2  9  2  3  1  0  4  0  1  5 
miR‐




410‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
411‐3p  0  0  0  0  0  2  0  0  0  0  1  0  1  2  0  0  0  0  0  0  0  0  0  2 
miR‐
411‐5p  0  0  0  0  0  1  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  0  0  1 
miR‐
421  0  0  0  0  1  0  0  0  0  0  1  0  0  1  0  0  0  1  0  0  0  0  0  0 
miR‐
423‐3p  14  16  22  30  91  122  6  11  18  52  194  35  20  69  14  297  18  92  5  28  31  48  12  55 
miR‐
423‐5p  272  193  765  259  834 
113
7  232  296  306  316 
507




7  451  137  651 
miR‐
424‐3p  0  1  2  1  3  3  0  0  1  5  30  2  0  1  1  5  1  11  1  1  7  2  0  3 
miR‐
424‐5p  0  0  0  0  1  0  0  0  0  0  1  0  0  0  0  1  0  0  0  1  0  0  0  0 
miR‐




4259  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
429  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  3  0  0  1  0  0  0 
miR‐
431‐5p  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  1  0  0  0  0  0  1 
miR‐
4322  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
432‐5p  1  0  0  0  0  17  0  0  0  0  22  0  2  6  0  9  0  3  0  0  0  0  0  4 
miR‐
4326  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
433‐3p  0  0  0  0  0  1  0  0  0  0  2  0  0  1  0  1  0  0  0  0  0  0  0  0 
miR‐
4433‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐










0  0  0  0  0  4  0  0  0  0  0  0  0  0  0  3  1  0  0  0  0  0  0  1 
miR‐
4443  1  0  0  0  1  1  1  0  1  0  2  0  0  0  0  1  0  2  0  0  1  0  0  4 
miR‐
4446‐3p  0  0  0  0  0  10  0  0  0  0  2  0  1  0  0  5  0  0  0  2  0  1  0  0 
miR‐
4467  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4473  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4474‐3p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




4482‐3p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
4488  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐
4489  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4497  0  0  0  0  0  1  0  0  1  0  0  3  0  1  0  3  0  0  0  0  1  0  0  2 
miR‐
4500  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4504  0  0  0  0  0  0  0  0  0  1  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4508  0  0  0  0  1  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
450a‐5p  1  0  0  0  1  1  1  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0  0  1 
miR‐




4510  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4511  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4513  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




























452‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
454‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
454‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




4635  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4647  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4658  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐




0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4663  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4664‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4665‐5p  0  1  1  0  1  3  1  0  0  0  0  0  0  0  0  2  0  1  0  1  0  0  0  0 
miR‐




4669  0  0  0  0  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
4670‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
4671‐5p  0  0  0  0  0  0  0  0  1  0  0  0  1  1  0  0  0  0  1  0  0  0  2  1 
miR‐
4672  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4676‐5p  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4677‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4683  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4685‐3p  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  2  0  0  0  0  0  0  0  0 
miR‐




4697‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4709‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
4714‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
4723‐3p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
4727‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4731‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4732‐3p  0  0  1  0  1  0  0  0  0  3  13  1  0  1  2  0  0  4  0  1  3  0  0  2 
miR‐
4732‐5p  0  1  5  0  3  2  0  1  2  3  19  6  0  5  3  2  0  10  0  1  6  0  2  4 
miR‐




4742‐3p  0  0  0  0  1  0  0  0  0  0  3  0  0  0  0  0  0  0  0  2  0  0  0  0 
miR‐
4742‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
4743‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
4745‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4746‐5p  0  0  1  1  0  0  0  0  0  1  4  0  0  0  0  4  0  0  0  0  0  0  0  1 
miR‐
4750‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4763‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4773  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐




4781‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  2 
miR‐
4800‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4804‐5p  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
483‐3p  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
483‐5p  0  0  1  0  5  3  0  1  3  0  0  1  0  0  0  8  0  3  5  5  0  1  0  2 
miR‐
484  2  1  4  0  10  5  2  0  0  7  42  3  0  14  1  19  2  12  0  0  3  1  0  5 
miR‐
485‐3p  0  0  1  0  0  5  0  0  0  0  2  0  0  1  0  3  0  0  1  0  0  1  0  0 
miR‐
485‐5p  0  0  0  0  0  0  0  0  0  1  3  0  0  0  0  2  0  1  0  0  0  0  0  1 
miR‐




















7  187  237  998  225  231  926 
miR‐
490‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
493‐3p  0  0  0  0  0  3  0  0  0  0  1  0  0  2  0  1  2  2  0  0  0  0  0  0 
miR‐
493‐5p  0  0  0  0  0  3  0  0  0  0  0  0  1  0  1  4  0  0  0  0  0  0  0  0 
miR‐
495‐3p  0  0  0  0  0  3  0  0  1  0  2  0  0  0  0  1  0  1  0  0  0  0  0  0 
miR‐
499a‐5p  0  0  0  0  3  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
5009‐5p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
500a‐3p  0  0  0  0  4  0  0  0  0  0  0  1  0  2  0  0  0  1  0  0  0  0  0  1 
miR‐




5010‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1  4  0  0  0  0  0  1 
miR‐
501‐3p  0  0  0  2  7  6  0  0  3  3  21  2  0  7  2  9  0  8  0  2  1  0  0  2 
miR‐
502‐3p  0  0  0  1  0  2  0  0  0  0  1  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
503‐5p  0  0  2  0  3  3  0  0  0  1  3  2  0  3  0  0  0  1  0  0  2  1  0  1 
miR‐
504‐5p  0  0  0  0  0  0  0  0  0  0  0  1  1  0  0  1  0  1  0  0  0  0  1  0 
miR‐
505‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
505‐5p  0  0  0  0  1  4  1  0  1  1  11  3  1  1  0  1  0  4  0  0  0  0  0  1 
miR‐
5090  0  0  0  0  0  0  1  1  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐






0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
509‐3p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
5100  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
511‐5p  0  1  0  0  1  0  0  0  7  0  8  0  0  0  0  2  0  2  0  0  0  0  0  0 
miR‐
514a‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
516a‐5p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
516b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
5187‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐




520a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
532‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1 
miR‐
532‐5p  6  4  15  5  19  20  4  4  9  14  126  14  5  10  11  36  9  59  2  6  12  7  3  16 
miR‐
541‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
542‐3p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
543  0  0  1  2  1  28  0  0  0  0  10  1  1  2  0  7  1  0  0  0  0  0  2  7 
miR‐
548ac  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
548e‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐








0  0  0  0  0  0  0  0  0  0  0  0  0  3  0  1  0  0  0  0  0  0  0  0 
miR‐
550a‐5p  0  0  0  0  0  1  0  0  1  3  12  3  0  2  0  0  0  3  0  1  1  1  0  4 
miR‐
551a  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
556‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
570‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
574‐3p  0  0  0  0  0  3  1  0  0  0  0  0  0  0  0  5  1  0  0  0  0  0  0  1 
miR‐
574‐5p  0  0  0  0  1  1  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐




576‐5p  0  1  0  0  0  0  0  0  0  1  1  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
579‐5p  0  1  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
580‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
581  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
582‐3p  0  1  0  1  1  0  0  0  1  1  2  0  0  0  0  2  0  0  1  0  0  1  0  0 
miR‐
582‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0 
miR‐
584‐5p  0  3  5  1  12  16  0  2  2  5  45  12  5  5  4  54  1  27  1  1  7  4  2  6 
miR‐
589‐5p  0  0  0  0  0  1  0  0  0  0  2  1  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐




6068  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6087  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
615‐3p  0  0  0  0  0  0  0  0  0  3  2  0  0  0  0  11  0  3  0  0  0  0  0  1 
miR‐
618  0  0  0  0  0  1  0  0  0  1  0  0  0  0  0  2  1  0  0  0  0  0  0  0 
miR‐
624‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
625‐3p  0  0  0  0  0  2  0  1  0  0  2  0  0  0  0  17  0  1  0  1  0  0  0  0 
miR‐
625‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
627‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐




628‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
629‐3p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
629‐5p  10  7  15  7  10  14  2  3  4  10  97  10  2  12  9  27  3  67  0  7  23  9  2  11 
miR‐
636  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
642a‐3p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6503‐3p  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6509‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐














0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6515‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
651‐5p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0 
miR‐
6516‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
652‐3p  0  0  0  0  1  2  0  0  0  0  19  1  0  1  0  2  0  1  0  0  0  0  0  0 
miR‐
654‐3p  0  0  0  0  0  2  0  0  0  0  2  1  0  1  0  1  0  0  1  0  0  0  0  0 
miR‐




655‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
658  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
659‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0 
miR‐
660‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
661  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
664a‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
664a‐5p  1  2  0  2  2  2  0  0  1  1  6  0  0  4  0  17  0  4  0  0  1  1  0  0 
miR‐
664b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐






0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6716‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6717‐5p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
6721‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6723‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6727‐5p  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6730‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
6734‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




6735‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6735‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  2  0  0  0  0  0  0 
miR‐
6736‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
6738‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0 
miR‐
6741‐3p  0  0  0  0  0  2  0  2  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6741‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0 
miR‐
6747‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
6750‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐




6767‐5p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
6770‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0 
miR‐
6772‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
6781‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6785‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐
6786‐3p  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




6788‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0 
miR‐
6790‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6793‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6802‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
6803‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6805‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
6806‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
6808‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  1 
miR‐




6813‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0 
miR‐
6815‐5p  0  0  1  0  0  0  0  0  0  0  3  1  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
6821‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6826‐5p  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6837‐3p  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6839‐5p  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6842‐3p  0  0  0  0  0  0  0  0  0  1  0  2  0  0  0  0  0  2  0  0  1  0  0  0 
miR‐
6842‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  4  0  0  0  1  0  0  0  0 
miR‐




6849‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6850‐5p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
6852‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  1 
miR‐
6859‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
6862‐5p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6865‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6866‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0 
miR‐
6868‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐




6873‐3p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6877‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
6881‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6884‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
7107‐3p  0  1  3  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  2  0  1 
miR‐
7110‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
744‐5p  1  2  2  0  7  46  1  1  2  7  22  4  4  15  1  59  1  6  3  7  3  12  1  4 
miR‐
758‐3p  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  2 
miR‐7‐




760  0  1  0  0  0  0  0  0  0  0  0  1  0  0  0  1  0  0  0  0  0  1  0  0 
miR‐
766‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  1 
miR‐
769‐5p  0  0  0  0  2  0  0  0  0  1  5  0  0  0  0  2  0  1  0  0  1  0  0  1 
miR‐
7704  0  0  0  0  3  0  0  0  1  0  0  1  0  1  0  3  0  0  0  0  0  0  0  2 
miR‐
7706  0  1  1  0  2  1  0  0  1  1  13  0  0  0  0  3  0  2  0  0  2  0  0  0 
miR‐
7848‐3p  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  0  0  0 
miR‐
7854‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
7976  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐




874‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
877‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
885‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  7  0  0  0  0  0  0  0  0 
miR‐
885‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  4  0  0  0  0  0  0  0  0 
miR‐








0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
92a‐3p  142  106  545  199 
103
8  620  114  180  162  374 
425
5  527  145  644  424  985  178 
232




92b‐3p  1  2  6  5  18  7  0  3  5  24  35  4  2  23  3  28  3  20  1  2  2  2  3  4 
miR‐
92b‐5p  1  0  0  1  1  0  0  0  0  2  11  0  0  4  0  1  0  2  0  1  5  0  0  0 
miR‐93‐
5p  0  0  3  3  11  3  0  3  0  0  34  3  0  3  2  3  3  10  0  1  4  1  1  2 
miR‐
937‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
939‐5p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐9‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
941  1  1  1  0  1  5  3  0  1  5  23  1  0  4  2  10  2  4  0  2  1  0  1  2 
miR‐
942‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




3p  0  0  0  0  0  0  0  0  0  0  2  0  1  1  0  3  0  1  0  0  0  0  0  0 
miR‐9‐
5p  0  0  0  0  1  0  0  0  0  0  8  0  0  1  1  0  0  1  0  0  3  3  0  2 
miR‐96‐
5p  1  2  1  0  0  0  1  0  0  1  6  0  0  0  0  0  0  1  0  0  0  0  0  1 
miR‐98‐
5p  3  2  2  1  14  35  0  1  2  2  31  4  3  12  2  19  5  9  0  4  0  10  1  10 
miR‐
99a‐5p  37  21  38  54  353  68  25  8  41  155  416  115  21  35  23  550  34  549  21  56  59  157  7  87 
miR‐
99b‐3p  0  0  0  0  4  2  0  0  0  1  2  0  0  0  0  2  0  0  0  5  1  0  0  0 
miR‐






















































5p  192  84  77  371  348  307  155 
255
0  477  152  209  175  170  56  105  425  128  763  193  293  992  73  808  899 
let‐7b‐
3p  0  1  0  1  1  1  1  15  3  0  2  1  0  0  0  3  0  2  1  0  3  1  4  2 
let‐7b‐
5p  338  427  400  564  466  343  283 
716






3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
let‐7c‐
5p  11  13  9  25  31  30  17  156  53  11  26  23  15  1  9  57  7  68  27  32  103  12  74  79 
let‐7d‐
3p  7  12  13  27  14  22  10  169  44  9  28  12  15  0  2  35  15  23  25  17  70  14  46  56 
let‐7d‐
5p  5  3  4  12  14  20  10  194  20  16  5  14  4  2  2  19  2  42  8  14  62  2  47  51 
let‐7e‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
let‐7e‐




3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
let‐7f‐
5p  90  38  40  156  157  103  72  936  187  57  95  61  80  16  37  167  34  259  77  101  425  42  351  365 
let‐7g‐
5p  32  15  46  72  70  65  40  659  108  26  47  40  25  8  27  103  28  147  28  47  233  23  151  199 
let‐7i‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
let‐7i‐
5p  175  143  115  466  252  129  193 
253
8  414  125  294  134  176  54  143  369  107  412  213  283  705  123  541  832 
miR‐1  1  0  3  0  2  2  0  1  0  0  1  1  7  0  8  0  5  1  0  0  0  0  2  2 
miR‐
100‐5p  6  0  9  0  2  6  1  36  5  26  1  1  46  1  127  2  90  5  0  11  26  1  10  16 
miR‐
101‐3p  6  3  10  20  21  14  13  277  27  5  33  13  13  5  4  29  12  17  6  20  38  3  18  41 
miR‐
103a‐3p  1  1  1  5  4  4  4  49  3  1  2  5  0  0  1  6  3  12  5  2  15  2  12  16 
miR‐




106a‐5p  0  0  0  0  0  0  0  1  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  3 
miR‐
106b‐3p  0  1  7  16  5  0  3  84  8  1  9  2  3  2  4  8  4  6  3  10  9  2  8  7 
miR‐
106b‐5p  0  0  0  0  2  3  0  5  1  1  0  1  0  0  0  0  0  0  0  0  1  0  2  0 
miR‐
107  1  1  2  0  1  1  1  17  2  0  1  1  0  0  0  0  0  1  0  0  0  0  3  2 
miR‐
10a‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
10a‐5p  16  16  11  33  30  20  10  164  30  14  19  12  35  2  13  48  8  52  43  24  114  13  52  62 
miR‐
10b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
10b‐5p  28  30  18  60  71  57  20  268  59  22  21  25  59  5  19  85  16  89  61  38  213  8  110  132 
miR‐








0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1193  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1224‐5p  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
1225‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
122‐5p  63  55  104  126  237  53  212  536 
159
5  63  239  125  110  75  55  115  161  176  337  111 
124
4  200  178  574 
miR‐
1226‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1228‐5p  0  0  0  0  0  0  0  3  0  0  0  0  1  0  0  0  0  1  0  0  0  0  0  0 
miR‐




124‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  3  0  0  0 
miR‐
1246  0  0  1  0  1  0  0  2  1  0  0  0  0  0  0  0  2  0  0  0  2  0  0  0 
miR‐
1248  0  0  0  0  0  0  1  2  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
1249  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
1254  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
125a‐3p  0  0  0  0  0  0  0  2  0  1  1  0  0  0  0  0  0  0  0  1  0  0  1  0 
miR‐










0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
125b‐5p  0  1  0  1  2  0  1  5  5  2  0  2  1  0  0  1  2  1  1  1  11  0  1  5 
miR‐
1261  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐


















126‐5p  1  2  0  5  0  3  1  18  1  4  0  2  0  0  0  1  0  6  1  3  8  0  6  12 
miR‐
1270  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐






0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
127‐3p  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  1  1  0  0  1  0  0 
miR‐
1277‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1278  0  0  0  0  0  0  0  3  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0 
miR‐
128‐3p  6  9  18  26  24  26  7  143  30  4  11  10  10  4  6  45  9  17  12  17  106  9  42  73 
miR‐
1284  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1287‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
1288‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




1293  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1294  0  0  0  0  0  1  0  3  0  0  0  0  0  0  0  0  0  1  0  0  0  0  1  1 
miR‐
1295a  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0 
miR‐
129‐5p  0  0  0  0  1  0  0  1  0  0  0  0  0  0  1  0  0  0  3  0  8  0  0  0 
miR‐
1299  0  0  0  1  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2 
miR‐
1301‐3p  0  0  0  1  4  1  0  0  1  0  2  0  0  0  0  1  0  1  5  1  2  0  0  0 
miR‐
1304‐3p  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
1306‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




1307‐3p  1  1  2  8  3  7  1  38  5  0  4  4  1  0  0  3  2  4  0  1  7  2  12  6 
miR‐
1307‐5p  0  1  0  0  1  0  0  8  0  0  2  0  1  0  0  0  0  1  0  0  2  1  1  0 
miR‐
130a‐3p  0  0  1  0  0  0  0  1  0  0  0  0  0  0  0  0  0  1  0  2  0  0  2  2 
miR‐
130b‐3p  1  0  1  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0  0  0  0  0  0  1 
miR‐
130b‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  2  0  0  0  1  0  0  0  1 
miR‐
1323  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
132‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
132‐5p  0  0  0  0  0  0  0  2  0  1  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐




134‐5p  0  0  2  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  0  1  1  0  0  1 
miR‐
135a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0 
miR‐
136‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
136‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
138‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
139‐3p  1  1  0  9  4  0  0  11  2  1  2  0  7  1  1  4  1  4  3  1  21  2  5  5 
miR‐
139‐5p  16  6  4  24  13  17  3  69  14  12  2  3  9  0  4  22  3  27  15  12  65  3  17  34 
miR‐
140‐3p  0  1  3  2  2  2  2  21  3  0  2  4  2  1  2  2  0  1  2  2  12  0  2  4 
miR‐




141‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
142‐3p  2  0  1  6  5  7  4  27  1  1  1  5  0  0  0  5  0  5  7  5  11  2  11  12 
miR‐
142‐5p  0  1  3  1  5  4  1  22  3  1  1  1  0  0  2  3  3  1  1  5  9  1  11  3 
miR‐
143‐3p  5  3  0  19  8  5  2  20  10  3  5  6  16  1  5  11  0  8  7  13  35  1  22  22 
miR‐
144‐3p  0  1  1  1  2  2  1  21  3  0  0  0  1  0  0  3  1  6  3  3  10  0  2  2 
miR‐
144‐5p  0  0  3  2  2  1  1  15  2  1  0  4  0  0  0  3  0  5  1  3  12  2  12  6 
miR‐
145‐3p  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  1  1 
miR‐
145‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐




146a‐5p  1  1  1  9  6  8  7  45  8  0  7  4  1  1  5  10  1  17  9  5  24  2  14  20 
miR‐
146b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
146b‐5p  0  1  2  1  4  4  1  45  8  1  0  4  0  1  2  8  0  18  8  3  23  1  6  15 
miR‐
147b  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
148a‐3p  80  75  103  317  160  111  146 
123
4  321  57  315  111  228  42  105  227  109  137  175  151  325  110  260  475 
miR‐
148a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  1 
miR‐
148b‐3p  1  6  8  19  6  11  7  77  12  4  10  2  4  0  6  13  7  7  4  8  17  4  6  26 
miR‐
149‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0 
miR‐




150‐5p  4  1  12  15  6  17  6  93  8  3  4  11  1  1  4  18  2  45  14  10  66  6  40  42 
miR‐
151a‐3p  16  10  10  67  18  14  12  168  34  6  53  11  32  2  17  27  15  20  14  23  55  8  26  70 
miR‐
151a‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
152‐3p  0  3  0  1  0  0  0  3  0  1  0  0  0  0  0  0  0  0  3  0  2  0  0  4 
miR‐
152‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
153‐3p  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
155‐5p  2  11  5  4  4  6  5  32  6  2  0  2  1  3  3  12  1  10  13  6  39  0  20  15 
miR‐
15a‐5p  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  1 
miR‐




15b‐5p  1  1  0  7  3  1  1  37  2  1  1  1  0  0  4  3  2  2  2  1  5  0  2  3 
miR‐16‐
2‐3p  0  3  1  4  11  7  3  64  11  0  5  4  0  1  0  8  3  9  2  5  7  1  10  13 
miR‐16‐
5p  7  3  11  16  24  23  6  204  28  7  9  19  5  4  3  23  6  30  4  20  37  5  34  29 
miR‐17‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0  0  0  0  0 
miR‐17‐




0  0  0  1  1  0  0  4  0  0  0  0  1  0  0  2  0  0  0  0  2  0  0  2 
miR‐
181a‐3p  0  0  0  0  0  1  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
181a‐5p  4  10  4  16  25  11  3  124  12  13  6  6  10  1  5  25  8  21  15  8  50  2  29  47 
miR‐




181c‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
181c‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
181d‐5p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1  0  1  1  0  0  0 
miR‐
182‐5p  10  3  2  12  2  4  4  112  12  4  5  2  1  0  2  6  6  17  3  3  27  1  20  26 
miR‐
183‐5p  3  4  5  14  7  8  1  86  9  6  5  3  2  2  2  8  11  24  1  17  24  6  21  35 
miR‐
184  3  1  0  1  2  3  2  26  2  0  2  2  0  1  118  0  1  3  0  1  0  0  1  8 
miR‐
185‐3p  0  0  0  0  0  0  1  1  1  0  0  0  0  0  0  1  0  0  2  0  0  0  0  0 
miR‐
185‐5p  6  3  14  17  10  44  4  228  36  9  11  27  9  2  5  19  7  35  7  10  50  2  37  46 
miR‐




188‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
188‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
18a‐3p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  1  0  0  0  0  1  0  0  4 
miR‐
18a‐5p  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  1  0  0  2  0  0  0 
miR‐
18b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0 
miR‐
1908‐5p  0  1  1  2  0  0  1  17  1  0  0  3  0  0  1  1  1  3  0  0  4  0  4  7 
miR‐
190a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
191‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




191‐5p  9  6  12  28  28  23  5  139  27  10  11  17  3  1  5  42  32  34  22  9  73  2  54  86 
miR‐
192‐5p  2  1  9  9  9  7  9  137  12  4  6  16  6  2  3  9  2  24  5  5  21  3  7  19 
miR‐
193a‐5p  0  0  0  1  1  2  1  3  8  0  0  0  0  0  0  4  0  2  0  1  7  0  3  3 
miR‐
193b‐5p  0  0  0  0  0  0  0  1  4  0  0  0  0  0  0  0  0  0  3  0  1  0  2  0 
miR‐
194‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
194‐5p  2  0  4  2  6  9  2  52  13  1  0  3  1  1  3  9  1  5  0  1  13  0  10  15 
miR‐
195‐3p  1  0  0  1  0  0  0  4  1  1  0  0  0  0  0  0  0  0  0  2  1  0  1  0 
miR‐
195‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0 
miR‐




196b‐5p  0  0  1  3  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
197‐3p  0  0  0  2  1  1  0  4  0  0  0  1  0  0  0  0  0  1  1  1  0  0  0  0 
miR‐
197‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
1976  0  0  0  0  0  0  0  4  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
199a‐3p  0  0  0  4  4  1  0  5  1  0  0  0  0  0  0  4  0  4  5  0  1  0  3  4 
miR‐
199a‐5p  0  0  0  1  0  0  0  2  2  0  2  1  0  1  1  0  0  1  0  0  3  0  4  6 
miR‐
199b‐3p  0  0  0  3  1  0  0  1  0  0  0  1  0  0  0  1  0  0  0  0  3  0  1  2 
miR‐
199b‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  4 
miR‐






0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
19b‐3p  0  0  0  1  0  2  0  7  0  0  0  1  0  0  0  1  1  0  0  1  2  0  3  1 
miR‐
200a‐3p  1  1  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  1  0  0  0  1  0 
miR‐
200a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
200b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
200b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
200c‐3p  0  0  2  0  1  0  0  2  0  0  0  0  1  0  0  0  0  0  1  0  1  0  2  0 
miR‐
202‐3p  0  0  0  0  0  0  0  3  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




204‐3p  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
204‐5p  0  0  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  2  0  0  1  0  0  0 
miR‐
206  0  0  0  1  0  0  0  3  6  0  0  0  1  0  1  1  0  0  3  1  1  0  2  1 
miR‐
20a‐5p  1  1  1  1  2  5  5  19  3  0  0  2  0  0  0  4  0  2  2  4  12  0  4  3 
miR‐
20b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
20b‐5p  0  0  0  0  0  0  0  2  0  0  0  1  0  0  0  1  0  0  0  0  1  0  0  1 
miR‐
210‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
2110  1  0  2  3  2  1  0  28  8  0  1  4  1  0  2  6  0  5  1  1  4  0  1  9 
miR‐




3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
214‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
214‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
215‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
215‐5p  1  0  0  0  0  1  0  6  3  0  0  0  0  0  0  2  0  1  0  2  1  0  1  0 
miR‐21‐
5p  16  14  38  50  53  40  18  582  85  24  24  40  18  8  9  65  34  72  44  30  134  5  81  156 
miR‐
216a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
216b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐










0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  10  0  0  0 
miR‐
221‐3p  0  0  0  3  1  1  0  6  1  0  0  2  0  1  0  3  3  1  1  2  7  0  3  9 
miR‐
221‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0 
miR‐
222‐3p  2  1  3  3  4  1  1  11  5  1  0  1  1  1  1  6  0  9  0  1  12  1  4  12 
miR‐
222‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
223‐3p  0  0  0  0  2  0  0  2  0  0  0  1  0  0  0  0  0  1  0  0  5  0  1  1 
miR‐




3p  18  32  32  50  46  51  28  740  86  11  42  34  15  12  15  83  37  54  29  40  107  14  126  140 
miR‐
224‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐22‐
5p  0  0  1  0  0  0  0  18  1  0  1  0  1  0  0  1  0  0  1  0  1  0  3  2 
miR‐
2278  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
2355‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
23a‐3p  0  0  0  2  0  0  0  1  1  0  0  0  0  0  0  1  3  2  0  0  0  0  2  1 
miR‐
23a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2 
miR‐
23b‐3p  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  3  0 
miR‐




3p  11  13  18  51  31  22  8  164  47  15  8  12  11  4  12  59  8  68  18  28  140  2  83  98 
miR‐25‐
3p  30  18  94  123  86  124  64 
141
5  154  42  114  108  57  32  56  201  69  135  46  120  268  36  152  279 
miR‐25‐




0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
26a‐5p  36  53  47  81  159  95  24  522  101  45  19  62  17  7  19  112  14  179  182  58  416  14  230  295 
miR‐
26b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
26b‐5p  4  1  6  2  7  4  3  36  8  3  1  4  2  0  0  7  0  9  3  6  14  0  7  11 
miR‐
27a‐3p  4  16  9  15  30  13  10  116  31  10  3  16  6  4  6  36  6  35  19  10  76  5  42  51 
miR‐




27b‐3p  5  8  6  10  12  8  3  50  29  6  4  8  4  0  3  23  4  16  4  6  49  2  19  23 
miR‐
27b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐28‐
3p  0  0  1  0  0  1  0  10  1  0  1  1  3  0  0  4  0  4  1  5  9  0  2  7 
miR‐28‐
5p  0  0  0  2  1  0  0  1  0  0  0  0  0  0  0  0  0  2  0  0  0  0  1  1 
miR‐
296‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
296‐5p  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




29c‐3p  0  0  0  0  0  1  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
29c‐5p  0  0  0  0  0  1  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
301a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
301b  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0 
miR‐
30a‐3p  7  4  1  12  4  9  4  49  7  5  9  5  5  1  4  10  2  9  9  4  26  3  22  23 
miR‐
30a‐5p  4  3  0  6  10  5  7  64  14  5  3  6  4  3  1  10  0  11  10  5  25  0  19  15 
miR‐
30b‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐










0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  1  0  1  1 
miR‐
30c‐5p  6  4  1  4  16  7  1  48  9  2  4  5  4  1  3  9  3  13  5  6  22  2  19  22 
miR‐
30d‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  0  1 
miR‐
30d‐5p  13  13  29  40  33  33  29  487  79  14  19  49  16  9  23  100  17  86  26  42  150  9  104  147 
miR‐
30e‐3p  3  4  2  9  13  8  4  40  6  3  11  5  6  2  5  12  5  21  7  12  24  5  23  20 
miR‐
30e‐5p  0  0  1  4  1  3  1  38  4  2  0  0  0  1  0  1  5  4  4  2  3  0  2  6 
miR‐
3122  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3127‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




3128  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3136‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
3138  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐








0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐
3157‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




3168  9  4  11  5  4  12  5  52  7  1  3  3  1  1  4  5  2  6  5  3  21  5  9  16 
miR‐
3173‐5p  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  1  0  0  0  0  0  0 
miR‐
3174  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3179  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3180‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3187‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3191‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3197  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐




320a  25  33  31  60  58  136  35  894  134  33  54  63  24  14  17  111  32  179  86  62  233  20  276  229 
miR‐
320b  4  16  3  6  7  14  10  132  36  3  10  5  6  1  2  13  4  31  9  5  25  4  31  31 
miR‐
320c  3  11  2  1  0  4  1  29  6  3  4  3  1  1  1  1  0  4  2  2  7  1  7  8 
miR‐
320d  1  0  0  1  0  0  1  11  0  1  0  0  0  0  0  2  0  4  3  0  4  0  2  1 
miR‐
320e  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
323a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
323a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
323b‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




5p  1  1  1  2  2  2  0  5  3  0  0  0  0  0  0  1  0  2  0  0  4  0  5  7 
miR‐
326  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
328‐3p  0  0  2  7  5  5  0  12  5  1  1  2  1  1  1  9  0  6  2  4  19  1  4  8 
miR‐
330‐3p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  1  0  0  0  1  2  0  0  1 
miR‐
330‐5p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1  0  0  0  0  1  0 
miR‐
331‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
335‐3p  0  0  1  0  0  0  0  2  1  0  0  0  0  0  0  0  0  1  0  0  0  0  1  0 
miR‐
335‐5p  2  0  1  0  1  0  0  3  0  0  0  0  0  0  1  1  0  1  0  0  0  0  0  0 
miR‐




337‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2 
miR‐
338‐5p  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  1  0  3  0  0  4  0  0  3 
miR‐
339‐3p  0  0  0  1  1  0  1  1  2  0  0  0  0  0  0  1  2  0  0  0  1  0  1  3 
miR‐
339‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
340‐3p  0  0  0  0  0  0  0  0  0  0  1  0  1  0  0  1  0  0  0  0  1  0  0  3 
miR‐
340‐5p  1  0  0  4  4  1  0  5  0  1  1  3  2  0  1  0  1  2  1  0  2  0  2  7 
miR‐
342‐3p  2  0  1  0  1  1  0  1  0  0  0  0  0  0  0  0  1  5  1  2  1  0  1  1 
miR‐
342‐5p  2  2  1  7  2  3  0  33  4  1  4  1  2  1  1  2  3  4  6  3  14  1  6  16 
miR‐




34a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3591‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3605‐3p  0  0  0  1  1  0  0  5  1  0  0  0  1  0  0  0  0  1  0  0  1  0  1  3 
miR‐
3605‐5p  0  0  0  0  0  0  0  1  1  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐
3613‐3p  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3613‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
361‐3p  0  0  0  0  0  0  1  1  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
3614‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐




361‐5p  0  1  0  0  1  1  0  2  4  0  0  1  0  0  0  0  1  0  0  0  1  0  0  2 
miR‐
3621  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
362‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
363‐3p  7  5  3  23  19  16  3  171  24  9  16  17  8  6  1  39  5  30  7  12  34  8  57  77 
miR‐
363‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  1  2 
miR‐
3656  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
365a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0 
miR‐
365a‐5p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐




3663‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
3675‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3682‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3688‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
3690  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0 
miR‐
3691‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
369‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
370‐3p  0  0  1  3  2  0  1  15  1  0  0  0  0  0  1  0  0  2  0  0  3  1  0  8 
miR‐




372‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
374a‐3p  0  0  0  0  0  0  0  4  0  0  0  0  0  0  0  0  0  1  0  0  1  0  2  0 
miR‐
374a‐5p  0  0  1  0  0  3  0  4  3  1  0  3  0  0  0  1  0  2  0  0  3  1  1  5 
miR‐
374b‐5p  0  0  0  1  0  4  1  0  0  1  0  0  0  0  0  0  0  1  0  1  0  0  1  1 
miR‐
375  1  0  2  0  5  1  3  6  9  1  0  2  1  1  2  1  0  0  1  4  7  1  7  7 
miR‐
378a‐3p  1  1  1  1  7  2  2  21  5  1  2  2  0  0  0  1  4  1  4  0  8  2  4  7 
miR‐
378a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
378c  0  0  1  0  0  1  0  2  1  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐




379‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
379‐5p  0  0  2  0  0  0  1  1  0  0  0  0  0  1  0  0  0  2  0  0  2  0  3  1 
miR‐
381‐3p  1  0  0  1  0  3  0  7  0  0  3  0  1  0  2  2  0  0  6  0  5  0  1  3 
miR‐
381‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
382‐5p  0  1  0  0  1  0  0  3  1  0  0  1  0  0  0  3  0  2  1  0  4  0  1  2 
miR‐
3909  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
3911  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
3912‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




3928‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
3934‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐
3936  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  3 
miR‐
3940‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1 
miR‐
409‐3p  0  1  3  4  0  0  0  4  1  0  4  0  0  2  1  1  1  2  0  2  9  1  0  15 
miR‐
409‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
410‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
411‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




421  0  0  1  0  0  0  0  2  1  0  0  0  0  0  0  1  2  0  0  0  0  0  0  0 
miR‐
423‐3p  7  8  6  40  16  22  11  168  32  6  27  19  12  1  4  34  11  27  17  18  97  14  41  65 
miR‐
423‐5p  247  265  293  682  316  196  386 
544






424‐3p  0  0  0  0  1  1  0  11  1  2  0  1  1  0  0  5  0  5  0  1  2  0  7  1 
miR‐
424‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
425‐5p  3  1  5  1  5  7  2  68  9  0  6  2  2  2  4  8  3  9  0  4  13  2  9  20 
miR‐
4259  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
429  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




4322  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
432‐5p  0  0  1  1  0  0  0  4  1  0  2  0  0  0  1  3  0  5  1  0  3  1  0  3 
miR‐
4326  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
433‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
4433‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0 
miR‐












4443  2  0  0  2  0  0  0  4  0  0  1  0  0  0  0  4  0  1  2  0  0  0  2  3 
miR‐
4446‐3p  0  0  1  0  0  0  0  3  3  0  0  1  0  0  0  0  0  1  0  0  2  0  0  0 
miR‐
4467  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  1  0  0  1  1 
miR‐
4473  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4474‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4477b  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4482‐3p  0  0  0  0  0  0  0  4  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4488  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




4497  0  0  0  0  1  0  0  3  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  2 
miR‐
4500  0  0  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4504  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4508  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
450a‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  1 
miR‐
450b‐5p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  1  0  2  0 
miR‐
4510  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
4511  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐








































452‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
454‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
454‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
455‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4635  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  1  1  0  0  0  0  0  1 
miR‐
4647  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐








0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0 
miR‐
4663  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
4664‐3p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4665‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  1 
miR‐
4667‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4669  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  1  0  0  0  0  0 
miR‐
4670‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




4672  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4676‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4677‐5p  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4683  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1  0  0  0  0  0 
miR‐
4685‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4688  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4697‐3p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4709‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




4723‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4727‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
4731‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
4732‐3p  1  1  0  1  0  1  0  6  2  0  2  0  0  0  1  1  0  0  0  0  1  2  3  3 
miR‐
4732‐5p  0  0  0  2  3  3  1  29  7  1  2  2  0  0  1  5  0  3  1  0  5  1  9  12 
miR‐
4741  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4742‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
4742‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




4745‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4746‐5p  0  0  3  2  0  0  0  3  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4750‐5p  0  0  0  0  0  0  0  3  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4763‐3p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4773  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4779  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
4781‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
4800‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  1  0  0 
miR‐




483‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
483‐5p  1  3  1  1  2  0  0  23  3  2  2  0  1  0  0  1  0  1  2  2  8  0  2  4 
miR‐
484  2  1  0  0  1  7  2  33  6  0  1  3  0  0  1  1  1  5  0  4  7  0  6  3 
miR‐
485‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  3  0  1  0  2  0 
miR‐
485‐5p  0  0  0  0  1  0  0  2  0  0  0  0  0  0  0  0  0  0  1  0  0  1  1  0 
miR‐
486‐3p  3  0  5  4  2  11  6  146  25  2  22  7  9  6  1  12  2  18  4  2  39  1  10  16 
miR‐


















490‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




493‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
495‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
499a‐5p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  0  0  0 
miR‐
5009‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
500a‐3p  0  0  0  0  0  0  0  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0 
miR‐
5010‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
5010‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0 
miR‐
501‐3p  0  0  0  0  1  1  0  31  2  1  0  0  0  0  1  2  1  6  0  1  4  0  6  6 
miR‐




503‐5p  0  1  0  1  0  0  0  5  1  0  0  2  0  0  0  2  1  2  1  0  0  0  3  1 
miR‐
504‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  1  0  1  0  0  0 
miR‐
505‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
505‐5p  0  0  0  0  0  1  1  11  1  1  0  1  1  0  0  1  0  2  0  1  1  0  2  0 
miR‐
5090  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
509‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




511‐5p  0  0  0  0  0  1  0  0  3  0  1  0  0  0  0  0  0  0  1  1  0  0  2  0 
miR‐
514a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
516a‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
516b‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
5187‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
5189‐5p  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
520a‐3p  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
532‐3p  0  0  0  0  0  0  0  4  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




541‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
542‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
543  1  0  3  3  1  1  1  11  2  1  0  0  0  0  1  6  1  2  4  1  8  1  2  7 
miR‐
548ac  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
548e‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  1 
miR‐
548j‐5p  0  0  0  1  0  0  0  1  1  0  0  0  0  0  0  0  0  0  1  1  0  0  0  0 
miR‐




0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐




551a  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
556‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
570‐3p  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
574‐3p  0  0  0  0  1  0  0  0  0  0  0  1  0  0  0  0  1  0  3  0  1  0  0  0 
miR‐
574‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  1  0  0  0  0 
miR‐
576‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0 
miR‐
576‐5p  0  0  0  0  1  0  1  0  0  0  0  0  0  0  0  3  0  1  0  0  0  0  0  0 
miR‐
579‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




581  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
582‐3p  0  1  0  0  2  0  0  0  0  0  0  0  1  0  0  0  0  1  3  0  1  0  1  0 
miR‐
582‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
584‐5p  1  0  1  10  2  3  5  25  2  0  4  2  4  0  0  6  0  2  5  9  7  2  3  22 
miR‐
589‐5p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0 
miR‐
598‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0 
miR‐
6068  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
6087  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐




618  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  1  0  0  0  0  0 
miR‐
624‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
625‐3p  1  0  0  0  1  0  0  1  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  2 
miR‐
625‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
627‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
628‐3p  0  0  0  0  0  0  0  1  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
628‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
629‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




636  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
642a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6503‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6509‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
















6515‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
651‐5p  0  0  0  0  0  1  0  0  0  0  1  0  0  0  1  0  1  0  0  0  0  0  0  0 
miR‐
6516‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  1  0  0  0 
miR‐
652‐3p  0  0  0  0  0  2  0  4  1  0  0  0  0  0  0  1  0  0  0  2  1  0  0  1 
miR‐
654‐3p  0  0  2  0  0  0  0  1  0  0  0  0  0  0  0  1  0  0  0  0  1  0  0  1 
miR‐
654‐5p  0  1  0  0  0  0  0  0  0  0  1  1  0  0  0  0  0  1  1  0  0  0  0  0 
miR‐
655‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
658  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐




660‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
661  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
664a‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
664a‐5p  0  2  1  0  1  0  0  4  1  0  0  0  0  0  0  1  0  1  0  0  0  0  1  0 
miR‐
664b‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐




0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6716‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐




6721‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6723‐5p  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6727‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6730‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6734‐3p  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6734‐5p  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
6735‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
6735‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐




6738‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6741‐3p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2 
miR‐
6741‐5p  0  0  0  0  1  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6747‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6750‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6750‐5p  0  0  0  0  0  0  0  4  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6767‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6770‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐








0  0  0  0  0  0  1  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6781‐5p  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  3  0  0  1  0 
miR‐
6785‐5p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6786‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6787‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0 
miR‐
6788‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6790‐3p  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




6802‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6803‐3p  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
6805‐5p  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6806‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6808‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6812‐3p  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
6813‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6815‐5p  0  0  1  0  0  0  0  4  1  0  0  0  0  0  0  0  0  0  0  0  0  0  1  3 
miR‐




6826‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6837‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
6839‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6842‐3p  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  1  0  0  0 
miR‐
6842‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6847‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0 
miR‐
6849‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
6850‐5p  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  1 
miR‐




6859‐5p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6862‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6865‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0 
miR‐
6866‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  0 
miR‐
6868‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6869‐5p  1  0  0  1  1  0  0  1  0  2  0  0  0  0  0  1  0  0  0  1  1  0  1  0 
miR‐
6873‐3p  1  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
6877‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




6884‐5p  0  0  0  0  0  0  0  3  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
7107‐3p  0  0  0  0  0  0  0  1  0  0  0  0  1  0  0  0  0  0  0  0  0  0  0  1 
miR‐
7110‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
744‐5p  1  1  1  9  6  0  0  12  5  0  4  3  1  0  3  5  0  3  5  4  5  0  4  10 
miR‐
758‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐7‐
5p  6  0  2  3  6  9  0  39  1  1  1  1  0  1  8  6  5  9  0  2  8  0  4  9 
miR‐
760  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
766‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  2  0  0  1 
miR‐




7704  0  1  0  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0 
miR‐
7706  0  0  0  1  0  0  0  18  6  0  2  0  3  2  1  2  1  3  0  0  3  0  1  3 
miR‐
7848‐3p  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
7854‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
7976  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
873‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
874‐3p  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
877‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐




885‐5p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐








0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0 
miR‐
92a‐3p  176  60  183  474  265  356  253 
391




92b‐3p  5  2  7  1  1  8  1  20  1  0  1  7  6  0  1  6  2  4  7  3  5  2  7  7 
miR‐
92b‐5p  0  1  0  0  1  0  0  4  1  0  1  0  1  0  0  1  0  0  0  0  1  1  0  0 
miR‐93‐




937‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1 
miR‐
939‐5p  0  0  0  0  0  0  0  2  1  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐9‐
3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0  0  0 
miR‐
941  1  0  1  1  0  1  0  5  2  0  2  1  4  0  0  4  0  5  2  1  3  1  1  4 
miR‐
942‐3p  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐
942‐5p  0  0  0  0  0  0  0  2  0  0  0  0  0  0  0  0  0  0  0  0  0  0  1  0 
miR‐95‐
3p  0  0  0  1  0  0  0  1  0  0  0  0  0  0  0  0  0  0  0  1  1  0  0  0 
miR‐9‐
5p  0  0  6  0  1  0  1  0  0  0  1  0  18  0  3  0  40  0  1  0  91  0  0  1 
miR‐96‐




5p  2  0  2  6  6  0  2  27  6  2  1  3  4  0  0  7  0  6  1  9  20  3  4  13 
miR‐
99a‐5p  30  19  14  39  41  35  15  129  93  12  14  23  24  5  11  42  8  82  46  29  197  21  114  130 
miR‐
99b‐3p  0  0  0  0  0  0  0  3  3  0  1  0  0  0  0  0  0  0  0  1  1  0  0  2 
miR‐
99b‐5p  23  6  8  24  21  14  15  168  20  18  10  13  24  3  8  33  14  42  31  19  110  5  53  71 
 
